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4Dear Colleague,
On behalf of my fellow members of the International and Local Organizing 
Committees, it is a pleasure to welcome you to the XI International Symposium  
on Insulin Receptors and Insulin Action.
The congress provides continuity to a series of outstanding symposia started in 
Italy in 1980. Since then, the symposium has been organized every three years in 
Europe and has brought forward recent advances in the description of insulin signal 
transduction and metabolism related to metabolic disorders such as Diabetes 
mellitus and Obesity. After 20 years since the Verona edition, the symposium is now 
returning to Italy.
The understanding of the pathogenesis of Diabetes mellitus and related disorders 
is being transformed by a number of discoveries. As a result of this activity, our 
perception of Diabetes and related disorders is changing both at the mechanistic and 
the clinical levels. The “XI International Symposium on Insulin Receptors and Insulin 
Action” will address various key topics related to the “New face of Diabetes in the XXI 
century”.
The meeting is composed of keynote lectures, plenary sessions, short oral 
presentations and poster sessions. We hope that you will find plenty of time for 
informal and formal discussions. We also wish you to take time to explore Naples and 
appreciate the strength of its history and long lasting traditions. Our intention is that 
this meeting will foster constructive scientific interactions and collaborations in the 
very unique and inspiring scenario of the bay of Naples.
I hope your visit will be memorable and wish to welcome you to Naples!
Francesco Béguinot, MD, PhD
Professor of Clinical Pathology,
Director, Dept. of Clinical Pathology
and Metabolic Disease Unit
“Federico II” University of Naples,
Chair, IR10
ph. +39 081 746 3248
fax +39 081 746 3235
beguino@unina.it
naples, Italy
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IR10 SPONSOR COMPANIES
We would like to thank all Companies offering their generous sponsorship to our Symposium:
GOLD
SILVER
PLATINUM
BRONZE
AND
6The Symposium is under the Aegis of:
European Association for the Study of Diabetes 
(EASD)
Ministero del Lavoro, della Salute  
e delle Politiche Sociali
Consiglio Nazionale delle Ricerche
Consiglio Universitario Nazionale
Conferenza dei Rettori delle Università Italiane
Istituto Superiore di Sanità
Assessorato alla Sanità della Regione Campania
and is supported by:
Polo delle Scienze e Tecnologie per la vita, 
Università degli Studi di Napoli Federico II
International Scientific Committee
Hans Ulrich Häring (Germany), President IR10
Domenico Accili (USA) 
Henning Beck-Nielsen (Denmark)
Francesco Béguinot (Italy), Chair IR10 
Jean-Louis Carpentier (Belgium)
Michael P. Czech (USA)
Pierre De Meyts (Denmark)
Suad Efendic (Sweden)
Barbara B. Kahn (USA)
C. Ronald Kahn (USA)
Eddy Karnieli (Israel)
Masato Kasuga (Japan)
Yannick Le-Marchand-Brustel (France)
Jesse Roth (USA)
Alan R. Saltiel (USA)
Simeon Taylor (USA)
Emmanuel Van Obberghen (France)
Morris F. White (USA)
Yehiel Zick (Israel)
Juleen Zierath (Sweden), Scientific Secretary IR10
Local Organizing Committee
Francesco Béguinot
Pietro Formisano
Francesco Giorgino
Claudia Miele
Francesco Oriente
Luca Ulianich
Paola Ungaro
Rossella Valentino 
 
 
Honorary Committee
Renato Lauro  
(IR10 Honorary President)
Eduardo Consiglio and Vincenzo Macchia 
(Honorary Committee Members)
Previous Editions
1980 Rome, Italy 
1983 Rome, Italy 
1987 Madrid, Spain 
1990 Verona, Italy 
1993 Munich, Germany 
1996 Copenhagen, Denmark 
1998 Jerusalem, Israel 
2001 Geneva, Switzerland 
2004 Nice, France 
2007 Stockholm, Sweden
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GENERAL INFORMATION
CONGRESS SECRETARIAT
I&C Srl
Via Andrea Costa 202/6 
40134 Bologna (Italy) 
Ph. +39 051 6144004
Fax +39 051 6142772
federica.schiassi@iec-srl.it 
stefania.parolari@iec-srl.it
CONFERENCE VENUE
Royal Continental Hotel
Via Partenope 38/44
80121 Naples
Ph. +39 081 2452068 
The Royal Continental Hotel is located on the Naples waterfront and offers an ideal location with superb 
views of the gulf and of Castel dell’Ovo.
BADGES
Participants are requested to wear their conference badge during all sessions, coffee breaks, lunches 
and social events. 
ITALIAN CME CREDITS
N. 11 CME credits have been assigned to the Congress from the Board for Accreditation of the Italian 
Ministry of Health for the professional figure of medical doctors and surgeons.
CONTACT INFORMATION DURING CONFERENCE
During the conference (October 28-29-30), messages to participants may be sent to the registration 
desk at the venue, Royal Continental Hotel: Federica Schiassi (+39 347 7865104), Stefania Parolari  
(+39 346 2217620); Fax: +39 081 7644616; e-mail: federica.schiassi@iec-srl.it; stefania.parolari@iec-srl.it
INTERNET CONNECTION
Internet access will be provided free of charge at the Congress Venue.
DRESS CODE
Dress will be informal throughout the conference, however jacket is recommended for the Gala Dinner.
S. Lorenzo Complex is an ancient building and no heating system is provided. Although Naples has 
usually a temperate climate, we suggest warm clothes for the dinner.
REGISTRATION DESk
The desk, at Royal Continental Hotel, will be open during the conference as follows:
u Wednesday October 27 from 15:00 to 20:00
u Thursday October 28 from 08:00 to 18:00
u Friday October 29 from 08:00 to 18:00
u Saturday October 30 from 08:00 to 19:00
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SOCIAL PROGRAM
Participation requires registration. Please contact the registration desk for the payment of the fee for 
accompanying persons. Transportation has to be arranged personally. Accompanying persons have to 
wear their conference badge during all sessions, coffee breaks, lunches and social events.
u THURSDAy, OCTOBER 28 – H. 20:00
Dinner at the Royal Continental Hotel Restaurant accompanied by live music entertainment
u FRIDAy, OCTOBER 29 – H. 08:30
RESERVED TO THE ACCOMPANYING PERSONS
Sightseeing Excavations of Ercolano
H. 08:15 Meeting point in the Royal Continental Hotel lobby
H. 08:30 Transfer by bus to the Excavations of Ercolano
H. 12:00 Transfer by bus to Pizzeria Regina Margherita, on the seafront of Naples
H. 13:00-14:30 Lunch and transfer to Royal Continental Hotel
In case of bad weather, the visit will be organized to the National Archeological Museum
Please confirm your participation to the Congress Secretariat within October 28 morning.
u FRIDAy, OCTOBER 29 – H. 20:00
Dinner at Complesso Monumentale S. Lorenzo Maggiore  
(Via Tribunali 316, Naples)
San Lorenzo Maggiore is one of the oldest churches in Naples. It is 
located at the precise geographic center of the ancient Greek-Roman 
city, at the intersection of Via San Gregorio Armeno and Via dei 
Tribunali. San Lorenzo Complex includes a church and a monastery. 
Beneath San Lorenzo, about half of an original Roman market has 
been excavated. The site has been open since 1992, the result of 25 
years of painstaking excavation. The market place is the only large-
scale Greek-Roman site excavated in the downtown area.
Six touristic guides will be available during the welcome cocktail 
to give information about the historical complex and to visit the 
underground excavations. A shuttle bus will be organized by the 
Congress Secretariat from the Royal Continental Hotel at 19:00.
Dress suggestion
S. Lorenzo Complex is an ancient building and no heating system is provided. 
Although Naples has usually a temperate climate, we suggest warm clothes for 
the dinner.
u SATURDAy, OCTOBER 30 – H. 19:00
Farewell cocktail at the Swimming Pool Foyer of the Royal Continental Hotel
10
TRANSPORTATION
TAXI: 
Radiotaxi Naples Telephone + 39 081 5564444. 
PUBLIC TRANSPORTATION 
(TAXI EXCLUDED):
UNICO NAPOLI: is the ticket that allows you 
to travel on all means of transportation in the 
Naples urban area.
The main fares are:
HOURLY TICKET: e 1,10 (valid for 90 minutes 
from validation)
DAILY TICKET: e 3,10 (valid from 00.00 to 
midnight of the day of validation). You must fill 
in the appropriate blanks with your name and 
date of birth and keeping with you an identity 
document to be shown if requested.
Tickets can be purchased in most of tobacco 
shops and newsstands. Once on the travel mean, 
you must validate your ticket in the ticket-
machine. If it is out of order you can valid writing 
by pen date and time.
HOw TO REACH:
THE CONGRESS VENUE ROYAL CONTINENTAL 
HOTEL (VIA PARTENOPE 38/44):
Bus
ANM – 152
STOP AT CASTEL DELL’OVO  
(bus stop in front of the hotel)
Bus
ANM – 601
STOP AT PIAZZA VITTORIA  
(bus stop behind the hotel)
THE MONUMENTAL COMPLEx  
S. LORENZO MAGGIORE (VIA TRIBUNALI 316):
Shuttle Bus
Shuttle busses will be organized by the Congress 
Secretariat leaving the Royal Continental Hotel 
on Friday October 29 at h 19:00. Their use to 
reach S. Lorenzo Complex is recommended.
Other travel means:
Trolleybus 
ANM - 201 
STOP AT PIAZZA CAVOUR
Busses 
SITA - Linea: Napoli - Pertosa 
STOP AT NAPOLI (VARCO IMMACOLATELLA)
ANM - C47 
STOP AT PIAZZA CAVOUR
ANM - E1 
STOP AT PIAZZA DEL GESÙ
ANM - R2 
STOP AT PIAZZA NICOLA AMORE
ANM - E1 
STOP AT VIA CIRILLO
ANM - E1 
STOP AT VIA DUOMO
ANM - CS 
STOP AT VIA DUOMO
ANM - E1 
STOP AT VIA FORIA
naples, Italy
October 28 - 30, 2010
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INFORMATION FOR SPEAkERS  
AND ABSTRACT PRESENTERS
SPEAkERS AND ORAL PRESENTERS
Slide center opening times:
October 27: 16:00-20:00
October 28-30: 07:30-19:00
You are kindly requested to report to the technical support team in the slide center no later than 2 hours 
before the respective scheduled session in order to copy the presentation onto the meeting computer.
Presentations must be in Power Point and no personal PC will be allowed.
The operating system is Microsoft Windows Office 2007 and converter for Macinthosh is available.
POSTER PRESENTERS
Mounting Time:
October 27 – from 18:00 to 19:00; October 28 – from 08:00 to 09:00 
Poster Area: 
you will find a dedicated Area for posters near the Lunch Area; don’t forget the number assigned to your 
Abstract; you will have to fix your Poster in the Panel showing the same number. In the Poster Area, you 
will find the necessary material to hang your poster.
Dismounting Time: 
October 30 – 19:00 to 20:00; our Organization will remove and eliminate all posters not dismounted by 
October 30, 20:00.
Discussion Time: 
your presence near your Poster is advised at all times during the Poster Session. However we remind 
you that you will be asked to be present on the day and at the time communicated in the acceptance 
letter.
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WEDNESDAY, OCTOBER 27
15:00-20:00
REGISTRATION DESK OPENING
THURSDAY, OCTOBER 28
09:00-09:30
OPENING CEREMONY AND WELCOME ADDRESS
Chairs: Hans Ulrich Häring (Tübingen, DE)  
and Francesco Béguinot (Naples, IT)
Welcome address of the President and the Organizer
Ulf Smith (Gothenburg, SE)
Welcome address of the President of the European 
Association for the Study of Diabetes
Gabriele Riccardi (Naples, IT)
Welcome address of the President of the Italian Diabetes 
Society
Gaetano Lombardi (Naples, IT)
Welcome address of the President of the Italian 
Endocrinology Society
09:30-10:30
MEETING INTRODUCTION
INSULIN ACTION IN 2010: PERSPECTIVES IN 
THE COMING DECADE
Chairs: Edwin Gale (Bristol, UK) and Jesse Roth 
(Whitestone, NY USA) 
09:30-09:50
Introduction - Jesse Roth (Whitestone, NY USA) 
Paired revolutions in intercellular 
communication: the tenth day of creation
09:50-10:10
Lecture 01 - C. Ronald Kahn (Boston, MA USA)
Continuing evolution in our concepts of insulin 
action and insulin resistance
10:10-10:30
Lecture 02 - Ulf Smith (Gothenburg, SE)
Understanding insulin signaling and action-also 
a future challenge
10:30-11:00
COFFEE BREAK 
11:00-12:30
ORAL SESSION 01
NEw CONCEPTS IN INSULIN SIGNAL 
TRANSDUCTION
Chairs: Masato Kasuga (Tokyo, JP)  
and Emmanuel Van Obberghen (Nice, FR)
11:00-11:30
Lecture 03 - Domenico Accili (New York, NY USA)
Unusual sites of insulin resistance
11:30-12:00
Lecture 04 - Takashi Kadowaki (Tokyo, JP)
Adipocyte control of insulin action
12:00-12:15
Oral Presentation 1 (C1-1) - Qiong L. Zhou
A novel protein enhances insulin-stimulated 
akt phosphorylation and glut4 translocation in 
adipocytes 
12:15-12:30 
Oral Presentation 2 (C1-2) - Barbara Salani
IGF-IR internalizes with caveolin-1 and ptrf/
cavin in hacat cells
12:30-14:30
POSTER SESSION 01 and BUFFET LUNCH
SCIENTIFIC PROGRAM
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THURSDAY, OCTOBER 28
14:30-15:30
ORAL SESSION 02
THE ROLE OF ADIPOSE TISSUE  
IN INSULIN ACTION
Chairs: Eddy Karnieli (Haifa, IL)  
and Francesco Purrello (Catania, IT)
14:30-15:00
Lecture 05 - Francesco Giorgino (Bari, IT)
The biological specificity of visceral fat
with the Unrestricted Educational Grant of Eli Lilly Italia
15:00-15:15
Oral Presentation 3 (C2-3) - Karin Stenkula
Insulin regulates the spatial distribution of 
glucose transporter-4 on the cell surface 
15:15-15:30
Oral Presentation 4 (C2-4) - Gregory Raciti
ANKRD26 gene ablation causes diabetes in 
mice 
15:30-16:00
COFFEE BREAK 
16:00-17:00
ORAL SESSION 03
INSULIN SIGNALLING IN PERIPHERAL 
TISSUES 
Chairs: Amira Klip (Toronto, CA)  
and Robert J. Smith (Providence, RI USA) 
16:00-16:30
Lecture 06 - Timothy E. McGraw (New York, NY USA)
AKT2 regulation of GLUT4 trafficking
16:30-16:45
Oral Presentation 5 (C3-5) - Isabelle Castan-Laurell
Chronic apelin treatment in HFD-fed mice 
improves b-oxydation and insulin resistance 
16:45 - 17:00
Oral Presentation 6 (C3-6) - Kurt Højlund
Is defect insulin signaling to mitochondria 
linked to insulin resistance in human muscle?
17:00-17:10
Francesco Béguinot (Naples, IT)
The past, the present and the future  
of the IR meeting community
Talk not included in the CME credit program
17:10-17:55
ORAL SESSION 04
INSULIN ACTION IN OBESITy
Roberto De Pirro Memorial Ceremony
Chairs: Samuel Cushman (Bethesda, MD USA)  
and Ulf Smith (Gothenburg, SE)
17:10-17:40
Lecture 07 - Hadi Al-Hasani (Nuthetal, DE)
Roberto De Pirro Memorial Lecture - Obesity 
genes and their impact on insulin action: lesson 
from mouse genetics
with the Unrestricted Educational Grant of Sanofi Aventis
17:40-17:55
Oral Presentation 6bis (C4-6bis) - Paul Pilch
Adiporedoxin, an adipocyte-enriched novel 
regulator of adiponectin assembly/secretion
Talk not included in the CME credit program
19:30
DINNER AT ROYAL CONTINENTAL HOTEL 
RESTAURANT
naples, Italy
October 28 - 30, 2010
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FRIDAY, OCTOBER 29
08:30-10:00
ORAL SESSION 05
GENETIC AND EPIGENETIC CONTROL  
OF INSULIN ACTION 
Chairs: Henning Beck-Nielsen (Odense, DK)  
and Michael P. Czech (Worcester, MA USA) 
08:30-09:00
Lecture 08 - Markku Laakso (Kuopio, FI)
Human gene variation affecting insulin action 
and secretion
09:00-09:30
Lecture 09 - I. Karen Temple (Southampton, UK)
Epigenetics and diabetes: lesson from neonatal 
diabetes and disorders of imprinting
09:30-09:45
Oral Presentation 7 (C4-7) - Raffaele Teperino
Environmental and epigenetic regulation of the 
diabetes-related PED/PEA-15 gene
09:45-10:00
Oral Presentation 8 (C4-8) - Stephan Scherneck
ZFP69 as a potential modulator of obesity-
associated diabetes
10:00-10:30
COFFEE BREAK 
10:30-12:00
ORAL SESSION 06
ENVIRONMENTAL CONTROL OF INSULIN 
ACTION AND NUTRIENT METABOLISM
Chairs: Angelika Bierhaus (Heidelberg, DE)  
and Philipp Gorden (Bethesda, MD USA)
10:30-11:00
Lecture 10 - Juleen Zierath (Stockholm, SE)
Metabolic regulation in diabetes through DNA 
methylation
11:00-11:30
Lecture 11 - Christopher B. Newgard (Durham, NC 
USA)
Metabolic drivers of insulin resistance and 
related disorders
11:30-11:45
Oral Presentation 9 (C5-9) - Katy Raddatz
Pkc epsilon regulates hepatic lipid metabolism 
during short term lipid oversupply
11:45-12:00
Oral Presentation 10 (C5-10) - Assaf Rudich
Activation of ASK1 in omental fat links adipocyte 
stress to whole-body insulin resistance
12:00-14:00
POSTER SESSION 02 and BUFFET LUNCH
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FRIDAY, OCTOBER 29
14:00-15:30
ORAL SESSION 07
b- AND α-CELLS IN INSULIN-RESISTANCE 
STATES 
Chairs: Jean-Louis Carpentier (Namur, BE)  
and Piero Marchetti (Pisa, IT)
14:00-14:30
Lecture 12 - Bernard Thorens (Lausanne, CH)
IGF-2 and IGF-1 receptor in the control of b-cell 
mass and function
14:30-15:00
Lecture 13 - Rohit N. Kulkarni (Boston, MA USA)
Intra-islet insulin signalling regulates α-cell 
function in vivo
15:00-15:15 
Oral Presentation 11 (C6-11) - Eugenia Tiziana 
Maniscalchi
MAPK activation in α TC1 cells after chronic 
palmitate exposure
15:15-15:30
Oral Presentation 12 (C6-12) - Avital Beck
Sirna screening for genes involved in cytokine-
induced pancreatic b cell death 
15:30-16:00
COFFEE BREAK
16:00-17:30
ORAL SESSION 08
INSULIN ACTION IN THE CNS 
Chairs: Ira D. Goldfine (San Francisco, CA USA)  
and Giuseppe Paolisso (Naples, IT) 
16:00-16:30
Lecture 14 - Jens C. Brüning (Cologne, DE)
Central regulation of energy metabolism by 
insulin
16:30-17:00
Lecture 15 - Suzanne Craft (Seattle, WA USA)
Insulin-resistance and neurodegeneration: 
novel mechanisms and therapeutic implications
17:00-17:15
Oral Presentation 13 (C7-13) - Toshiyasu Sasaoka
Impact of the elevation of lipid phosphatase 
ship2 on brain insulin action for the cognitive 
function in mice
17:15-17:30
Oral Presentation 14 (C7-14) - Tina Sartorius
Toll-like receptor2/4 deficiency protects from 
diet-induced brain insulin resistance
19:00
MEETING POINT IN THE ROYAL CONTINENTAL 
LOBBY FOR THE TRANSFER TO THE 
MONUMENTAL COMPLEx S. LORENZO 
MAGGIORE FOR THE GALA DINNER 
20:00
GALA DINNER AT THE MONUMENTAL 
COMPLEx S. LORENZO MAGGIORE
naples, Italy
October 28 - 30, 2010
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SATURDAY, OCTOBER 30
09:30-10:45
ORAL SESSION 09
METABOLISM AND CANCER 
Chairs: Pietro Formisano (Naples, IT)  
and Derek Le Roith (New York, NY USA) 
09:30-10:00
Lecture 16 - Reuben J. Shaw (La Jolla, CA USA)
AMPK signaling in glucose metabolism and 
growth control
10:00-10:30
Lecture 17 - Michael Pollak (Montreal, CA)
Insulin signalling and metformin in relation to 
cancer: new developments
with the Unrestricted Educational Grant of Sanofi Aventis
10:30-10:45
Oral Presentation 15 (C8-15) - Jutta Nagel 
Glargine and NPH insulin similarly increase 
colonic cell proliferation and ACF formation
10:45-11:15
COFFEE BREAK
11:15-12:30
ORAL SESSION 10 
INSULIN-ACTION AND CANCER
Session not included in the CME credit program
Chairs: Ira Pastan (Bethesda, MD USA)  
and Riccardo Vigneri (Catania, IT) 
11:15-11:45
Lecture 18 - Morris F. White (Boston, MA USA)
The dark side of IRS-2: cancer and neuro-
degeneration
11:45-12:15
Lecture 19 - Norbert Tennagels (Frankfurt am Main, 
DE)
Metabolic and mitogenic signalling of 
exogenous insulin(s)
12:15-12:30
Oral Presentation 16 (C9-16) - Michael Greene 
Breast cancer growth and activation of insulin/
IGF-1 signaling by circadian disruption
12:30-14:30
POSTER SESSION 03 and BUFFET LUNCH
18
SATURDAY, OCTOBER 30
14:30-16:30
ORAL SESSION 11
FUTURE STRATEGIES FOR TREATING 
DIABETES 
Chairs: Stefano Del Prato (Pisa, IT)  
and Giorgio Sesti (Catanzaro, IT) 
14:30-15:00
Lecture 20 - Fatima Bosch (Barcelona, ES)
Gene therapy in diabetes
15:00-15:30
Lecture 21 - Markus Stoffel (Zürich, CH)
MicroRNAs: regulators of metabolism and 
therapeutic targets
15:30-15:45
Oral Presentation 17 (C10-17) - Lucie Popineau 
GRB14 inhibition in mouse liver improves 
glucose tolerance and hepatic steatosis
15:45-16:00
Oral Presentation 18 (C10-18) - Olivier Bezy 
PKCD is a regulator of hepatic insulin sensitivity 
and modifies hepatosteatosis risk
16:00-16:15
Oral Presentation 19 (C10-19) - Shiri Karni Ahkenazi 
NFKB paradox: suppression of glut4 expression 
with concomitant translocation enhancement 
16:15-16:30
Oral Presentation 20 (C10-20) - Mashito Sakai 
Cited2 regulates hepatic gluconeogenesis by 
controlling PGC-1α activity
16:30-17:00
COFFEE BREAK
17:00-18:30
ORAL SESSION 12
DIABETES COMPLICATIONS
Chairs: Michele Muggeo (Verona, IT)  
and Yehiel Zick (Rehovot, IL) 
17:00-17:15
Oral Presentation 21 (C11-21) - E. Dale Abel 
Insulin signaling is a physiological regulator of 
myocardial autophagy in vivo
17:15-17:30
Oral Presentation 22 (C11-22) - Rossella Menghini 
Increased expression of TIMP3 protects against 
diabetes and atherosclerosis
17:30-17:45
Oral Presentation 23 (C11-23) - Janice Zabolotny 
Protein tyrosine phosphatase 1b (PTP1B) 
regulates wound healing
17:45-18:00
Oral Presentation 24 (C11-24) - Eugenia Carvalho 
Immunosuppressive agents alter glucose 
metabolism, blood pressure and heart rate in 
rats
18:00-18:30
Lecture 22 - Hans Ulrich Häring (Tübingen, DE)
President lecture - Insulin action in human 
brain
18:30-19:00
CONCLUSION CEREMONY
18:30-18:45
Francesco Béguinot (Naples, IT)
Conclusion remarks
18:45-19:00
XII meeting announcement
19:00
FAREWELL COCKTAIL AT THE SWIMMING POOL 
FOYER OF THE ROYAL CONTINENTAL HOTEL
naples, Italy
October 28 - 30, 2010
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SPEAkERS  
ABSTRACTS 
9:30-9:50 Thursday, October 28, 2010
• Jesse Roth
Receptors and intercellular 
communication: where we are and how 
we got here 
Jesse Roth
Feinstein Institute for Medical Research, North Shore-Long 
Island, New York (NY USA)
The Earth is three or four billion years old. Homo 
sapiens has been around for roughly 100.000 
years. Written language, which marks the 
beginning of “history”, is 5.000 years old. Adults 
who are over 50 have witnessed 1% of all history. 
The modern era of biology began about 150 years 
ago (L. Pasteur, C. Bernard, et al.). Those same 
adults have witnessed one third of all of the 
history of modern biology.
When I started medical school about fifty years 
ago, intercellular communication was the 
exclusive province of the nervous system and 
the endocrine system. The nervous system was 
largely hard wired and electrical transmission 
a prominent concept. The total number of 
neurotransmitters could be counted on one’s 
fingers (with no need for polydactyly), and this 
exclusive club was resisting the admission of 
new members. The endocrine system included a 
finite number of glands, each producing one or 
a few hormones that travelled through the blood 
to a limited roster of target cells.
Measurements of hormone levels in vivo (outside 
of the glands) were limited to steroid hormones 
and hCG in urine and thyroid hormones in 
blood (Tri-iodothyronine was just discovered 
the year before). Since these endocrine glands 
arose evolutionarily with the vertebrates, the 
hormones were thought to be restricted to 
vertebrates (Neurons were about twice as old, 
emerging with multicellularity).
In 2010, we know that every cell at every moment 
is releasing a set of (hormone-like) intercellular 
communication molecules to affect itself, its 
neighbors and cells at a distance. It is receiving 
many-fold more communication molecules 
from other cells in the body. Even bacteria are 
known to be communicating among one another 
within and across species (“quorum sensing”). 
There is a growing body of data that vertebrate 
and bacterial cells (e.g. in the intestine) are 
communicating.
Fifty years ago, we did not know how a hormone 
was recognized by its target cell. Second 
messengers, intracellular receptors, cell surface 
receptors were not even conceived of. They were 
absent from the textbooks.
A search of JBC, PNAS, and JCI titles and 
abstracts for the word “receptor” shows 
essentially no entries at all from 1940 to 1970. 
Then receptors suddenly took off. Since then, 
receptor papers represented a substantial 
minority of all papers in all three publications, 
right through December 2009. What were people 
thinking before “receptors”? How did receptors 
emerge? This assembly in its history captures 
that transformation.
9:50-10:10 Thursday, October 28, 2010
• C. Ronald kahn
Continuing evolution in our concepts of 
insulin action and insulin resistance
C. Ronald Kahn
Joslin Diabetes Center and Harvard Medical School, Boston 
(MA USA)
Since the discovery of the insulin receptor 
tyrosine kinase – now 30 years ago – the entire 
field of insulin action and insulin resistance has 
exploded with new information and new insights. 
Following the activation of the insulin receptor, 
multiple intracellular substrates and signaling 
proteins form a complex, diverging signaling 
network. Through various combinations of 
these molecules, over 2.000 different potential 
pathways of insulin signaling can be activated. 
By knocking-out and knocking-down specific 
components of the signaling system in isolated 
cells and specific tissues of intact animals, it 
has been possible to define many of the specific 
pathways that lead to various insulin actions 
and determine how they are modified in disease 
20
states. Using this approach, for example, 
we have been able to distinguish different 
pathways involved in control of glucose and lipid 
metabolism, as well as those pathways and 
genes that are primarily regulated by insulin 
itself versus those that are secondarily regulated 
by either diet or the metabolic alterations in 
diabetes. These approaches have allowed us 
to define the specific pathways responsible for 
hyperglycemia versus those responsible for the 
hyperlipidemia and accelerated atherosclerosis 
of type 2 diabetes. Likewise, pathways relating 
insulin action and insulin resistance have 
been mapped for various complications of 
the metabolic syndrome including formation 
of gallstones, increased risk for Alzheimer’s 
disease, and alterations in bone density and 
osteoporosis. Links between insulin action 
and mitochondrial dysfunction have also been 
established and shown to play a role in the 
altered metabolism of diabetes. Conversely, 
diabetes itself has been shown to alter insulin 
signaling and metabolism in both classical 
tissues of insulin action, such as liver, muscle 
and fat, and non-classical tissues, such as brain 
and b-cell. New components of the insulin 
action/resistance network are being identified, 
including a number of transcription factors, 
co-activators and co-repressors, and members 
of the sirtuin family of protein deacetylases. 
However, important challenges remain in both 
defining basic aspects of insulin action – for 
example, how do insulin and IGF-1 act through 
similar signaling networks but produce such 
different physiological effects – and basic 
aspects of insulin resistance – such as, where is 
the primary site of insulin resistance in people 
with genetic risk of type 2 diabetes. Solving 
these problems is not only of academic interest, 
it will provide insights into development of new 
treatments for diabetes, obesity and metabolic 
syndrome–epidemic diseases of the 21st century. 
10:10-10:30 Thursday, October 28, 2010
• Ulf Smith
Do we need to know more about insulin 
signalling and action?
Ulf Smith
Division of Endocrinology
The Hallett Center for Diabetes and Endocrinology
Rhode Island Hospital
Alpert Medical School of Brown University, Providence  
(RI USA)
Our understanding of insulin signalling and 
action has dramatically increased over the 
last decades. We also know a number of 
perturbations in the intracellular signalling 
cascade and action in insulin resistance but 
we still have had very limited information 
of potential genetic factors. In fact, the 
only common risk genotypes are related to 
polymorphisms in the PPARγ and IRS-1 genes. 
This is in contrast to the expanding number of 
identified risk genes for Type 2 diabetes which 
primarily appear to influence insulin secretion. 
So is there then a future for young scientists 
who want to study insulin signalling and action? 
In my view, there is a great need to further 
understand how and where insulin resistance 
develops. Obesity is by far the most common 
cause of insulin resistance emphasizing that 
the adipose tissue may play an important 
role. However, it is also possible that insulin 
resistance is primarily an environmental 
factor while the genetic predisposition for Type 
2 diabetes involves the b-cells and insulin 
secretion.
Irrespective of this, we badly need new 
therapeutic agents which improve insulin 
sensitivity and cardiovascular risk. The diabetes 
drugmarket has a global sale of around $ 29 
billion and in Europe alone it is $ 7 billion. This is 
predicted to further grow as the Type 2 diabetes 
epidemic continues.
Recent studies have shown additional health 
problems for patients with Type 2 diabetes 
since morbidity and mortality in certain forms 
of cancer are increased. Insulin resistance 
has also been implicated in this and we need 
to understand the signalling pathways for the 
growth-promoting effect of insulin and the 
cross-talk with the IGF-receptors. 
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These new challenges combined with the need 
for novel therapy in Type 2 diabetes should give 
a further boost to the research area and ensure 
future symposia on insulin receptors and action. 
11:00-11:30 Thursday, October 28, 2010
• Domenico Accili
11:30-12:00 Thursday, October 28, 2010
• Takashi kadowaki
Adipocyte control of insulin action
Takashi Kadowaki
Department of Diabetes and Metabolic Diseases 
Graduate School of Medicine, University of Tokyo (JP)
Adiponectin is an anti-diabetic adipokine, which 
facilitates glucose and lipid metabolism to 
increase insulin sensitivity. Decreased plasma 
adiponectin in obesity is causally involved in 
insulin resistance and metabolic syndrome. 
Adiponectin receptors, AdipoR1, AdipoR2, 
possess seven-transmembrane topology with 
the amino terminus located intracellularly, 
which is opposite to G-protein coupled receptors. 
In liver, activation of AdipoR1 by adiponectin 
stimulates AMP kinase (AMPK) pathway and that 
of AdipoR2 stimulates PPARα pathway, thereby 
decreasing gluconeogenesis and lipogenesis, 
increasing fatty acid oxidation, simultaneously 
causing suppression of inflammation and 
oxidative stress. In muscle, adiponectin- AdipoR1 
regulate PGC-1α expression via Ca2+/CaMKKb 
pathway and PGC-1α deacetylation and activation 
via and AMPK/SIRT1, respectively, leading to 
increased mitochondrial biogenesis impaired, 
exercise endurance and insulin resistance. In 
fact, skeletal muscle-specific AdipoR1 showed 
decreased PGC-1α expression and activity, 
decreased mitochondrial biogenesis, decreased 
type1 fibre, insulin resistance, endurance. 
Decreased adiponectin and adiponectin 
receptors in obesity are causally involved 
in obesity-linked diseases such as insulin 
resistance, metabolic syndrome, diabetes, 
decreased exercise endurance and vascular 
inflammation, and thus adiponectin and 
adiponectin receptors would serve as molecular 
targets of treatment strategy of these diseases.
REFERENCES
1) Nature Medicine 7:941-946, 2001, 2) Nature Medicine 8: 
1288-1295, 2002, 3) Nature 423: 762-769, 2003, 4) J. Biol. 
Chem. 279: 30817-30822, 2004, 5) Endocrine Reviews 26: 
439-451, 2005, 6 ) J. Biol. Chem. 281: 8748-8755, 2006, 7) 
J. Clin. Invest. 116: 1784-1792, 2006, 8) Nature Medicine 
13: 332-339, 2007, 9) Cell Metabolism 6:55-68, 2007, 10) 
FEBS Letters, 582: 74-80, 2008, 10) Nature, published 
online March 31 2010
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14:30-15:00 Thursday, October 28, 2010
• Francesco Giorgino
The biological specificity of visceral fat
Francesco Giorgino
Department of Emergency and Organ Transplantation
Section of Internal Medicine,
Endocrinology and Metabolic Diseases 
University of Bari School of Medicine (IT)
With excess energy storage, obesity develops, 
leading to increased risk for type 2 diabetes 
and cardiovascular diseases. The distribution 
of body fat appears to be even more important 
than the total amount of fat. Abdominal and, 
in particular, visceral adiposity is strongly 
linked to insulin resistance, type 2 diabetes, 
hypertension, dyslipidaemia, sleep apnea, 
and other complications of obesity. Visceral 
adiposity, manifested as a high waist 
circumference, is now accepted as a major 
component of the metabolic syndrome. Although 
the epidemiological association between visceral 
fat accumulation and excess risk of diabetes 
and of cardiovascular disease is striking, the 
biological mechanisms underlying the adverse 
impact of adipose tissue remain incompletely 
defined. Adipose tissue is a critical regulator of 
energy balance and substrate metabolism, and 
synthesizes several different substances with 
endocrine or paracrine functions, which regulate 
the overall energetic homeostasis. Evidently, 
adipose tissue is not only responsible for storage 
of energy, but operates as a highly active and 
dynamic tissue. Adipocytes produce hormones 
and cytokines, collectively called «adipokines», 
with pleiotropic effects on multiple tissues, 
leading to fine tuning of fuel utilization, energy 
homeostasis, and cardiovascular function. It 
should be also recognized that the functional 
attitude of visceral and subcutaneous 
adipocytes is programmed quite early during 
development and differentiation, due to inherent 
characteristics of the adipocyte precursors, 
multipotent cells that are resident in each 
fat depot and possess defined depot-specific 
genetic, biochemical and metabolic features. 
Thus, the biological specificity of the distinct 
adipose tissue depots may reside in the different 
biological profile of the resident cells, including 
the adipocyte precursors. In particular, adult 
adipose tissue contains a pool of abundant and 
accessible multipotent stem cells, generally 
termed adipose-derived stem cells (ASCs), 
that are able to replicate as undifferentiated 
cells, to develop as mature adipocytes, and 
to differentiate into multiple other cell types 
along the mesenchymal lineage, including 
chondrocytes, myocytes and osteoblasts, and 
also into cells of neuroectodermal origin, 
including neurons and astrocytes. Different 
populations of multipotent precursor cells can 
be isolated from human fat fragments. Thus, 
adipose precursors cells are a heterogeneous 
cells population. An impairment in the 
differentiation potential and biological function 
of ASCs may contribute to the development of 
obesity and related diseases.
16:00-16:30 Thursday, October 28, 2010
• Timothy E. McGraw
AkT2 regulation of GLUT4 trafficking
Timothy E. McGraw
Department of Biochemistry
Weill Medical College of Cornell University of New York 
(NY USA)
Insulin stimulates glucose transport by 
recruiting the GLUT4 glucose transporter to the 
plasma membrane. Here we use total internal 
reflection fluorescence microscopy to show that 
two trafficking motifs of GLUT4, a FQQI motif and 
a TELE-based motif, target GLUT4 to specialized 
vesicles that accumulate adjacent to the 
plasma membrane of unstimulated adipocytes. 
Mutations of these motifs redistributed 
GLUT4 to transferrin-containing recycling 
vesicles adjacent to the plasma membrane, 
and the degree of redistribution correlated 
with the increases of the GLUT4 mutants in 
the plasma membrane of basal adipocytes. 
These results establish that GLUT4 defaults 
to recycling endosomes when trafficking to 
specialized vesicles is disrupted, supporting 
the hypothesis that the specialized vesicles 
are derived from an endosomal compartment. 
Insulin stimulates both the accumulation of 
GLUT4 in the evanescent field and the fraction 
of this GLUT4 that is inserted into the plasma 
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membrane. Unexpectedly, these two steps are 
differentially affected by the development of 
insulin resistance. We ascribe this selective 
insulin resistance to inherent differences in the 
sensitivities of GLUT4 vesicle accumulation and 
insertion into the plasma membrane to insulin. 
Differences in insulin sensitivities of various 
processes may be a general mechanism for the 
development of the physiologically important 
phenomenon of selective insulin resistance. 
IRAP, a transmembrane aminopeptidase, is 
also cargo of the insulin-regulated membrane 
trafficking pathway. Here we show that it 
is essential for GLUT4 sorting to GSV. In 
unstimulated IRAP knockdown adipocytes 
(IRAP-KD), plasma membrane GLUT4 levels 
are elevated due to increased exocytosis. 
These changes correlate with a re-localization 
of GLUT4 from specialized compartments to 
endosomes. Thus IRAP controls sorting GLUT4 
to GSV, and therefore has a fundamental role in 
basal GLUT4 retention. The IRAP cytoplasmic 
domain rescues the IRAP-KD phenotype, 
demonstrating that the aminopeptidase activity 
is not required. Current evidence supports 
the model that AS160 RabGAP, which is 
required for basal intracellular retention of 
GLUT4, is recruited to GSV via an interaction 
with IRAP. However, AS160 recruitment to 
GLUT4 compartments and AS160 regulation 
of GLUT4 trafficking were unaffected by IRAP 
knockdown. These results demonstrate that 
AS160 is recruited to membranes by an IRAP-
independent mechanism, and that IRAP and 
AS160 have independent roles in basal GLUT4 
retention. 
17:10-17:40 Thursday, October 28, 2010
• Roberto De Pirro Memorial Lecture
• Hadi Al-Hasani
Obesity genes and their impact on insulin 
action: lessons from mouse genetics
Hadi Al-Hasani 
German Institute for Human Nutrition, Potsdam (DE)
Over the past years, human genome-wide 
association studies (GWAs) have revealed 
numerous genetic loci, some of which have been 
implicated to play roles in the pathogenesis 
of obesity and diabetes. However, very little is 
known about the molecular mechanisms by 
which these SNPs exert their function on the 
molecular and physiological level. Moreover, 
identification of relevant susceptibility genes for 
obesity and diabetes has been difficult, mainly 
because the risk has been attributed to the 
interaction of multiple variant genes with the 
environment, where each of these genes only 
makes a small contribution to overall heritability.
In addition to studies in humans, numerous 
genome-wide searches for obesity and diabetes 
genes, respectively, have been performed in 
mouse models. In this approach, two parental 
lines differing in a diabetes - and/or obesity 
- related phenotype are crossed to produce 
outcross populations that are then analyzed for 
molecular markers across the genome to search 
for obesity susceptibility loci (quantitative trait 
loci, QTL). These studies have shown a very 
complex picture of numerous QTL, contributing 
to the phenotype and gene/diet interactions. 
Nevertheless, identification of disease genes 
from these QTL has been mostly not successful.
Recently, we and others have succeeded in 
positional cloning of susceptibility genes for 
obesity and diabetes from polygenic mouse 
models. In this approach, subcongenic mouse 
strains were generated to establish minimal 
critical segments of the respective QTL, followed 
by gene expression profiling and sequencing 
of positional candidate genes. Among other 
allelic variants, we identified a loss-of-
function mutation in the gene Tbc1d1 which is 
predominantly expressed in skeletal muscle. In 
mice, inactivation of Tbc1d1 results in increased 
fatty acid oxidation and decreased glucose 
utilization in skeletal muscle. This shift in energy 
substrate preference from glucose to lipids 
as fuel in muscle confers leanness, improves 
glycemia, and leads to protection from diet-
induced obesity and diabetes. Our data indicate 
that dysregulation of substrate partitioning and 
adaptive organ crosstalk are key features in the 
development of obesity and diabetes.
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8:30-9:00 Friday, October 29, 2010
• Markku Laakso
Human gene variation affecting insulin 
action and secretion
Markku Laakso
Department of Medicine, University of Eastern Finland, 
Kuopio (FI)
Type 2 diabetes is a strongly inherited disease, 
but the genetic basis of this disease has 
remained largely unknown until recent years. 
Both impaired insulin secretion and insulin 
resistance, two main pathophysiological 
mechanisms leading to type 2 diabetes, have a 
significant genetic component. Genome-wide 
association studies (GWAS) published since 2007 
have substantially increased our knowledge 
on the genes increasing the risk of type 2 
diabetes. There are currently about 20 common 
loci that increase the risk of type 2 diabetes 
(> 10 new SNPs will be shortly published). 
Only a few of these SNPs are actually known 
to affect the structure of a gene product or 
gene expression with a credible link to glucose 
metabolism. Therefore, for the majority of the 
SNPs the functionality has not been proven 
yet, and it is possible that the causal variants 
are not the SNPs published, but are located 
at varying distances from the ‘real’ functional 
gene. However, the unexpected conclusion from 
these studies is that a large number of diabetes 
SNPs are close to genes expressed highly in 
the pancreas and several of these SNPs have 
been shown to be associated with reduced 
b-cell dysfunction in non-diabetic subjects. 
Only a few SNPs have been associated with 
insulin resistance (PPARG2, IRS1). Interestingly, 
type 2 diabetes risk SNPs do not much overlap 
with the SNPs regulating fasting or 2-hour 
glucose levels. The conclusion from these 
studies seems to be that in a majority of cases 
type 2 diabetes develops as a consequence of 
a combination of inherited b-cell defect and 
acquired insulin resistance (obesity, lack of 
exercise, etc.). Copy number variants are not 
likely to be important genetic determinants of 
type 2 diabetes. Genome-wide sequencing and 
large scale studies aiming to investigate the 
interaction between gene variants and lifestyle/
environmental factors will substantially increase 
our knowledge on gene-gene and gene-lifestyle 
interactions that are determining the “epidemic” 
of type 2 diabetes worldwide.
9:00-9:30 Friday, October 29, 2010
• I. karen Temple
Epigenetics and diabetes; lessons 
from transient neonatal diabetes and 
disorders of imprinting
I. Karen Temple
School of Medicine, University of Southampton (UK)
Different cells and tissue types in the body 
are characterised by different levels of gene 
expression despite each cell sharing the same 
genetic code. This variation in gene activity from 
cell to cell is achieved by different configurations 
of chromatin (DNA and associated proteins) 
that generally exists in either a transcriptionally 
permissive or silent state. Chromatin is modified 
partly through the addition or loss of small 
molecules such as acetyl groups to histone 
proteins or methyl groups to cytosine residues 
within CpG dinucleotides in the DNA sequence. 
These epigenetic changes can therefore alter 
gene expression without altering the DNA 
sequence. The reversibility of the epigenetic 
‘marks’ sets them apart from DNA mutation and 
they are heritable over rounds of cell division. 
Epigenetic modification can be influenced by 
environment, gene interaction or by stochastic 
error and there is a two fold higher rate of 
epimutation than DNA mutation. 
Epigenetic modification is well recognised as a 
cause of human disorders and is likely to play a 
pivotal role in the cause of complex disorders. 
The challenge is to identify consistent epigenetic 
alterations of aetiological significance, given that 
epigenetic modification of DNA differs between 
tissues, at different times of development within 
the same tissue and is sensitive to continual 
environmental factors.
Genomic imprinting is one of the best 
understood examples of epigenetic regulation 
of gene expression. The expression patterns of 
imprinted genes are characterised by expression 
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from only one allele (of the pair) in a consistent 
parent of origin manner. The pattern is set by 
targeted methylation within the male or female 
germ line that resists the post fertilisation waves 
of demethylation of the zygote. Imprinted genes 
are thought to play an important role in fetal 
growth and their carefully regulated expression 
is important for normal cellular metabolism. 
Imprinted genes are therefore candidate 
predisposition genes for disorders such as 
diabetes. 
Several well known disorders of imprinting 
predispose to type 2 diabetes including Prader 
Willi syndrome. However the main imprinted 
locus clearly linked to diabetes, is PLAGL1 at 
6q24. Genetic and epigenetic aberrations that 
result in overexpression of PLAGL1, cause 
transient neonatal diabetes (TND) with a high 
risk of type 2 diabetes in later life. 20% of 
TND (type 1) cases have an epigenetic loss 
of methylation to account for the phenotype. 
Studies to determine the cause of epigenetic 
aberrations identified in imprinting disorders 
may provide helpful insights into the causes of 
epigenetic aberrations in general. For example 
the work has led to the identification of ZFP57 
as a methylation control gene. Imprinted 
regions are also a possible explanation for 
the recent observation of sex dependent risk 
of transmission for more common types of 
Diabetes (DM1 and DM2).
10:30-11:00 Friday, October 29, 2010
• Juleen Zierath
Gene/environment influence on skeletal 
muscle insulin sensitivity in type 2 
diabetic patients
Juleen R. Zierath
Section of Integrative Physiology, Dept. of Molecular 
Medicine and Surgery, Karolinska Institutet, Stockholm (SE)
Skeletal muscle is an important site of insulin-
mediated glucose uptake and defects in this 
insulin target tissue precede the manifestation 
of Type 2 diabetes. Our central hypothesis is 
that activation of insulin-independent pathways 
to glucose transport in skeletal muscle may 
overcome the profound impairment in whole 
body glucose homeostasis associated with Type 
2 diabetes. Intensive research efforts have been 
directed towards understanding the regulation 
of insulin-dependent and insulin-independent 
pathways governing glucose metabolism 
and the factors causing insulin resistance in 
Type 2 diabetes. Physical exercise/muscle 
contraction elicits an insulin-independent 
increase in glucose transport and perturbation 
of this pathway may bypass defective insulin 
signaling. To date, the exercise-responsive 
signaling molecules governing glucose 
metabolism in skeletal muscle are largely 
unknown. Epigenetic modification through 
DNA methylation is implicated in metabolic 
disease and may play a role in the mechanism 
by which environmental factors influence 
metabolic responses in diabetes. Using whole 
genome promoter methylation analysis of 
skeletal muscle from normal glucose tolerant 
and Type 2 diabetic subjects, we identified 
cytosine hypermethylation of Peroxisome 
Proliferator-Activated Receptor γ Coactivator-1 
α (PGC-1α) in diabetic subjects. Methylation 
levels were negatively correlated with PGC-
1α mRNA and mitochondrial DNA (mtDNA). 
Bisulfite sequencing revealed that the highest 
proportion of cytosine methylation within PGC-
1α was found within non-CpG nucleotides. 
Non-CpG methylation was acutely increased in 
human myotubes by exposure to tumor necrosis 
factor-α (TNF-α) or free fatty acids, but not 
insulin or glucose. Selective silencing of the DNA 
methyltransferase 3B (DNMT3B), but not DNMT1 
or DNMT3A, prevented palmitate-induced 
non-CpG methylation of PGC-1α and decreased 
mtDNA and PGC-1α mRNA. We provide evidence 
for PGC-1α hypermethylation, concomitant 
with reduced mitochondrial content in Type 2 
diabetic patients, and link DNMT3B to the acute 
fatty-acid induced non-CpG methylation of 
PGC-1α promoter. By identifying the molecular 
mechanisms controlling insulin sensitivity, 
future development of pharmacological and 
physiological (exercise and diet) intervention 
strategies aimed to improve glucose 
homeostasis may be possible.
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11:00-11:30 Friday, October 29, 2010
• Christopher B. Newgard
Metabolic drivers of insulin resistance 
and related disorders
Christopher B. Newgard
Sarah W. Stedman Nutrition and Metabolism Center &
Department of Pharmacology & Cancer Biology
Duke University Medical Center, Durham (NC USA)
We seek to apply comprehensive metabolic 
analysis tools (sometimes called 
“metabolomics”) for understanding of 
mechanisms underlying chronic human diseases 
such as diabetes, obesity, and cardiovascular 
disease. Current approaches include analysis 
of metabolic flux by 13C NMR-based mass 
isotopomer analysis (in collaboration with 
Drs. Shawn Burgess and A. Dean Sherry and 
associates, Dallas, TX) and metabolic profiling 
of important groups of metabolic intermediates 
by both “targeted” and “unbiased” mass 
spectrometry (in collaboration with Drs. James 
Bain, Robert Stevens, Olga Ilkayeva, Brett 
Wenner, Michael Muehlbauer, Mark Butler, and 
David Millington at Duke). These tools have been 
used to investigate the metabolic mechanisms 
underlying development of peripheral insulin 
resistance in animals and humans. Studies 
led by Drs. Debbie Muoio and Tim Koves at 
the Stedman Center have demonstrated a 
“disconnect” between mitochondrial b-oxidation 
and TCA cycle activity that leads to accumulation 
of incompletely oxidized lipids in the 
mitochondria and impairment of insulin actions. 
We have also recently identified perturbations of 
branched chain amino acid (BCAA) catabolism 
in multiple cohorts of insulin resistant humans 
compared to normally insulin sensitive controls 
and have translated these findings to rodent 
models to demonstrate a contribution of BCAA 
to development of insulin resistance that is 
independent of body weight. We have also 
found that BCAA supplementation induces 
behavioral changes in rats that can be reversed 
by provision of tryptophan in the drinking water. 
Finally, in collaboration with Dr. Alan Attie at 
the University of Wisconsin, we have integrated 
transcriptomic and metabolomic analysis to 
identify new pathways that control hepatic 
gluconeogenesis and PEPCK expression. These 
examples will serve to illustrate the potential 
of comprehensive metabolic profiling methods 
for providing insights into diabetes and obesity 
mechanisms. 
14:00-14:30 Friday, October 29, 2010
• Bernard Thorens
IGF-2 and IGF-1 receptor in the control of 
b-cell mass and function 
Bernard Thorens
Department of Physiology and Center for Integrative 
Genomics
University of Lausanne (CH)
To preserve glucose homeostasis in face of 
increased metabolic demand, the pancreatic 
beta-cells increase their total number and/
or insulin secretion capacity and type 2 
diabetes is caused by defects in this adaptive 
mechanisms leading to reduced b-cell mass 
and reduced glucose competence. The 
molecular mechanisms that control b-cell 
replication or neogenesis from precursors, their 
glucose competence and protection against 
apoptosis are still uncompletely defined. The 
gluco-incretin hormones GLP-1 and GIP can 
induce b-cell proliferation, increased glucose 
competence and protection against apoptosis. 
To identify novel regulatory pathway controlling 
these trophic effects, we performed comparative 
transcriptomic analysis of islets from control and 
GipR-/-;Glp-1-R-/- mice, which show reduced 
glucose competence and increased sensitivity to 
cytokine-induced apoptosis. We found that IGF-1 
receptor expression was markedly reduced in 
the mutant islets. As the IGF-1 receptor signaling 
pathway is known for its anti-apoptotic effect, 
we explored the relationship between gluco-
incretin action, IGF-1 receptor expression and 
signaling, and glucose competence, proliferation 
and apoptosis. These studies led us to identify 
the presence in b-cells of an autocrine loop that 
depends on IGF-1R expression and secretion 
of IGF-2. We demonstrated that GLP-1 induced 
IGF-1R expression by a translational mechanism 
and a parallel phosphorylation of Akt. Akt 
phosphorylation was however dependent on 
IGF-2 secretion by the b-cells. Furthermore, we 
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showed that GLP-1-induced b-cell proliferation, 
protection against cytokine-induced apoptosis 
and increased glucose competence were 
dependent on IGF-1R up-regulation and IGF-
2 secretion. Thus, an IGF-2/IGF-1 receptor 
autocrine loop operates in b-cells and its 
activation is required for all GLP-1 trophic 
effects on b-cells. These data provides a novel 
integrated view of the GLP-1 and IGF-R signaling 
pathway in b-cell physiology.
14:30-15:00 Friday, October 29, 2010
• Rohit N. kulkarni
Intra-islet insulin signalling regulates 
α-cell function in vivo
Rohit N. Kulkarni 
Islet Biology and Regenerative Medicine, Joslin Diabetes 
Center and Department of Medicine, Harvard Medical 
School, Boston (MA USA)
Glucagon is an important counter-regulatory 
hormone to insulin, and counters hypoglycemia 
by enhancing hepatic glucose output and 
regulating gluconeogenesis. The secretion 
of glucagon from α cells is promoted by 
hypoglycemia, and inhibited by hyperglycemia 
as well as by insulin. In type 2 diabetes, 
enhanced glucagon secretion is often seen 
under hyperglycemia. On the other hand, 
glucagon non-responsiveness to hypoglycemia 
is observed to worsen in patients with type 1 
diabetes on long-standing insulin therapy. Data 
will be presented from studies to investigate the 
importance of insulin signaling in α cells using  
α cell specific insulin receptor (IR) knockout 
mice and will involve discussion regarding the 
role of intra-islet signaling in the control of  
α cell function and proliferation.
16:00-16:30 Friday, October 29, 2010
• Jens C. Brüning
Central regulation of energy metabolism 
by insulin
Jens C. Brüning
Institute for Genetics, University of Cologne (DE)
Insulin action in the CNS plays a critical role 
in the regulation of energy homeostasis and 
peripheral glucose metabolism. In turn, insulin 
resistance in the CNS significantly contributes to 
altered peripheral glucose metabolism. We have 
revealed a critical role for insulin action in agouti 
peptide related peptide (AgRP)-expressing 
neurons in mediating insulin’s ability to suppress 
hepatic glucose production. The presentation 
will focus on the role of insulin action in other 
defined neuronal populations and on the 
molecular mechanisms, how inflammatory 
signals inhibit neuronal insulin action.
16:30-17:00 Friday, October 29, 2010
• Suzanne Craft
Insulin-resistance and 
neurodegeneration: novel mechanisms 
and therapeutic implications
Suzanne Craft
Professor of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle (WA USA)
Our knowledge of the multifaceted role of insulin 
in the central nervous system has expanded 
rapidly in recent years. It is now apparent that 
perturbation of this role by insulin resistance 
and hyperinsulinemia can increase the risk 
for aging-related neurodegenerative disorders 
such as Alzheimer’s disease a number of 
mechanistic pathways, delineated in elegant in 
vitro and animal studies. We have investigated 
these pathways in humans using models of 
insulin resistance and hyperinsulinemia. We 
will present results suggesting that insulin-
associated effects on cerebral glucose 
metabolism, Ab regulation and inflammation 
contribute to AD pathophysiology. This premise 
raises the possibility that treatments aimed at 
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improving or overcoming insulin resistance will 
benefit patients with AD. We will present data 
testing this possibility in pilot therapeutic trials 
using insulin intranasal insulin. 
9:30-10:00 Saturday, October 30, 2010
• Reuben J. Shaw
AMPk signaling in glucose metabolism 
and growth control
Reuben J. Shaw 
Howard Hughes Medical Research Institute
Molecular and Cell Biology Laboratory
Dulbecco Center for Cancer Research
Salk Institute for Biological Studies 
La Jolla (CA USA)
AMPK is a highly conserved sensor of cellular 
energy status found in all eukaryotic cells 
which reprograms metabolism and suppresses 
cell growth upon its activation. The serine/
threonine kinase LKB1 is the upstream kinase 
which activates AMPK under conditions of low 
intracellular ATP. In addition, LKB1 is a human 
tumor suppressor gene mutated in the familial 
cancer condition Peutz-Jeghers syndrome (PJS), 
as well as in 30% of sporadic non small cell 
lung cancer (NSCLC). Consistent with playing 
key roles in tumor suppression and metabolic 
control, loss of function of LKB1 in genetically 
engineered mice leads to tumor formation or 
metabolic disease depending on the tissue 
deletion is induced in. In addition, utilizing liver-
specific LKB1 knockout mice, we demonstrated 
that the widely used type 2 diabetes therapeutic 
metformin acts to lower blood glucose through 
the LKB1 pathway in liver. To try to further 
undestand the molecular bases behind these 
profound anti-cancer and anti-diabetes effects, 
we have sought to identify new components of 
the AMPK pathway. As one arm of that effort, 
using a proteomic and bioinformatics approach, 
we have performed a screen to identify novel 
AMPK substrates which mediate its effects on 
cell growth and metabolism. One of the first new 
substrates we identified was the mTOR-binding 
subunit raptor, which we demonstrated as a 
critical substrate of AMPK mediating its effects 
on growth control. Phosphorylation of raptor by 
AMPK is required for the inhibition of mTORC1 
and for cell cycle arrest following energy stress. 
These findings uncover a novel conserved 
effector of AMPK that mediates its role as a 
metabolic checkpoint coordinating cell growth 
with energy status. More recently, we have 
also characterized novel substrates of AMPK 
involved in its transcriptional control of glucose 
metabolism in liver that relate to the ability of 
this pathway to control type 2 diabetes, which 
will be discussed.
10:00-10:30 Saturday, October 30, 2010
• Michael Pollak
Insulin signaling and metformin in 
relation to cancer: new developments
Michael Pollak
McGill University, Montreal (CA)
In contrast to insulin receptors (IRs) present on 
classic insulin target tissues, IRs of normal and 
transformed epithelial cells have no established 
role in the regulation of energy metabolism 
at the whole organism level. Rather, they may 
have physiologic roles resembling those of 
insulin-like signaling in primitive organisms, 
where receptor activation regulates apoptosis 
and proliferation. Much experimental and 
epidemiologic data support the hypothesis that a 
subset of cancers are responsive to physiologic 
insulin concentrations (reviewed in 1,2): as 
examples, (a) higher insulin levels are associated 
with poor prognosis of several common cancers 
such as prostate, colon, and breast, (b) insulin 
can stimulate cancer proliferation in vitro, and 
(c) there is circumstantial evidence that insulin 
is one of the mediators of the adverse effect of 
obesity on cancer prognosis.
In view of the above, research regarding 
targeting of insulin signaling (often in 
conjunction with targeting of IGF-I signaling) as 
a cancer treatment strategy has been proposed. 
Early efforts included the use of somatostatin 
analogues to lower insulin and IGF-I levels, 
but this was unsuccessful as the intervention 
achieved only minor reduction in ligand levels 
(3). Metformin is currently under study in 
this context, as it is known to reduce insulin 
naples, Italy
October 28 - 30, 2010
29
XI
InternatIonal
SympoSIum 
on InsulIn ReceptoRs
and InsulIn actIon
levels in settings of host insulin resistance 
and hyperinsulinemia, but metformin has little 
effect on IGF-I levels, or on insulin levels in the 
absence of baseline hyperinsulinemia. Small 
molecule insulin/IGF-I receptor kinase inhibitors 
are also being evaluated, and initial results 
justify further investigation as the expected 
metabolic toxicity is less than anticipated, 
and there is evidence of activity for particular 
subsets of cancers for which insulin and/or 
IGFs stimulate proliferation. Recent data in this 
area, including the use of treatment-induced 
hyperinsulinemia as a pharmacodynamic 
marker, will be reviewed. 
A related area of investigation concerns 
the hypothesis that exogenous insulin 
administration (or the administration of specific 
insulin analogues) may increase neoplastic 
proliferation. This is biologically plausible, 
but clinical and epidemiologic data remain 
controversial. While much attention has been 
given to the important issue of affinity of specific 
ligands to the various receptors in the insulin/
IGF receptor family, pharmacokinetic aspects 
are also important, as many forms of insulin 
therapy result in continuous exposure, in 
contrast to the more transient exposure seen in 
normal physiology. While it has been proposed 
that insulin therapy may slow cancer growth 
by reducing glucose levels (4), the fact that 
experimental tumors are growth inhibited in the 
hyperglycemic hypoinsulinemic environment of 
type I diabetes suggests that for some cancers, 
normoglycemic environments do not limit 
proliferation, but insulin facilitates aggressive 
behavior (5). 
Metformin and other biguinides are under 
study not only in relation to their insulin-
lowering properties mentioned above, but 
also in relationship to their action in activating 
AMP kinase and altering cellular energetics 
by inhibiting oxidative phosphorylation. While 
anti-neoplastic activity has been shown in many 
preclinical models, optimum design of clinical 
trials will require more information concerning 
pharmacokinetics and drug distribution, as 
well as identification of predictive biomarkers. 
This research direction is justified in part 
by epidemiologic research that associates 
metformin use in diabetes treatment with 
reduced cancer risk and cancer mortality – but 
relevance of these findings to non-diabetic 
populations remains to be established (6). 
1. Pollak M. Insulin and insulin-like growth factor 
signaling in neoplasia. Nat Rev Cancer 2008;8:915-28
2. Pollak M. Do cancer cells care if their host is hungry? 
Cell Metab. 2009 May;9(5):401-403
3. Pritchard K, Chapman M, Shepherd L, Pollak M. Octreotide 
plus tamoxifen in adjuvant treatment of breast cancer: 10 
year follow up of the NCIC MA.14 study. Submitted, 2010
4. Gerstein HC. Does insulin therapy promote, reduce, or 
have a neutral effect on cancers? JAMA. 2010;303(5):446-7.
5. Johnson JA, Pollak M, Insulin, glucose and the 
increased risk of cancer in patients with type 2 diabetes, 
in press Diabetoligica, 2010
6. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, 
Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. 
Diabetes and cancer: a consensus report. Diabetes Care. 
2010 Jul;33(7):1674-85
11:15-11:45 Saturday, October 30, 2010
• Morris F. white
The dark side of IRS-2: cancer and 
neurodegeneration
Morris F. White
Children’s Hospital Boston and Harvard Medical School, 
Boston (MA USA)
Dysregulation of the PI 3-kinase→AKT 
cascade contributes to metabolic disease 
and to oncogenesis. Insulin receptor (IR) and 
the type 1 insulin-like growth factor receptor 
(IGF1R) are two of the major regulators of 
PI3K signaling. Upon ligand-binding, the IR 
and IGF1R are autophosphorylated and recruit 
the adaptor proteins IRS1 and IRS2, which are 
phosphorylated by the receptor tyrosine kinase. 
The phospho-IRS proteins recruit the 85 kDa 
regulatory subunit of PI3K, which activates the 
110 kDa catalytic subunits, generates PtdIns-
3-4-5-P3, and activates PDK1, AKT1, AKT2, 
mTOR, and S6K cascades. Pten+/--mice develop 
tumors in multiple organs because of the 
reduced hydrolysis of PtdIns-3-4-5-P3. Although 
activation of PI3K→AKT cascade usually inhibits 
IRS2 expression, an elevation of IRS2 is often 
detected in tumor samples in which PTEN levels 
were compromised. To determine the potential 
30
contribution of IRS2 to tumor progression,  
Pten+/--mice were crossed with IRS2+/--mice. 
Deletion of IRS2 did not affect the initiation of 
neoplasia found in Pten+/--mice, but suppressed 
cancer cell growth, proliferation, and invasion 
through the basement membrane. Deletion 
of IRS2 also attenuated the expression of 
Myc in prostatic intraepithelial neoplasia in 
Pten+/--mice. In addition, the expression levels 
of IRS2 and MYC were highly correlated in 
human prostate cancer, and IRS2 stimulated 
MYC expression in cultured cells. Thus, IRS2 
promotes tumor progression in Pten+/--mice 
by stimulating both Myc and DNA synthesis 
(Szabolcs M et al. Am J Pathol 2009, 174:276–
286). IRS2 also plays a critical role in nutrient 
homeostasis because it mediates insulin 
signaling in liver, skeletal and cardiac muscle, 
b-cells, endothelial cells and brain. Peripheral 
insulin resistance contributes to metabolic 
disease and type 2 diabetes, whereas reduced 
neuronal insulin-like signaling can delay 
ageing, and less IRS2 signaling throughout the 
body or just in the brain extends mouse life 
span (Taguchi A et al. Science 2007, 317:369-
372). Aging is a major risk factor for the 
progression of neurodegenerative disease. To 
determine whether IRS2 signaling modulates 
neurodegeneration we investigated R6/2-mice 
that develop Huntington’s disease (HD) and 
die around 15 weeks of age. Increasing IRS2 
expression in the R6/2-brain (R6/2•IRS2ntg) 
reduced the life span to 11 weeks, whereas 
decreasing IRS2 throughout the body—except 
in the b-cells where it was needed to prevent 
diabetes (R6/2•IRS2+/- •IRS2btg)—extended life-
span to 25 weeks. The slower progression of HD 
was associated with more nuclear FoxO1, and 
increased concentration of Sod2 and Pparg1α. 
Aggregate formation typical of HD progression, 
along with astrocytosis and oxidative stress 
decreased in R6/2•IRS2+/-•IRS2btg-mice, while 
the number of autophagosomes increased and 
motor function improved. Our results show 
how the progression of HD—and life span 
in general—can be linked to the insulin-like 
signaling cascade through the IRS2-branch of 
the pathway (Sadagurski M. et al. submitted). 
In summary, IRS2 signaling is critical for 
nutrient homeostasis, but it also promotes 
tumor progression and neurodegeneration that 
diminishes longevity.
11:45-12:15 Saturday, October 30, 2010
• Norbert Tennagels
Metabolic and mitogenic signaling of 
exogenous insulin(s)
Norbert Tennagels 
R&D BD Diabetes, Frankfurt (DE)
Introduced more than 10 years ago, the 
treatment of diabetic patients with insulin 
analogs has been shown to provide a more 
efficient, reproducible, and convenient therapy 
than regular insulin. Depending on the 
pharmacokinetic and –dynamic profile and the 
underlying mode of action, which is achieved 
either by sequence or secondary modifications, 
insulin analogs may vary from insulin with 
respect to metabolic potency, stability, tissue 
specificity, onset and duration of action. Since 
these changes may lead to an altered interaction 
or activation profile of insulin and/or IGF 
receptor signaling pathways and in consequence 
may change metabolic or mitogenic responses, 
a careful investigation of acute and long-
term effects has to be a major focus in the 
development of these molecules. 
One prominent example for an unwanted effect 
is [AspB10]insulin, which has a higher affinity 
towards both insulin receptor (IR) and IGF-
1 receptor (IGF1R) than insulin, a prolonged 
occupancy time for the IR and has induced a 
higher incidence of breast cancer in rats and 
a higher proliferation rate of mammalian cell 
lines. This has led to the contention that insulins 
having a similar profile - especially an increased 
affinity towards IGF1R in vitro - might have a 
potential cancer promoting activity as well. 
However, the relevance of binding affinities to 
IGF1R and insulin therapy is still a matter of 
debate, since i) variable results for different 
insulin analogs from in vitro proliferation assays 
do not support this view with confidence and ii) 
additional aspects reflecting the in vivo situation 
e.g. the competition with endogenous free IGF-1 
or the distribution and the metabolism of an 
insulin analogs, critically affect the initiation 
of metabolic and mitogenic signaling as well. 
Insulin glargine, a long-acting basal insulin 
analog, displays the slightly increased IGF1R 
activity comparable to that of [AspB10]insulin 
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in vitro but did not show any difference in the 
incidence of mammary tumors in mice and rats 
compared to controls or NPH insulin in 2-year 
carcinogenicity studies. The analog undergoes 
rapid and significant metabolism in humans and 
animals leading to the formation of two main 
metabolites, M1 and M2, which have a metabolic 
profile comparable to the parent molecule but 
at the same time a mitogenic profile identical to 
insulin in vitro. Therefore it’s suggested that the 
degradation and the action of the metabolites 
significantly contribute to the established 
efficacy and safety of insulin glargine as 
observed in clinical practice and particularly 
in long-term clinical trials and emphasize the 
importance of examining all steps in the action 
of an insulin analog in vitro and in vivo. 
14:30-15:00 Saturday, October 30, 2010
• Fatima Bosch
Gene therapy in diabetes
Fatima Bosch
Center of Animal Biotechnology and Gene Therapy and 
Department of Biochemistry and Molecular Biology, 
Universitat Autonoma de Barcelona, Bellaterra, and CIBER 
de Diabetes y Enfermedades Metabólicas Asociadas 
(CIBERDEM), Barcelona (ES) 
Diabetes mellitus is a chronic disease with 
severe secondary complications driven by poor 
glycemic control for which there is no cure. 
Although insulin therapy allows type 1 diabetic 
patients to lead normal, active lives, it has 
associated risks, mainly acute hypoglycaemia 
and development of retinopathy, nephropathy 
and neuropathy. Gene therapy is a new approach 
to treat diabetes where the main aim is to 
develop a way to engineer tissues to maintain 
normoglycaemia. We previously demonstrated 
the feasibility of a potential gene therapy 
strategy based upon engineering skeletal 
muscle to take up glucose by co-expressing 
insulin and glucokinase (GK). Both genes act 
synergistically such that local production of 
human insulin (hIns) improves glucose uptake, 
whereas GK acts as a glucose sensor in a 
concentration-dependent manner to facilitate 
glucose disposal. We showed reversal of diabetic 
hyperglycemia in AAV1-treated diabetic mice. 
Our objective was to undertake a pre-clinical 
assessment of this combined therapy in diabetic 
beagle dogs as a step towards treatment of 
human diabetes. We wished to determine (1) 
the feasibility and relative efficiency of AAV1-
CMV-hIns treatment in large animals; (2) the 
minimal effective dose of AAV1-CMV-hIns; (3) 
the feasibility of co-injecting AAV1-CMV-hIns 
and AAV1-CMV-GK; and finally (4) the duration 
of effects, as well as any biochemical and safety 
issues. Our results indicate that a single viral 
injection can mediate long term survival for 
greater than two years with sustained benefit 
to glycemic control, body weight and with no 
detriment to physical performance. In this 
presentation, this new gene therapy approach 
for type 1 diabetes from our group will be 
discussed. 
15:00-15:30 Saturday, October 30, 2010
• Markus Stoffel
18:00-18:30 Saturday, October 30, 2010
• Ulrich Häring
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C01.1 - New concepts in insulin signal transduction
A NOVEL PROTEIN ENHANCES INSULIN-STIMULATED AKT PHOSPHORYLATION AND GLUT4 TRANSLOCATION IN ADIPOCYTES
Zhou Qiong L1, Jiang Zhen Y2, Holik John1, Mabardy Allan1, Straubhaar Juerg1, Nicoloro Sarah1, Chawla Anil1, Del Campo Claudia M1, Lambright 
David G1, Czech Michael P1
1University Of Massachusetts Medical School, Worcester, Usa; 2Burnham Institute For Medical Research, Orlando, Usa
Protein kinase B/Akt protein kinases control an array of diverse functions including cell growth, survival, proliferation and 
metabolism. We report here the identification of Pleckstrin Homology-like domain family B member 1 (PHLDB1) as an insulin 
responsive protein that enhances Akt activation. PHLDB1 contains a PH domain, which we demonstrated binds phosphatidylinositol 
(PI)(3,4)P2, PI(3,5)P2 and PI(3,4,5)P3, as well as an FHA domain and coiled coil regions. PHLDB1 expression is increased during 
adipocyte differentiation, and it is abundant in many mouse tissues. Both endogenous and HA or GFP tagged PHLDB1 displayed 
a cytoplasmic disposition in unstimulated cultured adipocytes, but translocated to the plasma membrane in response to insulin. 
Depletion of PHLDB1 by siRNA inhibited insulin stimulation of Akt phosphorylation but not IRS-1 phosphorylation. RNAi-based 
silencing of PHLDB1 in cultured adipocytes also attenuated insulin-stimulated deoxyglucose transport and myc-GLUT4-EGFP 
translocation to the plasma membrane, while knockdown of the PHLDB1 isoform PHLDB2 failed to attenuate insulin-stimulated 
deoxyglucose transport. Furthermore, adenovirus-mediated expression of PHLDB1 in adipocytes enhanced insulin-stimulated Akt 
and p70S6 kinase phosphorylation, as well as GLUT4 translocation. These results indicate that PHLDB1 is a novel modulator of Akt 
protein kinase activation by insulin.
C01.2 - New concepts in insulin signal transduction
IGF-IR INTERNALIZES WITH CAVEOLIN-1 AND PTRF/CAVIN IN HACAT CELLS
Salani Barbara1, Passalacqua Mario2, Maffioli Sara1, Briatore Lucia1, Contini Paola3, Cordera Renzo1, Maggi Davide1
1Department Of Endocrinology And Medicine (DISEM), University Of Genova, Genova, Italy ; 2Department Of Experimental Medicine (dimes), 
University Of Genova, Genova, Italy; 3Department Of Internal Medicine And Medical Specialties (DIMI), University Of Genova, Genova, Italy
Insulin like growth factor-I receptor (IGF-IR) is a tyrosine kinase receptor (RTK) that associates with caveolae, invaginations of the 
plasma membrane that regulate vesicular transport, endocytosis and intracellular signaling. IGF-IR internalization represents a key 
mechanism of down-modulation of receptor number on plasma membrane. IGF-IR interacts directly with Caveolin-1 (Cav-1), the most 
abundant protein of caveolae. Recently it has been demonstrated that the Polymerase I and Transcript Release Factor I (PTRF/Cavin) 
is required for caveolae formation and it affects their morphology. The role of Cav-1 and PTRF/Cavin in IGF-IR receptor internalization 
is still to be clarified. We have investigated the interaction of IGF-IR with Caveolin and PTRF/Cavin in the presence of IGF-I in human 
Hacat cells. We show that IGF-IR internalization triggers Cav-1 and PTRF/Cavin translocation from plasma membrane to cytosol and 
increases its interaction with these proteins. In fact Caveolin-1 and PTRF/Cavin co-immunoprecipitate with IGF-IR during receptor 
internalization. We found a different time course of coimmunoprecipitation between IGF-IR and Cav-1 compared to IGF-IR and PTRF/
Cavin. Cav-1 and PTRF/Cavin silencing by siRNA differently affect IGF-IR plasma membrane expression following IGF-I treatment: 
Cav-1 silencing affects significantly IGF-IR rate of internalization whereas PTRF/Cavin silencing decreases IGF-IR plasma membrane 
recovery. These data indicate that Caveolae play a role in IGF-IR internalization. Based on these findings, Cav-1 and PTRF/Cavin, new 
player in IGF-IR trafficking, could represent two relevant and distinct targets to modulate IGF-IR function.
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C02.3 - The role of adipose tissue in insulin action
INSULIN REGULATES THE SPATIAL DISTRIBUTION OF GLUCOSE TRANSPORTER-4 ON THE CELL SURFACE
Stenkula Karin G1, Lizunov Vladimir A2, Cushman Samuel W1, Zimmerberg Joshua2
1National Institute Of Diabetes And Digestive And Kidney Diseases, Nih, Bethesda, Usa; 2Eunice Kennedy Schriver National Institute Of Child 
Health And Human Development, Nih, Bethesda, Usa
Glucose transporter-4 (GLUT4) are key players in insulin-regulated glucose metabolism, insulin resistance, and type-2 diabetes. 
Nevertheless, the dynamic spatial organization of GLUT4 in the plasma membrane (PM) is unclear. Here, we applied multi-color TIRF 
microscopy to visualize HA-GLUT4-GFP/mCherry dynamic recycling in live adipose cells. We demonstrate that insulin regulates not 
only the exocytosis of GLUT4 storage vesicles, but also the PM distribution of GLUT4 themselves. In basal cells, we find the majority 
of GLUT4 distributed in bright spots close to PM that may represent GLUT4 vesicles, and intermediates of exo- and endocytosis of 
GLUT4, as well as domains/clusters of GLUT4 molecules in PM. We detected fusion of single GLUT4 vesicles by doubly labelling 
them with GLUT4-mCherry and insulin-regulated aminopeptidase (IRAP)-pHluorin. Indeed, domains (clusters) of GLUT4 molecules 
in PM are created by a mode of exocytosis that retains GLUT4 at the fusion site. Surprisingly, when insulin induces a burst of 
GLUT4 exocytosis, it does not merely accelerate this basal exocytosis, but rather stimulates ~60-fold another mode of exocytosis 
that disperses GLUT4 into PM, bypassing the domains. We further tested GLUT4 association with clathrin-coated pits which has 
been implicated in the recycling of GLUT4. However, in contrast to previous findings, clathrin does not initiate clustering of GLUT4. 
Rather, internalization of most GLUT4, regardless of insulin, occurs from pre-existing clusters via the subsequent recruitment of 
clathrin. Taken together, these data fit a new kinetic model that features multifunctional clusters as intermediates of exocytosis and 
endocytosis.
C02.4 - The role of adipose tissue in insulin action
ANKRD26 GENE ABLATION CAUSES DIABETES IN MICE
Raciti Gregory A1, Bera Tapan1, Gavrilova Oksana2, Pastan Ira1
1Laboratory Of Molecular Biology, Nci, Nih, Bethesda, Usa; 2Mouse Metabolism Core, Niddk, Nih, Bethesda, Usa
Background and aims: the ANKRD26 gene is expressed in most organs of humans and mice with expression in brain being 
particularly high. Mice with partial inactivation of Ankrd26 have hyperphagia, extreme obesity and an increase in body size. Mice with 
complete inactivation of the gene are homozygous lethal. Since obesity is one of the major risk factors for diabetes, we performed 
metabolic characterization of the Ankrd26 MT mice, to examine the possible role of the Ankrd26 gene in the regulation of glucose 
homeostasis. Results: six-month old Ankrd26 MT mice with extreme obesity, weighing ~ 55 grams, developed a severe impairment 
of glucose tolerance during GTT. This defect was accompanied by an impairment of glucose-induced insulin secretion. The MT mice 
also showed a decreased response to insulin during an ITT and had high fasting insulin levels, suggesting the presence of insulin 
resistance. To assess insulin resistance in individual tissues, we performed hyperinsulinemic-euglycaemic clamps in the Ankrd26 
MT mice. The mice exhibited whole body insulin resistance as measured by a reduced glucose infusion rate and glucose disposal. 
The effect was due to hepatic suppression of endogenous glucose production and reduction of 2-deoxy-glucose (DG) uptake into 
skeletal muscle and BAT. But 2DG uptake into WAT was not affected. Conclusion: the partial inactivation of the Ankrd26 gene in mice 
is sufficient to impair both insulin sensitivity and insulin secretion leading to the development of diabetes in MT mice. Further studies 
will be directed at determining the molecular mechanisms by which partial Ankrd26 inactivation leads to these abnormalities.
C03.5 - Insulin signalling in peripheral tissues
CHRONIC APELIN TREATMENT IN HFD-FED MICE IMPROVES b-OxYDATION AND INSULIN RESISTANCE
Camille Attané1, Chloé Rancoule1, Sophie Le Gonidec1, Camille Foussal1, Alexandre Bénani2, Cédric Dray1, Rocio Guzman-Ruiz3, Danièle Daviaud1, 
Mariano Ruiz-Gayo3, Luc Pénicaud2, Philippe Valet1, Isabelle Castan-Laurell1
1Inserm U858, Toulouse, France; 2Centre Des Sciences Du Gout Et De L’Alimentation, Dijon, France; 3University Of Ceu-San Pablo, Madrid, Spain
We have recently shown that acute apelin treatment decreases glycemia in mice and stimulates glucose uptake in skeletal muscle 
through an AMPK-dependent pathway. In insulin-resistant mice, apelin also increases total glucose utilization. Since apelin appears 
as a beneficial peptide acting on glucose metabolism, the aim of the present study was to know the impact of chronic apelin 
treatment in insulin-resistant mice on lipid metabolism by studying fatty acid b-oxidation and on insulin sensitivity. For this purpose, 
HFD-fed mice were treated by an ip injection of either apelin (0.1 µmole/kg/d) or PBS during 28 days. Apelin treatment decreased 
the respiratory quotient (0.74±0.01 vs 0.70±0.01, n= 12 p< 0.05) in HFD-mice suggesting a better utilization of lipids. Indeed, apelin 
treatment increased complete oxidation of [14C]palmitate in soleus muscle (161±15 vs 332±61 nmol CO2 released/g protein, n=10, p< 
0.01). This effect was abolished in muscle of DN-AMPK mice where AMPK is inactive. A better mitochondrial oxidative capacity was 
observed in soleus of apelin-treated mice since the impaired respiratory index (1.27±0.03 vs 1.19±0.04, n=7) was corrected and the 
citrate synthase activity increased. Moreover, apelin-treated mice exhibited a better insulin sensitivity due to a) a decrease of C18-1 
acylcarnitines levels in muscle homogenates (24.8±6.6 vs 12.7±3.7 nmol/g prot, n= 7), b) a better glucose tolerance and c) an increase 
of insulin-stimulated glucose uptake in isolated skeletal muscle (2.4 fold increase vs 1.4 in PBS-treated mice). Thus, chronic apelin 
treatment improves insulin resistance by acting on both glucose and lipid metabolism.
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C03.6 - Insulin signalling in peripheral tissues
IS DEFECT INSULIN SIGNALING TO MITOCHONDRIA LINKED TO INSULIN RESISTANCE IN HUMAN MUSCLE?
Højlund Kurt1, Zhao Xiaolu2, Kristensen Jonas M3, Skov Vibe H.1, Jensen Ole N2, Yi Zhengping4, Mandarino Lawrencce J4, Wojtaszewski Jørgen 
FP3, Beck-Nielsen Henning1
1Odense University Hospital, Odense, Denmark; 2Protein Research Group, University Of Southern Denmark, Odense, Denmark; 3Copenhagen 
Muscle Research Centre, University Of Copenhagen, Copenhagen, Denmark; 4Center For Metabolic Biology, Arizona State University, Tempe, 
Arizona, United States
Recent data suggest a link between insulin resistance and impaired mitochondrial oxidative phosphorylation (OxPhos) in human 
skeletal muscle. It remains, however, to be clarified whether mitochondrial dysfunction is a cause or consequence of insulin 
resistance. In addition to decreased abundance of OxPhos genes and proteins, we have shown compromised intrinsic function of 
mitochondria in muscle in type 2 diabetes (T2D) indicating a role for post-translational regulatory mechanisms. Supporting the idea 
that an impaired biological response to insulin contributes to mitochondrial dysfunction, we have now data showing that genetically 
determined insulin resistance due to a mutation in the insulin receptor gene (Arg1174Gln) causes down-regulation of OxPhos genes 
and proteins in muscle in vivo. There is growing evidence that several subunits in OxPhos are phosphorylated, and that several 
cytosolic kinases translocate into mitochondria in response to different stimuli. Recently, we reported that the catalytic beta-subunit 
in the ATP synthase complex are phosphorylated at several sites, and that some of these sites showed altered phosphorylation in 
muscle in obesity and T2D. In mitochondria isolated from human muscle, we have now identified 126 phosphorylation sites in 63 
mitochondrial proteins using phosphoproteomics. We are currently investigating how these phosphorylation sites respond to insulin. 
Based on these observations, we hypothesize that altered phosphorylation of OxPhos proteins in response to different stimuli 
including insulin could play a role for the association of mitochondrial dysfunction with insulin resistance, and hence contribute to the 
pathogenesis of T2D.
C04.6 bis - Insulin action in obesity
ADIPOREDOxIN, AN ADIPOCYTE-ENRICHED NOVEL REGULATOR OF ADIPONECTIN ASSEMBLY/SECRETION
Pilch Paul1, Jedrychowski Mark1, Meshulam Tova1, Ding Shi-ying1, Fried Susan1
1Boston University School Of Medicine, Boston, Usa
We have characterized by mass spectrometry the protein content of insulin-responsive Glut4 storage vesicles (GSVs) and GSV 
precursor compartments (JBC 2010, 285:104-14). In the latter compartments, we identified a member of the thioredoxin superfamily, 
whose members function to regulate cellular redox status and disulfide bond formation. We named this protein adiporedoxin 
(Arx) because it is expressed at appreciable levels only in brown and white fat and in testes, and it is markedly induced upon the 
differentiation of cultured adipocytes. Arx is a resident of the endoplasmic reticulum where secretory protein assembly and disulfide 
bond formation takes place, including for adiponectin, the insulin-sensitizing adipokine. To test the hypothesis that Arx might be 
involved in the assembly and/or secretion of adiponectin, we engineered fat cells over and under expressing Arx and determined that 
over expression enhanced adiponectin expression and secretion whereas under expression reduced adiponectin secretion. Chronic 
high fat feeding (HFD) of mice results in reduced adiponectin levels and insulin resistance, and therefore, we subjected mice to an 
HFD for 12 weeks, which resulted in a concomitant 90% loss of both adiponectin and Arx content in fat cells. Finally, we obtained 
mRNA array data from a cohort of obese humans and found that the expression of these two proteins was highly positively correlated 
(R = 0.77, P<0.05). Taken together, these data support the hypothesis that Arx is likely to be the principal regulator of adiponectin 
assembly and secretion, and thus its regulation and expression are likely to have important consequences for insulin sensitivity.
C04.7 - Genetic and epigenetic control of insulin action
ENVIRONMENTAL AND EPIGENETIC REGULATION OF THE DIABETES-RELATED PED/PEA-15 GENE
Teperino Raffaele1, Ciccarelli Marco2, Longo Michele2, Mirra Paola2, Manzo Italia2, Béguinot Francesco2, Ungaro Paola2
1Ecole Polytechnique Fèdèrale De Lausanne, Lausanne, Switzerland ; 2DBPCM, University Of Naples & IEOS-CNR, Naples, Italy
The molecular details of gene–environment interplay in type 2 diabetes (T2D) onset have recently received great attention. PED/PEA-
15 is a gene commonly overexpressed in tissues from T2D individuals and healthy subjects at high risk of developing diabetes (such 
as first degree relatives). Indeed, overexpression of the ped/pea-15 gene in mice, impairs glucose tolerance and leads to diabetes in 
conjunction with high-fat diet treatment. We have evaluated the influence of reactive oxygen species (ROS) on PED/PEA-15 regulation, 
representing oxidative stress a mechanism by which aberrant epigenetic programming leads to T2D. Incubation of THP-1 cells 
with hydrogen peroxide determines an increase in the binding of the transcription factor nuclear factor kB (NF-kB) to its response 
element on PED/PEA-15 promoter causing an up-regulation of PED/PEA-15 gene. This effect was accompanied by an increase 
both in dimethylation of lysine 4 (H3K4me2) and acetylation of Lysine 9 and Lysine 14 (AcH3) at PED/PEA-15 promoter and coding 
region, indicating that ROS determine chromatin modifications on PED/PEA-15 gene. Further co-immunoprecipitations experiments 
performed using NF-kB-p65 followed by H3K4me2 and AcH3 antibodies revealed both H3K4me2/NF-kB and AcH3/NF-kB complexes 
at the PED/PEA-15 promoter indicating that NF-kB recruitment is accompanied by histone di-methylation and acetylation at PED/
PEA-15 promoter. These results suggest that an inflammatory stimulus like hydrogen peroxide alter the epigenetic regulation of the 
PED/PEA-15 gene determining an increase of its expression. However, the former input starting the series of events leading to this 
alteration remains to be clarified.
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C04.8 - Genetic and epigenetic control of insulin action
ZFP69 AS A POTENTIAL MODULATOR OF OBESITY-ASSOCIATED DIABETES
Scherneck Stephan2, Vogel Heike2, Nestler Matthias2, Blüher Matthias1, Urbanski Sina2, Schulz Nadja2, Kluge Reinhart2, Schürmann Annette2, 
Joost Hans-Georg2
1University Of Leipzig, Leipzig, Germany; 2German Institute Of Human Nutrition Potsdam-rehbruecke, Nuthetal, Germany
Type 2 diabetes is a polygenic disease resulting from a combination of adipogenic and diabetogenic alleles. Here we report the 
identification of a candidate gene for the hyperglycemic effect of the mouse quantitative-trait locus (QTL) Nidd/SJL. The diabetogenic 
allele was contributed by the lean Swiss Jim Lambert (SJL) inbred mouse strain in an outcross population with New Zealand Obese 
(NZO) mice. In order to define a critical region of Nidd/SJL, we generated recombinant-congenic mouse lines carrying different 
intervals of the locus on the C57BL/6J background. These lines were crossed with NZO mice (reporter cross). Characterisation of 
the obese progeny led to the identification of a critical region of chromosome 4 comprising ten genes. Sequencing and expression 
profiling identified a striking variant of zinc finger domain transcription factor 69 (Zfp69). In NZO and C57BL/6J mice, an IAPLTR1a 
retrotransposon in intron 3 disrupted the gene by formation of a prematurely polyadenylated mRNA that lacked the coding sequence 
for the Krüppel-associated box (KRAB) and Znf-C2H2 domains of Zfp69. In contrast, the diabetogenic SJL allele generated a 
functional mRNA. When transferred to the B6.V-Lepob background, the diabetogenic Zfp69SJL allele produced hyperglycemia, 
reduced gonadal fat pads, and increased plasma and liver triglycerides. In addition, mRNA levels of the human ortholog of Zfp69, 
ZNF642, were significantly increased in white adipose tissue of patients with type 2 diabetes. Thus, the expression of the transcription 
factor Zfp69/ZNF642 in adipose tissue may play a role in the pathogenesis of type 2 diabetes.
C05.9 - Environmental control of insulin action and nutrient metabolism
PKC EPSILON REGULATES HEPATIC LIPID METABOLISM DURING SHORT TERM LIPID OVERSUPPLY
Raddatz Katy2, Turner Nigel2, Raftery Mark1, Frangioudakis Georgia2, Wilks Donna2, Preston Elaine2, Hegarty Bronwyn2, Leitges Michael3, 
Schmitz-Peiffer Carsten2
1University Of New South Wales, Sydney, Australia; 2Garvan Institute, Sydney, Australia; 3University Of Oslo, Oslo, Norway
Lipid oversupply is a major contributor to the development of insulin resistance. We have previously shown that deletion of the lipid-
activated protein kinase C, PKCε, augmented circulating insulin levels in long term fat-fed mice, thus maintaining glucose tolerance. 
However, an improvement of insulin action was not observed. Here, we used a one week high-fat diet to investigate the role of PKCε 
during the early phase of insulin resistance. While WT mice became glucose intolerant, PKCε-/- mice were protected. In contrast to 
our long term study this was accompanied by lower insulin levels indicating that insulin resistance was prevented. Proximal insulin 
signalling and glucose uptake into skeletal muscle was not improved in the PKCε-/- mice, suggesting the involvement of alternative 
mechanisms. Using iTRAQ as a quantitative proteomic approach, we identified several proteins involved in lipid metabolism and 
oxidative phosphorylation, which were differentially expressed in the liver of fat-fed PKCε-/- and WT mice, indicating a regulatory 
role of PKCε in these pathways. A more detailed analysis revealed increased levels of triglycerides, diacylglycerides, and cholesterol 
in the liver of fat-fed PKCε-/- mice due to a shift in lipid partitioning towards esterification instead of b-oxidation of fatty acids. The 
contribution of these alterations to improved insulin action is currently under investigation. Taken together, our data show that the 
role of PKCε changes during the development of glucose intolerance, contributing to insulin resistance only at an early stage and that 
the underlying mechanisms may include extensive changes in lipid metabolism.
C05.10 - Environmental control of insulin action and nutrient metabolism
ACTIVATION OF ASK1 IN OMENTAL FAT LINKS ADIPOCYTE STRESS TO WHOLE-BODY INSULIN RESISTANCE
Bluher Matthias1, Tarnovscki Tanya2, Beck-Haim Yulia2, Palgi Niv2, Kloting Nora1, Harman-Boehm Ilana2, Bashan Nava2, Rudich Assaf2
1University Of Leipzig, Leipzig, Germany; 2Ben-Gurion University, Beer-Sheva, Israel
In obesity adipocytes are exposed to various potential stressors, but what type of stress predominates in human obesity, and which 
stress-sensing signaling cascades are activated to induce adipose dysfunction remains poorly characterized. We have previously 
reported in humans that omental (OM), but not subcutaneous (SC) adipose tissue exhibits increased activation of JNK and p38MAPK. 
In analyzing upstream kinases, a signaling cascade involving the MKK3/6 and 4 (but not MKK7), and the MAP3K Ask1 (but not Tak1 or 
MLK3) could be verified by phosphospecific antibodies and inter-correlation analyses. Ask1 was more highly phosphorylated on the 
Thr845 activatory site in OM compared to SC, and compared to OM of lean persons, while the inhibitory Ser83 and Thr966 sites were 
phosphorylated to varying degrees. In TNFα-treated depot-specific adipocyte cell line, Thr845 phosphorylation occurred earlier than 
the increase in pSer83 and Thr966, and was more robust in intra-abdominal adipocytes than in SC. Protein and mRNA expression of 
Ask1 in human OM fat was higher than in SC, correlated with the degree of macrophage infiltration, but could be attributed at least 
partly to the adipocyte cell fraction. In-vitro, Ask1 mRNA was increased in intra-abdominal adipocytes in response to TNFα, FasL and 
oxidative stress, but not in response to the ER-stress inducer tunicamycin. Remarkably, a multivariate model revealed OM-Ask1-
mRNA as an independent predictor of whole-body insulin resistance assessed by clamp (b=-0.308, p=0.001, n=196). Collectively, OM 
Ask1 is regulated by combinatorial phosphorylation input and at the expression level, linking adipose stress with whole-body insulin 
resistance.
naples, Italy
October 28 - 30, 2010
37
XI
InternatIonal
SympoSIum 
on InsulIn ReceptoRs
and InsulIn actIon
C06.11 - b- and α-cells in insulin-resistance states
MAPK ACTIVATION IN ALPHA TC1 CELLS AFTER CHRONIC PALMITATE ExPOSURE
Maniscalchi Eugenia Tiziana1, Piro Salvatore1, Monello Adelina1, Mascali Loriana Grazia1, Urbano Francesca1, Iacoviello Linda1, Rabuazzo Agata 
Maria1, Purrello Francesco1
1Dipartimento Di Medicina Interna E Specialistica, Lab. di Medicina Molecolare, Università Degli Studi Di Catania, Ospedale Garibaldi, Catania, 
Italy
T2DM is characterized by insulin resistance at the cellular level, and by a concomitant enhanced glucagon release from alpha cells. 
Since MAPK can regulate Pax 6, a transcription factor that controls glucagon expression, an alteration in MAPK way could explain 
some aspects in the physiopathology. In this study we investigated the effects of chronic exposure to palmitate on IR, IGF-1R and 
MAPK way in pancreatic alpha cells. We cultured α-TC1-6 with palmitate (0.5 mM) for 48 h. After chronic palmitate exposure, an 
acute insulin stimulation was performed and IR, IGF-1R, MAPK, Pax 6 and glucagon expression were investigated. In our model, 
after chronic palmitate exposure, IR-P was impaired and acute insulin stimulation did not increase the phosphorylation. In contrast, 
after palmitate culture, basal IGF-1R-P was significantly higher than in control cells (p<0.05). Moreover, insulin already at 10-10 M, 
significantly increased this activity (p<0.01). In cells cultured with palmitate, basal P-Erk 44/42 and P-p38 was significantly (p<0.05) 
higher than in control cells, and insulin, already at low concentrations, further increased this activity. Pax 6 protein expression was 
also increased compared to control cells (p<0.01). Glucagon protein expression was 2.2 ± 1 AU in control α−TC1 cells, and 23.4 ± 2 AU 
(p<0.01) in cells cultured 48 h with palmitate. These results indicate that alpha cells exposed to palmitate show an activation in IGF-
1R/MAPKs pathway. Through these activations both Pax6 and glucagon expression were increased. Our data support the hypothesis 
that the chronic elevation of fatty acids contribute to alpha cell alterations frequently observed in Type 2 Diabetes.
C06.12 - b- and α-cells in insulin-resistance states
SIRNA SCREENING FOR GENES INVOLVED IN CYTOKINE-INDUCED PANCREATIC BETA CELL DEATH
Beck Avital1, Lavelin Irena1, Hart Yuval1, Volberg Tova1, Geiger Benjamin1, Zick Yehiel1
1Weizmann Institute Of Science, Rehovot, Israel
Pro-inflammatory cytokines are involved in inducing pancreatic b cell death, leading to the development of Type 1 diabetes. To 
elucidate the mechanisms underlying this process, a high throughput screen of 3850 mouse siRNAs was performed in cytokine-
treated Min6 b cell line. Cells were transfected with the various siRNAs and then treated with a combination of TNFα, IL-1b, and 
IFNγ. Apoptotic and necrotic activities were monitored by automatically assessing caspase-3/7 activity, cellular ATP content, and 
cell morphology. The resulting data were compared to control samples, and the corresponding Z-scores calculated. Several gene 
families were identified as promoting cytokine-induced b cell apoptosis, the most prominent being the cytokine receptor serine/
threonine kinases, and the ubiquitin ligases. Conversely, deubiquitinating enzymes appeared to reduce cytokine-induced b cell 
apoptosis. Protein phosphatases were mainly associated with necrotic, rather than apoptotic, b cell death. The screen confirmed the 
involvement of genes such as IRF7, CEBPB, JAK2 and Atg4, previously implicated in cytokine-induced b cell death, and reveled the 
involvement of several novel validated hits in this process. One of these hits, which belongs to the deubiquitinating enzyme family, 
was shown to act as novel mediator of cytokine-induced b cell death and insulin secretion in primary cultures of murine and human 
islets. Our results indicate that b cell death occurs via a combination of apoptotic and necrotic processes, mediated by novel as well 
as known genes. These findings open up a new prospect of genes involved in beta cell death and in the pathogenesis of diabetes.
C07.13 - Insulin action in the CNS
IMPACT OF THE ELEVATION OF LIPID PHOSPHATASE SHIP2 ON BRAIN INSULIN ACTION FOR THE COGNITIVE FUNCTION IN MICE
Sasaoka Toshiyasu1, Soeda Yoshiyuki1, Muranaka Hayato1, Mori Norihiko1, Wada Tsutomu1, Tsuneki Hiroshi1
1University Of Toyama, Toyama, Japan
Impaired insulin signaling in brain is implicated in the development of neurological disorders. However, the deteriorating mechanism 
of insulin action in brain is largely unknown. In the present study, we found that SHIP2, a negative regulator of insulin signaling, 
is expressed in brain of adult mice. When we expressed a dominant-negative mutant of SHIP2 in primary culture neurons, insulin 
signaling was augmented, implying physiological significance of endogenous SHIP2 in neurons. Interestingly, SHIP2 mRNA and 
protein levels were significantly increased in the brain of diabetic db/db mice. To reveal the impact of elevated expression of SHIP2, 
we investigated alterations of neuronal functions in transgenic mice overexpressing SHIP2. In the hippocampus and cerebral cortex 
of SHIP2-Tg mice, icv injection of insulin-induced phosphorylation of Akt was diminished. Neuroprotective effects of insulin, assessed 
by MTT assay, were significantly attenuated in cultured cerebellar granule neurons from SHIP2-Tg mice. Consistently, TUNEL assay 
demonstrated that the number of apoptosis-positive cells was increased in cerebral cortex of aged SHIP2-Tg mice. Furthermore, 
SHIP2-Tg mice exhibited impaired performance in two memory tests, the Morris water maze and a novel object recognition test. 
Importantly, impairment of synaptic long-term potentiation in hippocampus of db/db mice was effectively ameliorated by treatment 
with a SHIP2 inhibitor (AS1949490). These results suggest that maintenance of adequate SHIP2 levels is critical for the insulin action 
in brain, and inhibition SHIP2 is effective therapeutic approach to protect from the development of memory impairment in diabetes.
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C07.14 - Insulin action in the CNS
TOLL-LIKE RECEPTOR2/4 DEFICIENCY PROTECTS FROM DIET-INDUCED BRAIN INSULIN RESISTANCE
Tina Sartorius1, Anita M. Hennige1, Stefan Z. Lutz1, Cora Weigert1, Hans-Ulrich Häring1
1University Of Tübingen, Dept. Of Internal Medicine, Tübingen, Germany
In diet-induced obesity, fatty acids are known to activate inflammatory pathways that finally lead to insulin resistance. One potential 
mediator that links fatty acid signaling to insulin resistance is the toll-like receptor (TLR) family. To address the impact of TLR on 
insulin action in brain, primary astrocytes from TLR2/4-deficient as well as control mice were isolated. In astrocytes of mutants, 
insulin-mediated phosphorylation of AKT (S473) was enhanced and resistant to an inhibition by palmitate as observed in controls. 
While glucose uptake in presence of palmitate was diminished in control astrocytes, mutant cells were partly protected, accompanied 
by an elevated glycogen synthesis rate. In vivo, high-fat diet (HFD) fed mice deficient of TLR2/4 were protected from glucose 
intolerance and displayed lower IL-6 levels. Moreover, insulin-mediated tyrosine phosphorylation of IR and Irs2 was still present in 
brain of HFD fed mutants where it was absent in controls. In parallel, TLR2/4-deficient mice displayed an improved spontaneous 
locomotor activity accompanied by an increase in cortical activity assessed by radiotelemetry. To elucidate a mechanism in brain 
that links fatty acid signaling and inflammation to insulin resistance, we injected an IL-6-neutralizing antibody in HFD fed controls. 
Thereby, cortical activity as well as locomotion of controls was enhanced to levels of the mutants and tyrosine phosphorylation of IR 
and Irs2 in brain of HFD fed controls were restored. Taken together, our study suggests that palmitate induces cytokine expression 
that leads to impaired insulin action in brain via an IL-6 mediated mechanism that is absent in mice deficient of TLR2/4.
C08.15 - Metabolism and cancer
GLARGINE AND NPH INSULIN SIMILARLY INCREASE COLONIC CELL PROLIFERATION AND ACF FORMATION
Nagel Jutta M.6-7, Staffa Juergen6, Renner-Mueller Ingrid1, Horst David2, Vogeser Michael3, Langkamp Markus4, Hoeflich Andreas5, Goeke 
Burkhard6, Kolligs Frank T.6, Mantzoros Christos M.7
1Institute Of Molecular Animal Breeding And Biotechnology, Gene Center, Lmu Munich, Munich, Germany; 2Institute Of Pathology, Lmu Munich, 
Munich, Germany; 3Department Of Clinical Chemistry, Klinikum Grosshadern, Lmu Munich, Munich, Germany; 4Mediagnost Gmbh, Reutlingen, 
Germany; 5Laboratory Of Mouse Genetics, Research Institute For The Biology Of Farm Animals (fbn), Dummerstorf, Germany; 6Department Of 
Medicine II, Klinikum Grosshadern, Lmu Munich, Munich, Germany; 7Beth Israel Deaconess Medical Center, Boston, Usa
Abstract Aim: the insulin analogue glargine has a higher binding affinity than regular insulin for the IGF-1-receptor in vitro, raising 
questions about increased mitogenicity in vivo. Observational studies in humans have recently reported a potential association 
between insulin glargine and malignancies, but available evidence remains inconclusive. We directly compared glargine vs. NPH 
insulin’s effects on cell proliferation in colonic mucosa and on formation of aberrant crypt foci in diabetic mice, i.e. early stages of 
colorectal cancer development. Materials and Methods: mice (BKS.Cg-+Leprdb/+Leprdb/OlaHsd) were treated with insulin glargine 
(G), NPH insulin (NPH), or saline (NaCl). We assessed epithelial proliferation after long-term insulin treatment (18 weeks) by BrdU 
and Ki67 staining and analyzed the formation of aberrant crypt foci (ACF) in mice treated with insulin glargine or NPH insulin or 10 
weeks after initiation with 1,2-dimethylhydrazine. Results: insulin glargine treatment did not result in significantly different epithelial 
colonic proliferation compared to NPH insulin (G: 137±22; NPH: 136±15; NaCl: 100±20 (relative proliferation index)), but both insulin 
treated groups of mice had a higher proliferation index compared to the NaCl control group (p<0.001). Similarly, we observed no 
difference in ACF formation between glargine and NPH insulin treated mice (G: 132±12; NPH: 138±9; NaCl: 100±7 (relative number of 
ACF)), but ACF formation was significantly higher in insulin treated mice than in NaCl-treated control mice (p=0.001).
C09.16 - Insulin-action and cancer
BREAST CANCER GROWTH AND ACTIVATION OF INSULIN/IGF-1 SIGNALING BY CIRCADIAN DISRUPTION
Greene Michael1, Wu Jinghai1, Dauchy Robert2, Blask David2, Dauchy Erin2, Jitawatanarat Potjana1, Tirrell Paul1
1Bassett Research Institute, Cooperstown, Usa; 2Tulane University School Of Medicine, New Orleans, Usa
Disruption of either the central circadian system or the cell cycle increases the risk of cancer in humans. To investigate the role of 
circadian disruption in breast cancer growth in vivo, female nude rats bearing human breast cancer xenografts were exposed to 
a normal 12L:12D circadian condition or to low intensity of light at night (LAN) (0.08 µW/cm2). Exposure of tumor-bearing rats to 
LAN resulted in significantly accelerated growth of these xenografts. PCNA protein, a marker of cell proliferation, was continuously 
expressed at a high level throughout the 24 h period in breast cancer xenografts growing in nude rats exposed to the LAN. Daily 
rhythms of Akt and MAPK activation in the human breast cancer tumors were disrupted by LAN but did not track the changes in 
PCNA expression; however, PDK1 activation directly correlated with PCNA expression. Given PDK1’s pivotal role in insulin and IGF-1 
signaling, we questioned whether LAN disrupted circulating insulin or IGF-1 hormone levels in tumor-bearing rats. Serum insulin 
levels were dramatically elevated throughout the 24 h period in LAN-exposed tumor-bearing nude rats. Further, IGF-1 concentrations 
showed circadian disruption in LAN-exposed tumor-bearing nude rats. The essential role of PDK1 in breast cancer growth was 
further explored using cultured human breast cancer cells. In PDK1 knockdown human breast cancer cell lines, a reduction in PCNA 
protein level was observed, and serum stimulated proliferation was reduced by approximately 50%. Thus, interruption of the insulin/
IGF-1 signaling pathway may constitute a novel molecular mechanism of circadian regulated tumor growth.
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C10.17 - Future strategies for treating diabetes
GRB14 INHIBITION IN MOUSE LIVER IMPROVES GLUCOSE TOLERANCE AND HEPATIC STEATOSIS
Lucie Popineau1, Nadège Carré1, Michèle Caüzac1, Véronique Fauveau1, Catherine Postic1, Jean Girard1, Anne-Francoise Burnol1
1Institut Cochin, Inserm U1016, Cnrs Umr 8104, Université Paris Descartes, Paris, France
The molecular adapter Grb14 is specifically expressed in insulin sensitive tissues and modulates insulin signaling and action through 
its direct inhibitory effect on the receptor catalytic activity. In addition, insulin sensitivity is negatively correlated with Grb14 expression 
level in adipose tissue in different models of obesity or type 2 diabetes. Here we investigated the consequences of Grb14 depletion 
in the liver on the regulation of the glucido-lipidic metabolism. C57Bl6 and ob/ob mice were injected intraveinously with either a 
Grb14 adeno-shRNA or a control adenovirus and studied a week later. Decreased Grb14 expression induced an increase in insulin 
signaling (pAkt, pERK) and an improvement in glucose tolerance. Glycemia was decreased in shGrb14 treated mice, and was restored 
to control levels in ob/ob mice. In agreement with the improvement in liver insulin action, the expression of gluconeogenic genes 
(PEPCK, G6Pase) was decreased. However, unexpectedly, Grb14 depletion induced a striking decrease in glycolytic and lipogenic gene 
expression (SREBP-1c, ChREBP, ACC, FAS, SCD1), leading to a reduction in glycogen and lipid content in fed mice. In ob/ob mice Grb14 
depletion induced a 70% decrease in liver TG content. The paradoxical effect of Grb14 depletion on gluconeogenesis on one hand and 
on lipogenesis on the other hand suggests that Grb14 can control insulin signaling by acting at a step downstream from the insulin 
receptor. Furthermore the combination of these two effects should be beneficial to prevent obesity and type 2 diabetes which are both 
characterized by glucose intolerance and fatty liver, pointing out Grb14 as a potential new therapeutical target.
C10.18 - Future strategies for treating diabetes
PKCDELTA IS A REGULATOR OF HEPATIC INSULIN SENSITIVITY AND MODIFIES HEPATOSTEATOSIS RISK
Olivier Bezy1, Thien T. Tran1, Ryo Suzuki1, Jonathan Winnay1, Brice Emanuelli1, Marcelo Mori1, George L. King1, C. Ronald Kahn1
1Joslin Diabetes Center, Boston, Usa
C57BL/6 (B6) and 129S6/Sv (129) mice strains differ dramatically in their susceptibility to develop diabetes in response to genetic 
or diet-induced insulin resistance. This difference has been mapped to a region on chromosome 14 which contain the PKCdelta 
gene. PKCdelta expression in liver is higher in several mice models of diabetes, 2-fold higher in B6 mice compared to 129 and in B6 
mice, but not 129, increases in response to high-fat diet. Mice with global inactivation of the PKCdelta gene display increased insulin 
sensitivity with higher suppression of hepatic gluconeogenesis, improved hepatic insulin signaling, decreased gluconeogenic and 
lipogenic genes expression. Liver specific deletion of the PKCdelta gene also results in improved glucose tolerance, restores hepatic 
insulin signaling and protects mice on high fat diet from hepatosteatosis. Conversely, mice with liver specific PKCdelta overexpression 
develop hepatic insulin resistance and hepatosteatosis, with decreased insulin signaling and enhanced lipogenic genes expression. 
Thus, PKCdelta plays an important role in hepatic insulin resistance, hepatosteatosis and genetic differences controlling hepatic 
insulin resistance. PKCdelta may be a new target for treatment of metabolic syndrome.
C10.19 - Future strategies for treating diabetes
NFKB PARADOx: SUPPRESSION OF GLUT4 ExPRESSION WITH CONCOMITANT TRANLOCATION ENHANCEMENT
Karni Ashkenazi Shiri1, Armoni Michal2, Rozentzweig Ben Yosef Dafna2, Harel Chava2, Volpin Gershon3, Karnieli Eddy4
1B. Rappaport Faculty Of Medicine, Technion-Israel Institute Of Technology And Institute Of Endocrinology, Diabetes And Metabolism, Rambam 
Medical Center, Haifa, Israel; 2Institute Of Endocrinology, Diabetes And Metabolism, Rambam Medical Center, Haifa, Israel; 3Orthopedic Dept. 
West Galilee Medical Center, Nahariya, Israel; 4B. Rappaport Faculty Of Medicine, Technion-Israel Institute Of Technology And Institute Of 
Endocrinology, Diabetes And Metabolism, Rambam Medical Center, Haifa, Israel
The link between inflammation, insulin resistance and type 2 diabetes mellitus (DM2) is now well-established. While NFkB activity 
is enhanced in DM2, its role in regulating the insulin-responsive glucose transporter 4 (GLUT4) gene expression and function is 
yet unclear. GLUT4 regulation at transcriptional level was studied in vitro in skeletal muscle-derived L6 myotubes using transient 
co-expression assays. Co-expression of NFkB subunits p65, p50 or both with a GLUT4 promoter reporter, dose-dependently 
suppressed basal promoter activity by 90%, 60% and 80%, respectively. GLUT4 translocation was assessed by measuring cell surface 
levels of GLUT4 (CS-GLUT4) in GLUT4-myc L6 myoblasts. Co-expression of p65 increased basal CS-GLUT4 by 200%, similar to the 
effect of insulin alone, while p65 and insulin combined together induced a 250% enhancement. While p50 was without effect, when 
co-expressed with p65 in equimolar amounts, a 300% of CS-GLUT4 was evident, and insulin had no additional effect. Interestingly, 
co-expression of p65 and p50 increased cellular levels of the 14-3-3 protein, while their silencing by siRNA reduced 14-3-3 expression. 
Most importantly, using co-IP, we found that p65 enhanced a critical step in Glut4 translocation, namely, the interaction of 14-3-3 
with AS160. Thus, while NFkB represses GLUT4 gene expression on one hand, it enhances its translocation to the cell surface via 
enhancing 14-3-3-AS160 interaction, on the other. These novel modes of action of NFkB present potential targets for type 2 diabetes 
therapy.
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C10.20 - Future strategies for treating diabetes
CITED2 REGULATES HEPATIC GLUCONEOGENESIS BY CONTROLLING PGC-1α ACTIVITY
Mashito Sakai1, Michihiro Matsumoto1, Masato Kasuga1
1National Center For Global Health And Medicine, Tokyo, Japan
Hepatic gluconeogenesis is critical in the adaptation to fasting conditions and contributes to hyperglycemia under hepatic insulin 
resistance in diabetic patients. Many transcriptional regulators cooperatively control the gluconeogenic program during fasting. It 
has been reported that the CBP/p300-binding transcriptional coactivator Cited2 binds HNF4α and plays a crucial role during liver 
development. Despite the physiological importance of HNF4α and CBP in controlling gluconeogenesis, the role of Cited2 remains 
unknown. We investigated the role of Cited2 in hepatic gluconeogenesis by using gain- and loss-of-function approaches in vitro and 
in vivo. In hepatocytes, the overexpression of Cited2 resulted in a 2-fold increase in cAMP-induced expression of gluconeogenic genes 
such as G6Pase and Pepck, leading to a 2-fold increase in glucose levels in the media. Cited2 deletion in hepatocytes attenuated 
cAMP-dependent induction of gluconeogenic genes. Hepatic expression of Cited2 in vivo increased gluconeogenic gene expression 
and blood glucose levels under both fasting and fed conditions. cDNA microarray analysis revealed that Cited2 overexpression in vitro 
enhanced cAMP-dependent induction of genes regulated by PGC-1α, such as Ppara, Cpt1a, as well as G6Pase and Pepck. Therefore, 
we examined the effect of Cited2 on gluconeogenic gene expression induced by PGC-1α in vitro. Overexpression of Cited2 enhanced 
PGC-1α-induced gluconeogenic gene expression, but Cited2 deletion attenuated the expression. These data strongly suggest that 
Cited2 upregulates PGC-1α function, and the molecular mechanism underlying the upregulation is currently being investigated.
C11.21 - Diabetes Complications
INSULIN SIGNALING IS A PHYSIOLOGICAL REGULATOR OF MYOCARDIAL AUTOPHAGY IN VIVO
Zhang Quan Jiang1, Sena Sandra1, Christian Riehle1, Parra Valentina1, Abel E. Dale1
1University Of Utah, Salt Lake City, USA
Fasting increases autophagy in hearts, which is reversed upon re-feeding. To investigate the role of insulin signaling in this 
process, we generated mice with cardiomyocyte-restricted deletion (CKO) of IRS1 and IRS2. These mice exhibited increased rates 
of myocardial autophagy that could not be reduced upon re-feeding. The unrestrained autophagy led to progressive cardiomyocyte 
loss, heart failure and premature mortality. Autophagy was also increased in hearts of mice with CKO of insulin (CIRKO) but not 
IGF-1 (CIGFRKO) receptors respectively, indicating a specific role for insulin signaling. To determine if the suppression of autophagy 
by insulin signaling was mediated via an increase in nutrient uptake versus direct activation of mTOR via activation of Akt. We 
studied H9C2 cardiomyocytes in which autophagy was induced in serum-free media lacking glucose (G) and amino acids (AA) but 
supplemented with 0.5 mM pyruvate (starvation media, SM). Cells were then incubated with 100 nM insulin (INS) in the presence or 
absence of G (5 mM) or AA (0.1 mM). INS increased Akt phosphorylation in SM, but this was reversed by the addition of AA indicating 
AA-induced insulin resistance. Starvation-induced autophagy was reversed either by INS or AA +G to equivalent degrees. Addition 
of INS in the presence of G + AA, did not reduce autophagy further. Thus, starvation-induced autophagy in cardiomyoyctes can be 
reversed independently by insulin or nutrients and AA attenuates cardiomyocyte autophagy under conditions of insulin resistance. In 
conclusion, insulin signaling regulates cardiomyocyte autophagy in vivo independently of nutrient mediated signaling to mTOR.
C11.22 - Diabetes Complications
INCREASED ExPRESSION OF TIMP3 PROTECTS AGAINST DIABETES AND ATHEROSCLEROSIS
Menghini Rossella1, Casagrande Viviana1, Marino Arianna1, Cavalera Michele1, Lauro Davide1, Menini Stefano2, Pugliese Giuseppe2, Sbraccia 
Paolo1, Lauro Renato1, Federici Massimo1
1University Of Rome Tor Vergata, Rome, Italy; 2Sapienza University Of Rome, Rome, Italy
TIMP3 has been identified as a gene-modifier for diabetes phenotype in and is decreased in atherosclerotic plaque from patients with 
Type 2 diabetes and in tissues of humans and mice affected by obesity. To analyze the potential anti-diabetic and anti-atherosclerotic 
effects of TIMP3 we used a transgenic approach to reconstitute TIMP3 levels in macrophages. Transgenic (Tg) mice were identified 
by RT-PCR and confirmed by Southern blot. In the Diet Induced Obesity (DIO) model, we observed that Tg mice compared with WT 
showed a significant improved glucose tolerance and insulin sensitivity and increased insulin induced glucose uptake in forelimbs 
(FDG-PET scan); Histology of white adipose tissue (WAT), liver, kidney and aorta showed accumulation of lipids, intense fibrosis and 
increased inflammatory markers in WT compared with Tg. Tg revealed also significant reduction in visceral adipose tissue, adipose 
tissue vascularization and reduced mean adipocyte area. Expression profiling indicated in Tg mice a decrease of inflammatory genes 
and an improvement in metabolism related genes, in both WAT and liver. Next we analyzed the effect of Timp3 overexpression in an 
atheoslcerotic model (LDLR) fed Western Diet for 12 weeks. Histology of aortic roots from LDLR-Tg mice revealed reduction in plaque 
surface, F4/80, CD3 and nitrotyrosine staining, increased collagen content and no necrotic cores, when compared to LDLR. Gene 
expression profiles in liver and aorta suggest reduced oxidative stress and less activation of inflammatory pathways in LDLR-Tg. 
Our data indicate that macrophage specific overexpression of TIMP3 protects from metabolic inflammation and related metabolic 
disorders.
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C11.23 - Diabetes Complications
PROTEIN TYROSINE PHOSPHATASE 1B (PTP1B) REGULATES WOUND HEALING
Zabolotny Janice M.1, Leal Ermelindo1, Kontoes Iraklis1, Kuchibhotla Sarada1, Tecilazich Francisco1, Pradhan Leena1, Veves Aristidis1
1Beth Israel Deaconess Medical Center, Boston, Usa
The major complication of diabetes leading to hospitalization is diabetic foot ulceration (DFU). DFU significantly lowers the quality 
of life of diabetic patients and can lead to amputation. PTP1B negatively regulates a network of growth factor signaling pathways 
that promote wound healing, including insulin, leptin, epidermal growth factor (EGF), platelet derived growth factor (PDGF), and 
vascular endothelial growth factor (VEGF), via dephosphorylation of their respective receptors or associated kinases. In mice, PTP1B 
expression is induced in a variety of tissues by obesity- or diabetes-associated inflammation as well as treatment with tumor necrosis 
factorαα. Our data indicate that diabetes was associated with increased inflammatory cytokines, aberrant growth factor levels, and 
elevation in the extracellular matrix metalloproteinases involved in inactivating growth factors and that these abnormalities were 
associated with failure to heal DFU. Immunohistochemical analysis of forearm skin biopsies and discarded foot skin specimens 
revealed PTP1B was elevated in skin of diabetics at risk for DFU compared to non-diabetics. Moreover, in PTP1B-deficient mice, 
healing of full thickness excisional skin wounds was enhanced by 37% compared to wildtype controls at day 10 post wounding. 
Preliminary studies also indicate wound healing was enhanced by 48% in streptozotocin (STZ)-induced diabetic PTP1B-deficient 
mice compared to diabetic wildtype controls. These data suggest that elevated PTP1B expression may be an additional intracellular 
mechanism contributing to failure to heal in diabetics with DFU and that PTP1B inhibitors may have utility to enhance healing of DFU.
C11.24 - Diabetes Complications
IMMUNOSUPPRESSIVE AGENTS ALTER GLUCOSE METABOLISM, BLOOD PRESSURE AND HEART RATE IN RATS
Pedro Joana1, Sereno Jose2, Lopes Patricia1, Reis Flavio2, Carvalho Eugenia1
1Center For Neuroscience And Cell Biology, University Of Coimbra, Coimbra, Portugal; 2Institute Of Pharmacology & Experimental Therapy At The 
Medicine Faculty Of The University Of Coimbra, Coimbra, Portugal
Immunosuppressive agents (IA), such as, Cyclosporin A (CsA) cause post-transplant diabetes (PTD), a serious metabolic complication 
of solid organ transplant. Sirolimus (Sir) is a new option because of identical efficacy with apparent less side-effects, compared to 
CsA. Our aim is to elucidate the mechanisms by which in vivo IA treatment causes metabolic and cardiovascular abnormalities. Rats 
were treated with CsA or Sir for 3, 6 and 9 weeks. Glucose uptake in isolated adipocytes. glucose tolerance tests (GTT), heart rate and 
blood pressure were measured. Already after 3 weeks of treatment with CsA animals show a significant increase in blood glucose 
during a GTT as compared to vehicle treated animals at 15 (333.0±39.3 vs 196.0±44 p<0.01) and 30 min (304±32 vs 180±34 p<0.05) time 
points. This was not observed in the Sir treated animals for 3 weeks. These effects worsened with 6 and 9 weeks of treatment. CsA-
treated rats display significantly increased SBP (p<0.001) at 6 and 9 weeks and DBP at all times (p<0.01), when compared with vehicle 
treated rats. The same profile was obtained with Sir for SBP and DBP vs the control group (p<0.05). The CsA induced increased HR 
after 6 weeks of treatments (p<0.005) was not observed in the Sir-treated rats. In addition, insulin-stimulated glucose uptake is 
totally impaired already after 3 weeks exposure to either drug compared to vehicle treated animals. These results demonstrate that 
the in vivo studied IAs not only impair glucose uptake in adipocytes but they also disrupt blood pressure and heart rate as compared 
to vehicle treated animals. These alterations can contribute to development of PTD.
POSTER ABSTRACTS
P01.1 - New concepts in insulin signal transduction
A NOVEL DOMAIN MEDIATES INSULIN INDUCED PROTEASOMAL DEGRADATION OF IRS-1
Boura-Halfon Sigalit1, Shuster-Meiseles Timor1, Beck Avital1, Petrovich Katia1, Gurevitch Diana1, Ronen Denise1, Zick Yehiel1
1Weizmann Institute Of Science, Rehovot, Israel
Insulin receptor substrate-1 (IRS-1) plays a pivotal role in insulin signaling therefore its degradation is exquisitely regulated. Here 
we show that insulin-stimulated degradation of IRS-1 requires the presence of a highly conserved Ser/Thr-rich domain, we named 
DIDI (Domain Involved in Degradation of IRS-1). DIDI (aa 386-430 of IRS-1) was identified by comparing the intracellular degradation 
rate of several truncated forms of IRS-1 transfected into CHO cells. The isolated DIDI domain, underwent insulin stimulated Ser/
Thr phosphorylation, suggesting that it serves as a target for IRS-1 kinases. The effects of deletion of DIDI were studied in Fao rat 
hepatoma and in CHO cells infected with adenoviral constructs expressing Myc-IRS-1WT or Myc-IRS-1D386-430. Deletion of DIDI 
maintained the ability of IRS-1D386-434 to undergo ubiquitination while rendering it insensitive to insulin-induced proteasomal 
degradation which affected IRS-1WT (80% at 8h). Consequently, IRS-1D386-434 mediated insulin signaling (activation of Akt, and 
glycogen synthesis) better than IRS-1WT. IRS-1D386-434 exhibited a significant greater preference for nuclear localization, compared 
to IRS-1WT. Higher nuclear localization was also observed when cells expressing IRS-1WT were incubated with the proteasome 
inhibitor MG-132. The sequence of DIDI is conserved >93% across species, from fish to mammals, as opposed to ~40% homology of 
the entire IRS-1. These findings implicate DIDI as a novel, highly conserved domain of IRS-1 which mediates its cellular localization, 
rate of degradation and biological activity, with a direct impact on insulin signal transduction.
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P01.2 - New concepts in insulin signal transduction
PREP1 REGULATES HEPATIC LIPOGENESIS THROUGH SHIP2-MEDIATED AMPK INHIBITION
Cabaro Serena1, Oriente Francesco1, Iovino Salvatore1, Cassese Angela1, Blasi Francesco2, Formisano Pietro1, Béguinot Francesco1
1DBPCM & IEOS-CNR, Università Degli Studi Di Napoli “Federico II”, Naples, Italy; 2IFOM (firc Institute Of Molecular Oncology), Milan, Italy
Prep1 is an homeodomain transcription factor belonging to TALE (Three Aminoacid Loop Extension) proteins, which regulate the 
overall size of the organism and individual organs. Our preliminary experiments have shown that the hepatic Prep1 levels are 
increased in high fat diet treated mice. To further study the function of Prep1 on hepatic lipid metabolism, we have used Prep1 
hypomorphic mice (Prep1i/+), which express only 55-57% of protein. Triglyceride levels measured both in the blood and in the liver 
of Prep1i/+ mice are reduced by 35 and 75%, respectively. In parallel, the expression of the lipogenetic enzyme FAS (Fatty Acid 
Synthase) is decreased. Western Blot analysis has shown in Prep1i/+ mice liver increased phosphorylation of PKCzeta, LKB1, AMPK 
and ACC, which may control FAS expression and triglycerides production. mRNA and protein levels of the lipid phosphatase SHIP2, 
an inhibitor of PI3Kinase/PKCzeta signaling, are reduced by 40% in Prep1i/+ mice liver. In order to confirm these data, Prep1 has been 
overexpressed in HepG2 (Human Hepatoma cell line) cells. High levels of Prep1 induce an increase of triglycerides production and 
FAS expression, while PKCzeta, LKB1, AMPK and ACC phosphorylation is strongly reduced. Moreover, SHIP2 levels are increased by 
50% and chromatin IP experiments indicate that Prep1 can bind SHIP2 promoter region. These data suggest that Prep1 increases 
hepatic triglycerides production by increasing SHIP2 levels thereby inhibiting the PKCzeta/AMPK signaling.
P01.3 - New concepts in insulin signal transduction
ERK1/2- AND MTOR-DEPENDENT PHOSPHORYLATION OF IRS-2: REGULATION AND FUNCTION
Fritsche Louise1, Neukamm Sabine1, Kremmer Elisabeth2, Lehmann Rainer1, Schleicher Erwin D.1, Häring Hans U.1, Weigert Cora1
1University Hospital Tübingen, Department Of Internal Medicine IV, Tübingen, Germany; 2Institute Of Molecular Immunology, Helmholtz Center, 
Munich, Germany
The IRS proteins are essential transducers of the insulin signal and their function is regulated via multiple phosphorylations. The 
dysregulation of IRS-1 phosphorylation is implicated in the development of insulin resistance and type II diabetes. The aim of our 
study was to identify and characterise novel Ser phospho-sites of IRS-2 and investigate their role in (patho)physiological insulin 
signaling. Monoclonal antibodies were generated against potential phospho-sites which were identified with in vitro kinase assays 
and with bioinformatical programs. Phospho-site specific functions were studied with Ala-mutants. In vivo Ser phosphorylation of 
IRS-2 was studied in hepatic tissue of mice. Insulin induced a strong phosphorylation on Ser 641, Ser 675 (both located in the IRS-
2-unique KRLB domain), and Ser 907 (adjacent to Grb2-binding Tyr 911) in Fao hepatoma cells (endogenous IRS-2) and in HEK293 
cells (ectopically expressed IRS-2). Phosphorylation on these sites was a late event (60 to 90 min) of insulin signaling and could also 
be demonstrated in mice. Experiments with pharmacological inhibitors and siRNA indicated that Ser 907 is ERK1/2-dependently 
phosphorylated and mTOR, but not p70S6K1, phosphorylated Ser 675. Inhibition of mTOR with rapamycin prevented the insulin-
induced IRS-2 degradation in Fao cells and the introduction of a 675 Ala-mutation led to increased half-life of ectopically expressed 
IRS-2 in HEK293 cells. IRS-2 has multiple potential Ser/Thr phospho-sites, three of which were identified and characterised in this 
study. Ser 675 might be involved in the regulation of IRS-2 protein stability; the function of other sites is currently under investigation.
P01.4 - New concepts in insulin signal transduction
ROLE OF STRA13 IN INSULIN REGULATION OF HEPATIC LIPID METABOLISM
Nomura Kazuhiro1, Ogawa Wataru1, Emi Aki1, Hosooka Tetsuya1, Kasuga Masato2
1Kobe University Graduate School Of Medicine, Kobe, Japan; 2International Medical Center Of Japan, Tokyo, Japan
In the liver, insulin stimulates the synthesis of fatty acids thorough the up-regulation of the transcription factor SREBP1c. The 
mechanism how insulin regulates the expression of SREBP1c is still ambiguous, however. We have now found that hepatic expression 
of Stra13, a member of bHLH family transcription factors, was stimulated by insulin both in vitro and in vivo. In primary cultured 
hepatocytes, overexpression of Stra13 resulted in the up-regulation of SREBP1c, and the reduction of Stra13 with the use of short 
hairpin RNA (shRNA) inhibited insulin-induced expression of SREBP1c, indicating that Stra13 contributes to insulin-induced 
expression of SREBP1c. Stra13 was found to suppress and enhance the promoter activity of the SREBP1c gene by binding to an E-Box 
in the promoter region of and to the intron1 of the SREBP1c gene, respectively. Insulin prevents the binding of Stra13 to the suppressor 
region and promotes it to the enhancer region. In obese KKAy mice, the hepatic abundance of Stra13 as well as of SREBP1c was 
greater than those of control mice. The reduction of Stra13 in the liver with the use of an adenovirus vector encoding shRNA of Stra13 
decreased the expression of SREBP1c along with that of the downstream genes of SREBP1c including stearoyl-CoA desaturase1 or 
fatty acid synthase. The reduction of hepatic Stra13 in KKAy mice markedly ameliorated hypertriglyceridemia. These results suggest 
that Stra13 controls hepatic lipid metabolism thorough the regulation of SREBP1c and that the Stra13 pathway serves as a potential 
therapeutic target of dyslipidemia of obese individuals.
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P01.5 - New concepts in insulin signal transduction
THE ROLE OF THE AKT SUBSTRATE APE (GIRDIN, GIV) IN INSULIN SIGNALLING
Hartung Angelika1, Häring Hans-Ulrich1, Lammers Reiner1
1Department Of Internal Medicine IV, University Of Tübingen, Tübingen, Germany
Akt kinases are important mediators of the insulin signal. Several Akt substrates are directly involved in glucose homeostasis, 
e.g. GSK3 and AS160. Recently, Akt phosphorylation enhancer (APE) has been described as a new Akt substrate. It is expressed 
ubiquitously in mammals and highly in a variety of cancer cell lines. Based on its actin and microtubule binding domains it is involved 
in remodelling of actin cytoskeleton and cell motility. In addition, APE is also a Gαi–interacting protein and controls the Gαi triggered 
cell migration. However, not much is known about its role in insulin signalling. To investigate the function of APE we established 
C2C12 cells which permanently overexpress APE. With this approach we found that Akt is constitutively active, as determined by its 
phosphorylation at Thr308. Consequently, GSK3 phosphorylation was also increased after insulin stimulation. One possible reason 
for this are changes in the expression of several proteins. The insulin receptor was upregulated and tyrosine phosphorylation of IRS-1 
enhanced. For medium-term insulin responses, the cells had higher insulin sensitivity with glycogen synthesis peaking at 1 nM of 
insulin stimulation. Of note, these effects were independent of APE phosphorylation by Akt, as an Akt phosphorylation site mutant 
behaved similar to wild type. We conclude that APE could be an important mediator of the insulin dependent Akt signalling in muscle 
cells.
P01.6 - New concepts in insulin signal transduction
THE INSULIN RECEPTOR ISOFORM A PLAYS A ROLE IN THYROSPHERES GROWTH AND DIFFERENTIATION
Malaguarnera Roberta1, Pandini Giuseppe2, Vigneri Riccardo2, Belfiore Antonino1
1Endocrinology Unit, Department Of Clinical And Experimental Medicine, University Of Catanzaro, Catanzaro, Italy; 2Endocrinology Unit, 
Department Of Internal Medicine And Medical Specialties, University Of Catania, Catania, Italy
The isoform A of the insulin receptor (IR-A) is a high affinity receptor not only for insulin but also for IGF-II, at variance with the 
second IR isoform (IR-B), which only binds insulin. IR-A is preferentially expressed in prenatal life and it contributes to development 
through IGF-II mediated activation. Previously, we demonstrated that increased IR-A is associated to loss of differentiation. We now 
hypothesized that IR-A may play a role in stem cells biology. We aimed to evaluate IR-A expression and function in thyroid stem cells. 
We established cultures of stem cells from normal human thyroid tissues as non-adherent thyrospheres. Thyrospheres were then 
allowed to differentiate under adherent conditions in presence of serum and TSH. mRNA and protein expression of IR isoforms, as 
well as of IGF-II, were assessed before and after differentiation, by quantitative real time PCR and western blot analysis. The effects 
of insulin and IGF-II on stem cells growth and self-renewal ability were also evaluated. We found that IR-A and IGF-II were expressed 
at high levels in normal thyrospheres and decreased in differentiating cells. The IR-A was the predominant isoform in thyrospheres 
while IR-B was predominant in differentiating cells. Insulin and IGF-II were both able to stimulate thyroid cancer stem cell growth but 
not self-renewal. Our data suggest that IR-A and autocrine IGF-II play a critical role in the biology of thyroid stem cells. While high 
IR-A levels are associated with cell stemness, IR downregulation and isoform switch to a predominant IR-B are associated with cell 
differentiation. IR-A appears, therefore, a new player in human stem cell growth and differentiation.
P01.7 - New concepts in insulin signal transduction
NEW SUBSTRATES INVOLVED IN INSULIN RECEPTOR ISOFORM A SIGNALING
Morcavallo Alaide1, Gaspari Marco1, Pandini Giuseppe2, Cuda Giovanni1, Larsen Martin Røssel 3, Vigneri Riccardo2, Belfiore Antonino1
1University Magna Graecia, Catanzaro, Italy; 2University Of Catania, Catania, Italy; 3University Of Southern Denmark, Odense, Denmark
Recent evidences suggest that the two IR isoforms (IR-A and IR-B) may have partially different functions. IR-B is the predominant 
isoform in adult tissues and binds only insulin, while IR-A is predominantly expressed in fetal and transformed cells and binds both 
insulin and IGF-II. In order, to clarify the biological significance of IR-A we aimed at obtaining an unbiased map of IR-A signalsome 
after stimulation with either insulin or IGF-II. We used R-/IR-A cells, fibroblasts overexpressing the human IR-A and knocked-out for 
the IGF-I receptor, and applied a proteomics strategy based on stable isotope labeling aminoacid in cell culture (SILAC). Cells were 
stimulated with either insulin or IGF-II (10 nM), subjected to phosphotyrosine proteins enrichment and to LC-MS/MS analysis. We 
identified 57 IR-A substrates: 19 were known IR mediators while 38 were not previously related to IR signaling. Only 20 substrates 
were activated by both ligands while the remaining 37 were activated by only one ligand. These novel IR-A mediators fell into the 
following functional categories: signal transduction, proliferation, cell motility, cytoskeleton rearrangement, apoptosis, cell to matrix 
interaction, cell transformation, DNA-repair, endocytosis, metabolism, angiogenesis, tyrosine kinase receptor. The involvement of a 
subset of these mediators was validated by western blot. In conclusion, we identified novel IR-A signaling mediators, which will help 
defining the biological functions of this IR isoform. The majority of these mediators are differentially activated by insulin and IGF-II, 
implying that IR-A may elicit different functions in response to different ligands.
44
P01.9 - New concepts in insulin signal transduction
INSULIN RECEPTOR ISOFORM SELECTIVE ANALOGUES GIVE TISSUE-PREFERENTIAL BIOLOGICAL EFFECTS
Vienberg Sara1, Bouman Stephan1, Sørensen Heidi1, Stidsen Carsten1, Kjeldsen Thomas1, Glendorf Tine1, Sørensen Anders1, Olsen Grith1, Andersen 
Birgitte1, Nishimura Erica1
1Novo Nordisk A/s, Maaloev, Denmark
The relative expression patterns of the two insulin receptor isoforms, +/- exon11 (IR-B/A respectively), are tissue dependent. Therefore 
we have developed insulin analogues with different binding affinities for the two insulin receptor isoforms, to test whether tissue-
preferential biological effects can be attained. In rats and mice, it was found that IR-B was the most prominent isoform in liver (>95%) 
and fat (>90%), whereas in muscles IR-A was the dominant isoform (>95%). As a consequence, insulin analogue INS-A, which has a 
higher relative affinity for the human IR-A, was found to have a higher relative potency (compared to human insulin, HI) for glycogen 
synthesis in rat muscle strips (26%) than for glycogen accumulation in rat hepatocytes (5%) and for lipogenesis in rat adipocytes 
(4%). In contrast, the INS-B analogue, which has an increased affinity for human IR-B, had higher relative potencies (compared to 
HI) for inducing glycogen accumulation (75%) and for lipogenesis (130%) than for affecting muscle (45%). For the same blood glucose 
lowering effect upon acute i.v. dosing to male NMRI mice, INS-B gave a significantly (p<0.01) higher degree of IR phosphorylation in 
liver than HI. These in vitro and in vivo results indicate that insulin analogues with IR isoform-preferential binding affinity are able to 
elicit tissue-selective biological responses, depending on the IR-A/B expression pattern.
P01.10 - New concepts in insulin signal transduction
A NOVEL ROLE FOR UNOCCUPIED INSULIN AND IGF-1 RECEPTORS IN THE CONTROL OF APOPTOSIS
Boucher Jeremie1, Macotela Yazmin1, Bezy Olivier1, Mori Marcelo1, Kriauciunas Kristina1, Kahn C. Ronald1
1Joslin Diabetes Center, Boston, Usa
Insulin and IGF-1 are potent and complementary anti-apoptotic hormones. In wild-type (WT) brown preadipocytes with both 
receptors intact, or with knockout of either the insulin receptor (IR) or the IGF-1 receptor (IGF1R), serum withdrawal induces rapid 
apoptosis that can be rescued by addition of insulin or IGF-1. Surprisingly, double knockout (DKO) cells lacking both insulin and IGF-1 
receptors, show remarkable resistance to apoptosis. Serum deprivation induced strong activation of caspase 3, DNA fragmentation, 
and apoptosis as indicated by FACS analysis of annexin binding in WT, IRKO and IGFRKO cells, but not in DKO cells. Resistance to 
apoptosis was observed in both the extrinsic pathway induced by TNFα or FAS ligand and the intrinsic pathway induced by growth 
factor deprivation, DNA damage or oxidative stress. The apoptosis resistance in DKO cells was due to decreased levels of the 
pro-apoptotic protein Bax and an increase in the anti-apoptotic proteins Bcl2, Bcl-xL, XIAP and Flip, which occurred through post-
transcriptional control of expression. Furthermore, expression of IR and/or IGF1R in DKO cells restored their sensitivity to apoptosis. 
More surprisingly, expression of a kinase dead mutant of the IR restored apoptosis sensitivity, indicating that the kinase activity 
of the IR is not required for the pro-apoptotic effect of the unoccupied receptor. Thus, the insulin and IGF-1 receptors have unique, 
bidirectional roles in the control of cell survival. Insulin and IGF-1 binding to and activating their receptors block apoptosis, whereas 
unliganded insulin and IGF-1 receptors acting independent of kinase activity provide a permissive effect in cell death.
P01.11 - New concepts in insulin signal transduction
THE MOTOR PROTEIN KIF1B-ALPHA IS A NOVEL AKT SUBSTRATE
Kovacs Anna-Maria1, Häring Hans-Ulrich1, Lammers Reiner1
1Department Of Internal Medicine IV, Tübingen, Germany
Akt is an important player in insulin signalling, and therefore it is important to identify and investigate new Akt substrates. Here 
we investigated the role of the new Akt substrate KIF1B-alpha, a motor protein which is involved in mitochondrial transport. 
Heterozygous knockout mice suffer from progressive muscle weakness. KIF1B-alpha may play a role in mitochondrial dysfunction 
that was shown to be associated with type 2 diabetes. Computer analysis indicated that KIF1B-alpha is an Akt substrate. The 
phosphorylation of KIF1B-alpha by Akt was shown in an in vitro kinase assay. IGF1-induced phosphorylation of KIF1B-alpha was 
prevented by inhibition of Akt with the inhibitor Akti-1/2. This phosphorylation site is additionally a target for several other kinases 
and one of two 14-3-3 binding sites. Overexpression of 14-3-3 binding deficient KIF1B-alpha mutants resulted in delayed cell 
spreading accompanied by impaired reorganization of the microtubules and disturbed mitochondrial relocalisation. Our results 
show that KIF1B-alpha is a convergence point for different pathways, including the Akt pathway. The phosphorylation and 14-3-3 
binding is important for the correct function of KIF1B-alpha. Furthermore, KIF1B-alpha is not only transporting mitochondria along 
microtubules but is also involved in microtubule organisation and cell spreading. Therefore, KIF1B-alpha may be important for the 
function of mitochondria, but may also be involved in the development or repair of tissues.
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P01.12 - New concepts in insulin signal transduction
CGMP-DEPENDENT PROTEIN KINASE DEFICIENCY CAUSES LIVER INFLAMMATION AND HYPERGLYCEMIA
Stefan Z. Lutz1, Anita M. Hennige1, Andreas Peter1, Cora Weigert1, Susanne Feil1, Juergen Machann1, Robert Feil1, Hans-Ulrich Häring1
1University Of Tübingen, Tübingen, Germany
The NO⁄cGMP⁄cGMP-dependent protein kinase I (cGKI) signaling pathway regulates cell functions that play a pivotal role in the 
pathogenesis of type 2 diabetes mellitus. However, the impact of a dysfunction of this pathway for glucose metabolism in vivo is 
unknown. Therefore, the consequences of a genetic deletion of cGKI were analyzed in mice that express cGKI selectively in smooth 
muscle (cGKI-SM) to obtain a viable phenotype. In controls, cGKI protein was detected in hepatic stellate cells, but not in hepatocytes, 
skeletal muscle, fat cells or pancreatic islets. As compared to control animals, cGKI-SM mice had higher energy expenditure 
associated with lower body weight and fat mass and increased insulin sensitivity. Mutant mice showed higher fasting glucose levels, 
while insulin levels and glucose tolerance tests were similar to controls. IL-6 expression was strongly upregulated in the liver of 
cGKI-SM mice and accompanied by increased STAT3 (Tyr 705) phosphorylation and serum IL-6 levels. Moreover, the number of 
macrophages in the liver was higher in cGKI-SM mice. Insulin-stimulated tyrosine phosphorylation of the insulin receptor (IR) in the 
liver was impaired in cGKI-SM mice. In contrast to cGKI-SM mice, conditional knockout mice lacking cGKI only in the nervous system 
had normal levels of fasting glucose as well as hepatic IL-6 expression and IR phosphorylation. Together, a loss of cGKI in hepatic 
stellate cells affects liver metabolism via a paracrine mechanism by enhanced IL-6 signaling and macrophage infiltration that finally 
results in a complex metabolic phenotype including hepatic insulin resistance and fasting hyperglycemia.
P01.13 - New concepts in insulin signal transduction
EFFECTS OF LIPID-INDUCED ENDOPLASMIC RETICULUM STRESS ON INSULIN ACTION IN LIVER CELLS
Achard Caroline 1, Laybutt Ross1
1Garvan Institute Of Medical Research, Sydney, Australia
Obesity and associated lipid oversupply is a likely cause of insulin resistance (IR) in peripheral tissues incuding liver, but the 
mechanisms responsible remain unknown. We investigated the role of endoplasmic reticulum (ER) stress in hepatic IR induced by 
palmitate, a saturated fatty-acid. In human hepatoma HepG2 cells and in mouse isolated hepatocytes, exposure to palmitate dose- 
(250-750 µmol/l) dependently led to activation of two arms of the ER stress response (increased PERK and EIF2α phosphorylation, 
XBP1 splicing and CHOP expression, JNK activation), associated with defective insulin signalling (decreased insulin-stimulated 
Akt phosphorylation) and reduced insulin action (insulin-stimulated glycogen synthesis). In presence of chemical chaperones 
(trimethylamine N-oxide or tauroursodeoxycholic acid), palmitate-induced insulin signalling defect was partially reversed, 
demonstrating that ER stress makes a necessary contribution to lipid-induced IR in liver cells. As ER stress response has been 
described as a protective signalling pathway, we also investigated the consequences of chronic mild ER stress on insulin signalling. 
Strikingly, chronic exposure of HepG2 cells to low level thapsigargin, tunicamycin or palmitate led to enhanced insulin signalling. This 
was associated with an attenuated ER stress activation in response to subsequent high-level palmitate or thapsigargin exposure. 
Our results suggest chronic exposure of liver cells to low-level palmitate induces an adaptive ER stress response that enhances 
insulin signalling. However, more severe ER stress induced by chronically elevated palmitate overwhelms the adaptive response and 
contributes to hepatic IR.
P01.14 - New concepts in insulin signal transduction
IDENTIFICATION OF NOVEL PHOSPHORYLATION SITES IN IRS2 AND INTERACTION WITH 14-3-3 PROTEINS
Neukamm Sabine1, Lehmann Rainer1, Häring Hans-Ulrich1, Schleicher Erwin D.1, Weigert Cora1, Mackintosh Carol2, Morrice Nick2, Kalbacher 
Hubert3
1Internal Medicine IV, University Hospital Tübingen, Tübingen, Germany; 2Mrc Protein Phosphorylation Unit, College Of Life Sciences, University 
Of Dundee, Dundee, Scotland, Uk; 3Interfacultary Institute Of Biochemistry, University Of Tübingen, Tübingen, Germany
Approach 14-3-3 proteins are dimers that dock onto two phosphorylated serine-/threonine residues on hundreds of intracellular 
proteins, including sites that are activated upon insulin stimulation. The 14-3-3s can integrate signals from different signalling 
pathways, block the interactions of targets with other proteins or alter the conformation of the target protein. In the diabetic state 
the regulation of insulin signalling is disturbed, therefore the investigation of the interaction of 14-3-3s with IRS-2 is one more step 
in the understanding of the insulin signalling network. Methods HEK293 cells were transiently transfected with GFP-IRS2 and after 
stimulation IRS2 was purified using the GFP-nanotrap immobilized antibody, which was followed by Mass Spectometric analysis to 
identify phosphorylated peptides. To show the interaction of 14-3-3 with IRS2 the Far-Western Blotting technique using recombinant 
14-3-3 or a mix of BMH1 and BMH2 (yeast forms of 14-3-3) was used. Results/Outlook 14-3-3 proteins interact with IRS2 in an insulin-
dependent manner. Twenty-nine phosphorylated amino acid residues were identified on IRS2, including sites that are being tested 
for their potential binding to 14-3-3s. Insulin-dependent phosphorylation of specific serines was verified in cell culture studies. 
Among the other sites, one is located in the pleckstrin homology domain. Whether this phosphorylation affects the function of IRS2 by 
altering recruitment to the plasma membrane or interaction with components of the signal transduction pathway is currently under 
investigation.
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PROTEIN KINASE C EPSILON ABLATION IMPAIRS INSULIN RECEPTOR TRAFFICKING BUT NOT SIGNALLING
Pedersen David1, Schmitz-Peiffer Carsten1
1Garvan Institute Of Medical Research, Sydney, Australia
We have previously shown that protein kinase C epsilon knockout (PKCε KO) mice are protected from glucose intolerance induced by 
a high fat diet, in part through reduced hepatic insulin clearance. Understanding the PKCε-dependent regulation of insulin receptor 
(IR) trafficking may enable modulation of insulin clearance to treat glucose intolerance through enhanced insulin availability. We 
investigated the role of PKCε in this process using wild type (WT) and PKCε KO mouse embryonic fibroblasts (MEFs). PKCε KO MEFs 
had greatly reduced fluorescently-labelled insulin uptake and this was associated with a reduction in the insulin-stimulated IR 
redistribution within the cell, analysed by immunoblotting of fractions derived from Opti-Prep density gradient centrifugation. Insulin-
stimulated IR Tyr 1162/1163 phosphorylation was also reduced, with a maximum difference at 2 min. This defect in IR phosphorylation 
did not, however, translate to defective downstream signalling with PKCε KO MEFs tending to have enhanced Akt/PKB, Erk1/2 and 
IRS-1 tyrosine phosphorylation over a 30min insulin-stimulated time course. A potential candidate for mediating these effects is 
growth factor receptor-bound protein 14 (Grb14) which can act to prevent tyrosine dephosphorylation specifically of the IR. We found 
Grb14 protein expression was reduced in PKCε KO MEFs, which may explain the alterations in both IR phosphorylation and trafficking. 
Thus reduced insulin uptake by PKCε KO MEFs is associated with altered IR trafficking and reduced IR phosphorylation, however, 
downstream insulin action is not inhibited, allowing for alterations in insulin clearance without defects in liver insulin action.
P01.16 - New concepts in insulin signal transduction
REGULATION OF PED/PEA-15 ExPRESSION LEVELS BY E3 LIGASE ITCH/AIP4
Perfetti Anna1, Porcaro Grazia1, Béguinot Francesco1, Formisano Pietro1
1DBPCM & IEOS/CNR Università Degli Studi Di Napoli Federico II, Napoli, Italia
Phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes (PED/PEA)-15 is an anti-apoptotic protein originally 
identified in astrocytes as a protein kinase C (PKC) substrate and found upregulated in insulin target tissues of patients with type 2 
diabetes. PED/PEA-15 has been described to be upregulated also in several human tumor cell lines and following experimental skin 
carcinogenesis. Thus, the increase of PED/PEA-15 appears to be involved in different pathogenetic states. We have previously shown 
that PED/PEA-15 is an ubiquitinated protein and it is degraded by the proteosome. However, the protein/s responsible for PED/PEA-
15 ubiquitination has/have not been identified so far. Here we show that the E3 ligase Itch/AIP4 interacts with PED/PEA-15 in the 
keratinocyte cell line HaCat, that expresses endogenous levels of both proteins. Itch/AIP4 has been reported to be phosphorylated 
and, thus, activated by JNK. Accordingly, treatment of HaCat cells with anisomycin, a well known JNK activator, induced PED/PEA-
15 ubiquitination and degradation. Moreover, when HaCat cells were treated with anisomycin in the presence of the JNK inhibitor 
SP600125, PED/PEA-15 ubiquitination and degradation were inhibited, in spite of a preserved interaction between the two proteins. 
In perspective, these data might contribute to understand the ubiquitination process of PED/PEA-15 and the role that its eventual 
deregulation might play in different pathogenetic conditions, such as diabetes and cancer.
P01.17 - New concepts in insulin signal transduction
GENETIC MUTATION OF P66SHC PROTEIN AT SER36 PREVENTS OxIDATIVE STRESS IN HUMAN LIVER CELLS
Perrini Sebastio1, De Stefano Francesca1, Natalicchio Annalisa1, Tortosa Federica1, Peschechera Alessandro1, Cignarelli Angelo1, Ficarella 
Romina1, Melchiorre Mariangela1, Losurdo Fabrizio1, Laviola Luigi1, Giorgino Francesco1
1Endocrinology & Metabolic Diseases, University Of Bari, Bari, Italy
The p66 Shc protein isoform (p66Shc), through its phosphorylation (Ph) on Ser36, modulates the intracellular oxidative balance. In 
this study, the role of p66Shc in cellular responses to oxidative stress was studied in human HepG2 liver cells. Wild-type p66Shc 
and mutant p66Shc, in which Ser36 had been replaced by Ala (p66Shc-Ala36), were selectively overexpressed in HepG2 cells 
following infection with recombinant adenoviruses. Intracellular ROS generation, in the presence of the DHE probe, was evaluated by 
fluorimetric analysis. Subcellular FoxO3a localization was investigated by confocal microscopy. Overexpression of wild-type p66Shc 
was associated with increased p66Shc Ph on Ser36, both under basal conditions and following exposure to H2O2 (by 8.0- and 10-fold, 
respectively; p<0.001 vs mock-infected or non-infected control cells). HepG2/p66Shc cells showed increased ROS synthesis, both 
basally and after H2O2 exposure (p<0.005). In addition, Erk-1/2 and Akt Ph levels were increased, and FoxO3a also showed enhanced 
Ph and consequently reduced nuclear localization (p<0.01 vs controls). Pretreatment of HepG2/p66Shc cells with the MEK inhibitor 
UO126 significantly reduced Erk-1/2 Ph and p66Shc Ph on Ser36 (p<0.001 vs controls), and this was associated with reduced basal and 
H2O2-stimulated ROS synthesis (p<0.01 vs controls). In contrast, HepG2/p66Shc-Ala36 cells showed blunted responses to oxidative 
stress, since following H2O2 exposure Ph of Erk-1/2, Akt and FoxO3a was markedly reduced, and ROS synthesis was completely 
abolished (p<0.001 vs. HepG2/p66Shc cells). The p66Shc/Erk/Foxo3a pathway represents a novel modulator of oxidative stress-
induced injury in liver cells.
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P01.18 - New concepts in insulin signal transduction
WNT CO-RECEPTORS LRP5/6 MODULATE PHOSPHORYLATION LEVELS OF KEY INSULIN SIGNALING MEDIATORS
Palsgaard Jane1, Emanuelli Brice1, Kahn C. Ronald1
1Joslin Diabetes Center, Harvard Medical School, Boston, Usa
Low-density lipoprotein receptor-related proteins 5 and 6 (LRP5 and LRP6) are important co-receptors in the wnt signaling pathway. 
The wnt signaling system is a major regulator of embryonic development and activation of the pathway inhibits adipogenesis. 
Crosstalk between insulin and wnt signaling pathways have been indicated in several ways. One example is the tyrosine 
phosphorylation of LRP6 in response to insulin which was recently reported in a phosphoproteomic study. We created LRP5, LRP6, 
and LRP5/6 double knockdown cell lines using a lenti virus shRNA approach in 3T3L1 preadipocytes. These cells had a blunted 
response to wnt3a treatments assessed by beta-catenin accumulation and LRP6 serine phosphorylation. However, decreased levels 
of LRP5/6 did not abolish the inhibitory effect of wnt3a on adipogenesis. Interestingly, LRP5 knockdown cells had more or less no 
response to insulin treatments in terms of GSK3beta, ERK1/2, MEK1/2 and SHC phosphorylation. Phosphorylation of mTOR and p70 S6 
Kinase was greatly impaired in both LRP5 and LRP6 knockdown cells. This impairment of the insulin signaling pathway was not found 
when treating with IGF1. Whether or not this finding represents a true difference in insulin and IGF1 signaling mechanisms needs to 
be verified. Additionally, we observed an aggregation of LRP5 and the insulin receptor in response to insulin which further supports 
that the two pathways interact. This data suggest that especially LRP5 plays an important role in insulin signaling and identifies a 
new level of insulin and wnt signaling crosstalk. Whether these findings play a role in the insulin response in vivo will need to be 
determined in future studies
P01.19 - New concepts in insulin signal transduction
IMMUNE-METABOLIC PICTURE OF T1D: A FOLLOW-UP STUDY DURING INSULIN TREATMENT
Galgani Mario2, Nugnes Rosa1, Franzese Adriana1, Matarese Giuseppe2
1Dipartimento Di Pediatria Università Degli Studi Di Napoli, Naples, Italy; 2Istituto Di Endocrinologia Ed Oncologia Sperimentale IEOS - CNR, 
Naples, Italy
Type 1 diabetes (T1D) is an immune-mediated disease originating from the selective destruction of beta cells following immune 
infiltration of the islets of Langerhans. Immune response and metabolic state are reciprocally influenced during autoimmune attack 
associated with T1D and both are involved in its pathogenesis. Our study intends to analyze in details the immune/metabolic profile 
of pediatric patients with T1D at the onset and after 12-18 months of disease. Circulating levels of several molecules associated 
with inflammation and metabolic responses (Leptin, LepR, MPO, sICAM, sCD40L, and Resistin) were analyzed in 48 patients (23 M, 
15 F) with new onset T1D (age 3.4-15; BMI 17.77±3.54) and 23 age-BMI-matched controls. Citofluorimetric analysis of immune cells 
population (CD4+, CD8+, DCs, NK cells) was concomitantly performed in both groups. Circulating levels of metabolic parameters were 
significantly different in two study groups, in particular patients showed higher levels of LepR, sICAM and lower levels of MPO, Leptin 
and Resistin when compared to age-matched control subjects. Immune cell analysis showed an increasing number of NK cells in T1D 
subjects associated with reduced number of T cell memory population. Immune-metabolic analysis performed after 12-18 months 
of disease displayed a significant reduction of LepR and further increase of NK cell. Our data show the existence of a characteristic 
immuno-metabolic profile in patients and represent the starting point for future more extensive and correlative studies aiming at 
better define specific diagnostic immune-metabolic profile that reflects disease staging and severity in relationship with insulin 
signalling
P01.20 - New concepts in insulin signal transduction
CHARACTERIZATION OF ADP1- POLYPHOSPHOINOSITIDE PHOSPHATASE INVOLVED IN INSULIN SIGNALING
Kryvych Sergiy1, Behrens Verena1, Himmelbauer Heinz 2, Hase Marie1, Schulz Nadja1, Scherneck Stephan1, Schürmann Annette1
1German Institute Of Human Nutrition Potsdam-Rehbrücke, Potsdam, Germany; 2Centre For Genomic Regulation, Barcelona, Spain
Type 2 diabetes and obesity represent one of the major health problems of modern civilization. Therefore molecular mechanisms 
of insulin action became an objective of numerous investigations. One of the major players of insulin signaling cascade is 
phosphatidylinositol 3,4,5- triphosphate (PIP3), which is required for the recruitment and activation of protein kinase B (PKB)/Akt, 
which in turn mediates downstream effects of insulin. Inositol polyphosphate phosphatases transform PIP3 into its inactive form 
via dephosporylation thus eventually decreasing amount of active PKB/Akt. ADP1 is a polyphosphoinositide phospatase specific for 
PIP3. We investigated the effects of its loss in mice. Adp1 knockout mice were produced by means of gene trapping. They displayed 
gender-dimorphic changes in insulin signalling. Male knockout mice showed lower insulin secretion rates and a slight tendency 
towards enhanced insulin sensitivity when compared to wild-type littermates. Such effect is likely to occur due to negative feedback 
mechanism activated by insulin in pancreatic beta-cells. In contrast, female mice did not demonstrate any alterations in insulin 
secretion levels and insulin sensitivity. However slight but significant increase in their body mass was observed. This increase was 
due to higher lean mass and to lesser extent due to elevated body fat content of these mice. Such changes might be a consequence 
of central alteration of insulin action. In summary, loss of function of ADP1 causes gender-dimorphic alterations in insulin secretion. 
Furthermore central insulin action is likely to be affected in female mice
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P01.21 - New concepts in insulin signal transduction
SOLUBLE INSULIN RECEPTOR ECTODOMAIN IS ELEVATED IN THE PLASMA OF PATIENTS WITH DIABETES
Yuasa Tomoyuki3, Nagaya Hisao3, Hashida Seiichi1, Umehara Asako1, Yokota Ichiro2, Obata Toshiyuki3, Ebina Yousuke3
1Department Of Human Life Science Division Of Life Style Diseases Institutes For Health Science Tokushima Bunri University, Tokushima, 
Japan; 2Department Of Pediatrics Graduate School Of Medicine The University Of Tokushima, Tokushima, Japan; 3Division Of Molecular Genetics 
Institute For Enzyme Research The University Of Tokushima, Tokushima, Japan
Soluble insulin receptor ectodomain, which consists of a whole α subunit and a part of b subunit (soluble IRα), was found to exist 
in human plasma. We developed the ELISA system for human specific insulin receptor α subunit using two kinds of monoclonal 
antibodies against distinct epitopes on human insulin receptor α subunits. The plasma soluble IRα levels of both type 2 and type 
1 diabetic patients undergoing various treatments were significantly elevated compared with the control group which had been 
confirmed to be normoglycemic by oral glucose tolerance test. According to the analysis of the correlations of soluble IRα levels 
with the clinical parameters of type 2 diabetic patients, there were significant positive correletions between soluble IRα and blood 
glucose levels, including fasting blood glucose and A1c levels. We further confirmed that soluble IRα levels of new-onset type 1 
diabetic patients decreased parallel to blood glucose levels by intensive insulin therapy. In addition, soluble IRα levels had reached 
plateau earlier than glycoalbumin and A1c levels. Furthermore, we found that urinary soluble IRα levels had a correlation with soluble 
IRα levels in the serum, and the urinary soluble IRα levels in patients with diabetes was significantly higher than those in healthy 
volunteers. We have continued to determine a biological meaning of soluble IRα through various clinical investigations. Regarding the 
mechanisms of soluble IRα generation, we have proposed the hypothesis that insulin receptors on the plasma membrane receive the 
“shedding”, meaning that a proteinase is activated by a stimuli (e.g. hyperglycemia) and then cleaves insulin receptors.
P01.22 - New concepts in insulin signal transduction
TOWARDS THE STRUCTURAL BASIS OF “INSULIN RECEPTOR SUBSTRATE-1 (IRS-1)” FUNCTION
Khan Zaigham M1, Mueller Steffen1, Persson David1, Kambach Christian 2, Kalbacher Hubert1, Lehmann Rainer3, Schleicher Erwin D3, Häring 
Hans-Ulrich3, Voelter Wolfgang1, Stehle Thilo4
1Interfaculty Institute For Biochemistry, University Of Tübingen, Tübingen, Germany; 2Paul Scherrer Institut, Life Sciences, Ch-5232 Villigen, 
Switzerland; 3Division Of Clinical Chemistry And Pathobiochemistry, University Of Tübingen, Tübingen, Germany; 4Department Of Pediatrics, 
Vanderbilt University School Of Medicine, Nashville, Tn 37232, Usa
Insulin Receptor Substrate-1 (IRS-1) is a key component of multiple intracellular signaling pathways. Human IRS-1 harbors numerous 
physiologically important phosphorylation motifs. It is well established that phosphorylation of serine residues results in inhibition of the 
association of IRS-1 with its cognate binding partners. However, the structural basis underlying this process is not understood. Moreover, 
the studies conducted previously mostly focused on “one site-one effect” phenomenon due to the unavailability of phosphorylated-
residue-specific antibodies. Nevertheless, the disruption of association of IRS-1 with its binding partners has been reported for multiple 
different residues. Therefore, it might be the phosphorylation of the Ser-rich domain rather than a single Ser-residue that subsequently 
abolishes the binding. We focused on the association of IRS-1 with the insulin receptor to address this issue. We designed different 
boundaries of the hypothetical “PTBD-associated-Ser-rich domain” and generated glutamate mutants of pertinent serine residues and 
the combination thereof for Surface Plasmon Resonance analysis. The bacterially expressed protein fragments were characterized to 
ensure their proper fold. We are currently screening the mutants individually to estimate the strength of inhibition. This will be followed 
by testing of the cohort of mutants to identify the minimum number of the Ser-residues required to abrogate the binding per se. We 
anticipate that our finding will illuminate the determinants of interactions of IRS-1 with its binding partner(s). The elucidation of the 
structural basis of the IRS-1 function is the ultimate goal of our project.
P01.23 - New concepts in insulin signal transduction
OLEATE REGULATES HEPATOMA PROLIFERATION AND SENSITIVITY TO RAPAMYCIN THROUGH MTOR
Arous Caroline1, Naïmi Mourad1, Van Obberghen Emmanuel1
1Inserm U907, Medecine Faculty, Nice-Sophia Antipolis Faculty, Nice, France
Epidemiological studies indicate that high-fat diet and obesity are associated with increased risk of liver cancer. While the impact of 
fatty acids on cancer development is highly controversial, several studies suggest the involvement of fatty acids in generation of liver 
tumors. Here we explored the effects of the monounsaturated fatty acid, oleate, on signaling pathways and proliferation in the human 
hepatoma cell line, HepG2. We found that a low dose of oleate increased HepG2 cell proliferation, whereas a high dose inhibited it. In 
addition, oleate affected major growth-promoting signaling pathways in HepG2 cells. Remarkably, we found that the mTor pathway 
appears to be the only one activated by a low dose of oleate, but inhibited by a high dose. In contrast, the PI3K and MAPK pathways were 
not differentially modulated by oleate. These preliminary results suggest the involvement of mTor in the oleate-mediated proliferative 
effects. Further, oleate at low and high dose increased and decreased, respectively, the translation of cell cycle regulators. Importantly, 
the mTor inhibitor rapamycin reduced the translation of those cell cycle regulators and the proliferation of HepG2 cells in absence of 
oleate, but not when present at low concentration. This suggests the occurrence of an oleate-mediated regulation of mTor, which may 
render mTor resistant to rapamycin. While caution is required in extrapolating to the human situation, our results support the notion 
that western diet promotes hepatoma proliferation through oleate-mediated mTor activation, and may limit the therapeutic use of 
rapamycin-derived mTor inhibitors to reduce deregulated hepatic proliferation.
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P01.24 - New concepts in insulin signal transduction
COMPARATIVE PATHWAYS OF THE INSULIN RECEPTOR AND INSULIN UPON INTERNALIZATION IN RAT LIVER
Bernard Desbuquois1, Khadija Tahiri2
1Institut Cochin, Université Paris Descartes, Cnrs Umr 8104, Inserm U 567, Paris, France; 2Inserm Umr-s 747, Université Paris Descartes, Centre 
Universitaire Des Saints-Pères, Paris, France
Endosomes (ENs) have been identified as the main locus at which both insulin and the activated insulin receptor (IR) accumulate 
upon internalization in rat liver. In this study analytical cell fractionation methods have been used to compare the pathways of the IR 
and insulin in liver and to assess their association with lysosomes (LYs). Following injection of insulin to rats (25 µg/100 g body wt), the 
bulk of liver IRs as detected by ligand binding and Western blot underwent a rapid transfer from high density elements sedimenting 
in nuclear (N) and microsomal (P) fractions, enriched in plasma membrane (PM) markers, to low density elements sedimenting 
in the P fraction, enriched in Golgi and EN markers. This change was detectable at 2 min, maximal at 15 min and fully reversed in 
2 h. At 2-5 min, the acid-extractable insulin associated with P and EN fractions distributed similarly to the IR, but after 30 min it 
became in part separable from the IR, being shifted towards higher densities. Although insulin injection led to a slight increase in 
IR and insulin content in large granule (ML) fractions, most of this material migrated at lower densities than LY markers on density 
gradients. However, an EN to LY transfer of both insulin and IR, accompanied by a degradation of IR-b subunit, did occur in a liver 
cell-free system, and under these in vitro conditions ENs containing biotinylated insulin were shown to fuse with avidin-loaded LYs. It 
is concluded that, following co-translocation of insulin and the IR from the PM to ENs, the IR progressively segregates from insulin, 
and although capable of undergoing lysosomal transfer in vitro, is in major part recycled.
P01.24 bis - New concepts in insulin signal transduction
FUNCTIONAL CHARACTERIZATION OF THE 5’FLANKING REGION OF THE RAT INSULIN RECEPTOR GENE
Martine Collinet1, Sylvie Bortoli1, Bernard Desbuquois2
1Inserm Umr S-747, Université Rene Descartes, Centre Universitaire Des Saints-Pères, Paris, France; 2Inserm U567, Cnrs Umr 8104, Institut 
Cochin, Université Paris Descartes, Paris, France
We have previously cloned a 0.9 kb portion of the 5’flanking region of the rat insulin receptor (IR) gene (-1143 to -252 bp upstream 
from the ATG) and shown that the region extending from -536 to -386 displays a marked sequence identity with the corresponding 
region of the mouse (92%) and human (81%) genes (Genebank data base, accession number AJ06071). In the present study, some 
functional properties of the -1143/-252 fragment of the rat IR gene have been characterized. Several transcriptional initiation sites 
(two major sites at -455 and -394, and four minor sites at -430, -381, -367 and -361) have been identified using a RNase protection 
assay. When fused to the luciferase reporter gene in the PGL3 expression vector and transiently transfected into Fao rat hepatoma 
cells, the -1143/-252 fragment displayed promoter activity. Deletion of the -1143/-760 region little affected activity, but additional 
deletion of the -759/-464 region led to a 90% decrease in activity. Treatment of cells with vanadate, previously shown to inhibit the 
transcriptional activity of the endogenous IR gene, led to a significant, dose-dependent decrease in the activity of the -1143/-252 IR-
luciferase construct (40% at 0.125 mM and 70% at 0.250 mM). Vanadate treatment also led to a significant, comparable decrease in 
the activity of the -759/-252 and -463/-252 IR-luciferase constructs. These data indicate that the -759/-464 region of the rat IR gene is 
important for promoter activity and suggest that DNA elements localized downstream this region, which remain to be identified, are 
involved in the ability of vanadate to inhibit activity.
P02.25 - The role of adipose tissue in insulin action
A ROLE FOR G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) IN INSULIN RESISTANCE AND OBESITY
Garcia-Guerra Lucia3, Nieto-Vazquez Iria3, Vila-Bedmar Rocio3, Jurado-Pueyo Maria2, Zalba Guillermo1, Diez Javier1, Murga Cristina2, Fernandez-
Veledo Sonia3, Mayor Jr. Federico2, Lorenzo Margarita3
1Division Of Cardiovascular Sciences, Center For Applied Medical Research, University Of Navarra, Pamplona, Spain; 2II Dpto. BiologÍa Molecular 
And Centro De BiologÍa Molecular Severo Ochoa (csic-uam), Madrid, Spain; 3Dpto. BioquÍmica Y BiologÍa Molecular II. Facultad De Farmacia. 
Universidad Complutense De Madrid And Ciber De Diabetes Y Enfermedades Metabólicas Asociadas (ciberdem), Madrid, Spain
Insulin resistance is associated with the pathogenesis of metabolic disorders as type-2-diabetes and obesity. Given the 
sociopathological importance of these syndromes, we set out to explore the possible role that G protein-coupled receptor kinase 
2 (GRK2), first identified as a G protein-coupled receptor regulator, could have as a modulator of insulin responses. We analyzed 
the influence of GRK2 levels in the development of insulin resistance in myoblasts and adipocytes with experimentally increased 
or silenced levels of GRK2, and in GRK2+/- animals expressing 50% lower levels of this kinase by using three different models of 
insulin resistance: TNFα infusion, aging and high fat (HFD) feeding. Glucose transport, whole body glucose and insulin tolerance, 
the activation status of insulin pathway components, and the circulating levels of important mediators were measured, and the 
development of obesity and adipocyte size with age and HFD was analyzed. Altering GRK2 levels markedly modifies insulin-mediated 
signaling in cultured adipocytes and myocytes. GRK2 levels are increased by approximately 2-fold in muscle and adipose tissue in the 
animal models tested, and in lymphocytes from metabolic syndrome patients. In contrast, hemizygous GRK2 mice show enhanced 
insulin sensitivity and do not develop insulin resistance by TNFα aging or HFD. Furthermore, reduced GRK2 levels induce a lean 
phenotype and decrease age-related adiposity. Overall, our data identify GRK2 as an important negative regulator of insulin effects, 
key to the etiopathogenesis of insulin resistance and obesity, what uncovers this protein as a potential therapeutic target in the 
treatment of these disorders.
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P02.26 - The role of adipose tissue in insulin action
ADIPOSE MAP4K4 DEFICIENCY ENHANCES INSULIN SENSITIVITY AND LOWERS HEPATIC GLUCOSE OUTPUT
Guntur Kalyani1, Aouadi Myriam 1, Tesz Gregory1, Nicoloro Sarah1, Hagan Nana1, Wang Mengxi1, Jung Dae Young 1, Friedline Randall 1, Kim Jason1, 
Czech Michael 1
1University Of Massachusetts Medical School, Worcester, Usa
In an RNAi based screen, the Ste20 protein kinase ortholog Map4k4 was identified in our laboratory as an inhibitor of PPARγ 
expression and triglyceride deposition in 3T3-L1 adipocytes. The effect of Map4k4 on PPARγ appears to be mediated through 
regulation of protein synthesis rather than transcription or protein degradation. To investigate the role of Map4k4 suppression on 
adipose tissue function and whole-body metabolism, we produced transgenic mice that express an shRNA that attenuates Map4k4 
expression selectively in adipose tissue. Map4k4 AdKD mice became obese on CHO or HFD and displayed significantly more adipose 
tissue, enhanced PPARγ protein levels, but lower lean mass than control mice. Remarkably, adipocytes from Map4k4 AdKD mice 
exhibited striking hypertrophy with increased triglyceride storage, but this was accompanied by markedly reduced macrophage 
infiltration. This increased adiposity in Map4k4 AdKD mice was not due to changes in energy expenditure, physical activity or caloric 
intake compared to control mice. Importantly, although Map4k4 AdKD mice were more obese than controls, fasting glycemia was 
lowered, GTT was normal and they exhibited enhanced insulin sensitivity compared to control littermates matched for weight. This 
could be attributed to reduced hepatic glucose production observed in Map4k4 AdKD mice under basal and hyperinsulinemic clamp 
conditions. Thus, Map4k4 deficiency in adipose cells improves adipose function to store triglyceride, with beneficial effects on liver 
glucose production and whole body glucose homeostasis. This increased insulin sensitivity occurs in spite of the obesity displayed by 
the Map4k4 AdKD mice.
P02.28 - The role of adipose tissue in insulin action
DGK DELTA ExPRESSION IS REQUIRED FOR ADIPOGENESIS
Lowe Chris2, Zierath Juleen1, O’Rahilly Stephen2, Rochford Justin2
1Karolinska Institute, Stockholm, Sweden ; 2Institute Of Metabolic Science, Cambridge, Uk
Diacylglycerol (DAG) is both a second messenger of intracellular signalling and a key intermediate in the synthesis of lipids. 
Consequently, intracellular DAG levels are tightly regulated by DAG kinases such as DGK delta. Mice lacking DGK delta show skeletal 
muscle insulin resistance and develop metabolic disease whilst decreased DGK delta is observed in the skeletal muscle of humans 
with insulin resistance. Although DGK delta is also highly expressed in adipose tissue its involvement in adipocyte development 
and function has not been investigated. Here we show that DGK delta is highly induced during adipogenesis and abundantly and 
selectively expressed in the mature adipocyte fraction of adipose tissue. Further, we show that inhibition of DGK delta expression, 
using shRNA, leads to an inhibition of adipogenesis. We find a marked reduction in lipid accumulation and reduced expression of 
key adipogenic markers. Notably, the early induction of the essential transcription factor PPAR gamma appears normal. However, 
this expression is not maintained as adipogenesis proceeds, implying an impairment of PPAR gamma activity. Together, these data 
demonstrate that DGK delta is required for adipogenesis.
P02.29 - The role of adipose tissue in insulin action
AHNAK- A NOVEL REGULATOR OF GLUT4: ROLE IN OBESITY AND INSULIN RESISTANCE
Rozentzweig Ben-Yosef Dafna1, Harel Chava1, Armoni Michal1, Ciaraldi Theodore P2, Henry Robert R2, Karnieli Eddy1
1Institute Of Endocrinology, Diabetes And Metabolism, Rambam Medical Center And B. Rappaport Faculty Of Medicine, Technion -Israel Institute 
Of Technology, Haifa, Israel; 2San Diego Healthcare System And Department Of Medicine, University Of California, San Diego, United States
High levels of free fatty acids such as arachidonic acid (AA) play an important role in insulin resistance, obesity and type 2 diabetes 
(DM2). This lipotoxicity is associated with reduced GLUT4 expression and function. Elevated levels AA repress GLUT4-promoter 
(GLUT4-P) via specific region but the mediator remains elusive. Using this region as a bait in AA-treated cardiomyocytes, followed 
by mass spectrometry analysis, we identified AHNAK, a giant phosphoprotein, known to be involved in calcium and lipid metabolism, 
attached to GLUT4-P. This was subsequently confirmed by ChIP assay. In subcutaneous adipose tissue obtained from obese patients 
undergoing bariatric surgery, AHNAK mRNA correlated with weight loss degree of (R2=0.943 ; p<0.005). Similarly, compared to 
lean controls, AHNAK mRNA were ~2 fold increased in adipocytes of aged/obese rats. Transient expression of AHNAK in primary 
rat adipocytes repressed transcription from GLUT4-P which was partially curtailed by insulin, via nuclear exclusion of AHNAK, 
as observed by immunofluorescent staining. Further, AHNAK silencing enhanced Glut4 protein by 2-fold, and protected it from 
AA-induced repression. The potential role of AHNAK on GLUT4 translocation was studied in muscle–derived L6 GLUT4myc cells. 
Compared to mock transfection, AHNAK silencing increased basal and insulin-stimulated cell surface levels of GLUT4 to ~150% 
and ~230%, respectively. In conclusion, AHNAK is a novel regulator of GLUT4, reduces its gene expression, impairs its translocation 
machinary, thus contributing to the pathogenesis of insulin resistance. Hence, AHNAK may serve as potential molecular therapeutic 
target in obesity and DM2
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P02.30 - The role of adipose tissue in insulin action
BMI-INDEPENDENT INFLAMMATION IN OMENTAL ADIPOSE TISSUE ASSOCIATED WITH INSULIN RESISTANCE
Hardy Olga2, Perugini Richard2, Nicoloro Sarah2, Gallagher-Dorval Karen2, Puri Vishwajeet1, Straubhaar Juerg 2, Czech Michael 2
1Boston University, Boston, Usa; 2University Of Massachusetts Medical Center, Worcester, Usa
Obesity is an important risk factor for resistance to insulin-mediated glucose disposal, a precursor of type 2 diabetes and other 
disorders. To identify molecular pathways in adipose tissue that may result in obesity-associated insulin resistance in human 
subjects, we exploited the fact that not all obese individuals are prone to insulin resistance. Thus, the degree of obesity as a 
variable was removed by studying morbidly obese subjects of similar body mass index (BMI) values who are insulin-sensitive (IS) 
versus insulin-resistant (IR). Combining gene expression profiling with computational approaches, we determined the global gene 
expression signatures of omental and subcutaneous adipose tissue samples obtained from 10 obese-IR and 10 obese-IS patients 
undergoing gastric bypass surgery. Gene sets related to chemokine activity and chemokine receptor-binding were identified as most 
highly expressed in the omental tissue from obese-IR compared to obese-IS subjects, independent of BMI. These upregulated genes 
included chemokines CCL2, CCL3, CCL4, CCL8, CXCL2, CXCL10 and IL8/CXCL8, and were not differentially expressed in subcutaneous 
adipose tissues between the two groups of subjects. Strikingly, insulin resistance, but not BMI, was associated with increased 
macrophage infiltration in the omental adipose tissue, as was adipocyte size, in these morbidly obese subjects. Our findings strongly 
support the hypothesis that inflammation of omental adipose tissue mediates insulin resistance in human obesity.
P02.31 - The role of adipose tissue in insulin action
THE HUMAN LIPODYSTROPHY PROTEIN BSCL2/SEIPIN BINDS THE KEY LIPOGENIC ENZYME LIPIN 1
Aubry Evelyne1, Dennis Rowena1, Lowe Chris1, Sembongi Hiroshi1, Ito Daisuke2, O’Rahilly Stephen1, Siniossoglou Symeon1, Rochford Justin1
1University Of Cambridge, Cambridge, Uk; 2Keio University, Tokyo, Japan
Patients with congenital generalised lipodystrophy (CGL) suffer severe insulin resistance demonstrating the importance of functional 
adipose tissue for metabolic homeostasis. Homozygous loss of function mutations in BSCL2 cause the most severe form of CGL 
reported. The protein encoded by this gene, BSCL2/seipin, is localised to the endoplasmic reticulum (ER) membrane and plays 
an essential role in adipocyte differentiation, whilst disruption of BSCL2/seipin in non-adipose cells impairs the formation of lipid 
droplets. However, the molecular function of BSCL2/seipin in adipocyte development remains unknown. Lipin 1 is a key enzyme 
of triglyceride synthesis which, unlike other enzymes in this process, lacks a transmembrane domain. Here we demonstrate that 
in developing adipocytes lipin 1 translocates to the ER under lipogenic conditions where it binds BSCL2/seipin. Moreover, BSCL2/
seipin and lipin 1 are co-localised where the ER contacts small, newly-formed lipid droplets. The ability of BSCL2/seipin to act as 
an ER membrane anchor for Lipin 1 during lipogenesis suggests the first molecular mechanism whereby congenital BSCL2/seipin 
deficiency may cause severe lipodystrophy.
P02.32 - The role of adipose tissue in insulin action
DEFICIENCY IN ERK1 PROTECTS OB/OB MICE FROM INSULIN RESISTANCE WITHOUT AFFECTING OBESITY
Jennifer Jager2, Véronique Corcelle2, Thierry Gremeaux2, Kathiane Laurent2, Aurélie Waget1, Yannick Le Marchand-Brustel2, Rémy Burcelin1, 
Frédéric Bost2, Jean-François Tanti2
1Inserm U858, Toulouse, France; 2Inserm U895, Team 7, Nice, France
ERK activity is increased in adipose tissue from obese and type II diabetic animals and patients. Strong evidences suggest that 
activation of ERK is implicated in the down-regulation of insulin signaling and action in insulin resistance state. Here, we perform 
genetic inactivation of ERK1 in leptin-deficient mice (ob/ob) to determine whether the lack of ERK1 could improve insulin sensitivity 
and metabolic disorders in obese mouse models. ob/ob-ERK1-/- mice were obtained by crossing ERK1-/- mice with ob/ob mice. 
Mice were studied at 12 weeks of age. Body weight and adiposity were comparable between ob/ob-ERK1-/- and ob/ob mice. However, 
ob/ob-ERK1-/- mice did not develop hyperglycemia and their glucose tolerance was improved compared to ob/ob mice. Using 
hyperinsulinemic euglycemic clamp, we showed an improved whole-body insulin sensitivity of ob/ob-ERK1-/- mice, due to an increase 
of glucose uptake in skeletal muscles. Moreover, ob/ob-ERK1-/- mice were partially protected against hepatic steatosis with a strong 
reduction in Acetyl-CoA Carboxylase expression. The ob/ob-ERK1-/- mice also showed markedly reduced adipose tissue inflammatory 
markers expression, and the adipose tissue insulin sensitivity during euglycemic clamp was improved. Our results indicate that 
the specific targeting of ERK1 could protect obese mice against insulin resistance and liver steatosis by decreasing adipose tissue 
inflammation and by increasing muscle glucose uptake. Our results indicate that deregulation of ERK1 pathway could be an important 
component in obesity-associated metabolic disorders.
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TWEAK PREVENTS TNF-α-INDUCED INSULIN RESISTANCE IN HUMAN VISCERAL ADIPOCYTES
Vazquez-Carballo Ana1, Chacon Matilde R.2, Vila-Bedmar Rocio1, Lorenzo Margarita1, Vendrell Joan2, Fernandez-Veledo Sonia1
1Complutense University, Madrid, Spain; 2Pere Virgili Institute, University Hospital Of Tarragona Joan XXIII, Tarragona, Spain
Insulin resistance is an important contributor to the pathogenesis of type 2 diabetes and obesity is a risk factor for its development. 
In the obese state an altered secretion pattern is observed and mediators released from adipocytes and macrophages, including 
TNF family members, have been suggested to impair insulin action in peripheral tissues. Tumor necrosis factor-like weak inducer 
of apoptosis (TWEAK) is a recently identified pro-inflammatory cytokine that regulates multiple cellular responses. Tweak could 
be involved in the pathogenesis of chronic inflammatory diseases but its physiological role in adipose tissue is still not known. The 
objective of the present study was to dissect the differential effects of Tweak vs. TNF-α on human visceral adipocytes. We analyzed 
the impact of these cytokines on glucose uptake and insulin action in a human visceral adipocytic cell line with high capacity to 
differentiate. TNF-α and Tweak activates different intracellular signaling pathways. TNF-α induces insulin resistance by JNK1/2-
dependent mechanism, impairing insulin-stimulated glucose uptake and insulin signaling at the IRS-1/Akt level. By contrast, Tweak 
does not induce JNK1/2 activation and in consequence insulin sensitivity on glucose uptake is not affected. Moreover, pre-treatment 
with Tweak prevented TNF-α-dependent JNK1/2 activation, restoring insulin signaling and insulin-induced glucose uptake. In 
conclusion, Tweak shows a protective role against TNF-α-induced insulin resistance in human visceral adipocytes. Our results 
suggest the balance of TNF family members on adipose tissue as a key factor in the pathogenesis of obesity-associated metabolic 
disorders.
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PHLPP1 INCREASES IN ADIPOSE TISSUE OF OBESE SUBJECTS CORRELATING WITH INSULIN RESISTANCE
Mannino Gaia1, Andreozzi Francesco1, Greco Annalisa1, Hribal Marta Letizia1, Raciti Gregory Alexander2, Iadicicco Claudia2, Miele Claudia2, 
Pontiroli Antonio E.3, Folli Franco4, Sesti Giorgio1
1University Of Catanzaro, Catanzaro, Italy; 2IEOS-CNR E DBPCM, University Of Naples “Federico II”, Naples, Italy; 3University Of Milan, Milano, 
Italy; 4University Of Texas Health Science Center, San Antonio, Usa
Insulin signalling pathway is altered in the adipose tissue of obese subjects. Akt plays a key role in insulin signal transduction. 
It was recently identified an Akt-specific phosphatase named PH domain leucine-rich repeat protein phosphatase (PHLPP) that 
dephosphorylates Akt in the Ser473 and has two isoforms (PHLPP1/2). It is not known whether PHLPP1/2 levels are increased in the 
target tissues of insulin action in the presence of insulin-resistance. To address this issue, we have analysed the expression of the 
two PHLPP isoforms in the adipose tissue of 70 obese (BMI=44±8) and 10 normoglycemic normoweight control subjects (BMI=25±3). 
Of the 70 obese subjects, 26 were NGT, 11 IFG, 17 IGT, 16 T2D. PHLPP1 expression was increased in obese group compared with the 
normoweight group (p<0.001) and was inversely related with Akt phosphorylation on Ser473 (r=-0.43;p=0.03). In the obese group, 
PHLPP1 expression did not change between subjects with different glycemic tolerance. After correction for age and sex, PHLPP1 
expression correlated with BMI (r=0.33;p=0.005), waist (r=0.34;P=0.005), fasting insulinemia (r=0.31;p=0.01) and HOMA index 
(r=0.26;p=0.02), but not with plasma glucose levels, in fasting condition and 2h after oral glucose loading, total cholesterol and HDL, 
triglycerides, leptin, TNFα and resistin. PHLPP2 expression did not correlate with anthropometric or metabolic parameters including 
BMI, waist, insulinemia and HOMA index. These data suggest that PHLPP1 over-expression could be a new molecular mechanism 
of insulin-resistance in obese subjects and that PHLPP1 could be a new therapeutic target in the treatment of insulin-resistant 
conditions.
P02.35 - The role of adipose tissue in insulin action
THE ROLE OF INCREASED S-NITROSYLATION IN IMPAIRED INSULIN-INDUCED ANTILIPOLYSIS IN OBESITY
Ovadia Hilla1, Bashan Nava1, Rudich Assaf1
1Ben-Gurion University, Beer-Sheva, Israel
Nitrosative stress occurs systemically in obesity and diabetes, and is suggested to contribute to the development of insulin resistance 
in muscle, but its role in adipose tissue dysfunction is unknown. In the present study we evaluated S-nitrosylation in adipose 
tissue mouse models of obesity, and assessed in 3T3-L1 adipocytes the ability of NO donors (GSNO, SNAP) to impair insulin action. 
Increased total S-nitrosylation of adipose tissue proteins was observed in high fat fed and ob/ob mice compared to lean controls, 
potentially due to enhanced iNOS and decreased thioredoxin reductase activities. As previously demonstrated in skeletal muscle, 
NO donors increased S-nitrosylation of IR, IRS1 and PKB causing mild reduction in insulin stimulated PKB phosphorylation. Yet PKB 
activity as demonstrated using phospho-PKB substrate antibody (PAS) and insulin-stimulated glucose uptake were not significantly 
impaired. Rather, exposure of 3T3-L1 adipocytes to the NO donor specifically blocked the antilipolytic action of insulin. Diminished 
ability of insulin to decrease p-PKA substrates phosphorylation in response to isoproteranol, including HSL and perilipin, pointed 
to impairment in PDE3B activation. Flag-PDE3B was readily S-nitrosylated by NO donors, and point mutants of PDE3B revealed 
that Cys768 and Cys1040, both adjecent to the catalytic site, superficially exposed, and predicted to be non-bonding in the native 
protein, were preferred sites of S-nitrosylation of PDE3B. Thus, PDE3B may constitute a newly-identified, adipose specific target of 
S-nitrosylation, contributing to impaired anti-lipolytic effect of insulin- a common characteristic of adipose dysfunction in obesity.
naples, Italy
October 28 - 30, 2010
53
XI
InternatIonal
SympoSIum 
on InsulIn ReceptoRs
and InsulIn actIon
P02.36 - The role of adipose tissue in insulin action
THE MAMMALIAN LIFE-SPAN DETERMINANT P66SHCA MEDIATES OBESITY-INDUCED INSULIN RESISTANCE
Chiatamone Ranieri Sofia1, Fusco Salvatore1, Panieri Emiliano1, Labate Valentina1, Mele Marina1, Tesori Valentina1, Ferrara Anna Maria1, Maulucci 
Giuseppe1, De Spirito Marco1, Martorana Giuseppe Ettore1, Galeotti Tommaso1, Pani Giovambattista1
1Catholic University Medical School, Rome, Italy
Obesity and metabolic syndrome result from excess calories intake and genetic predisposition and are mechanistically linked to 
type II diabetes and accelerated body ageing; abnormal nutrient and insulin signaling participate in this pathologic process, yet 
the underlying molecular mechanisms are incompletely understood. Mice lacking the p66 kD isoform of the Shc adapter molecule 
live longer and are leaner than wild type animals, suggesting that this molecule may have a role in metabolic derangement and 
premature senescence by overnutrition. We found that p66 deficiency exerts a modest but significant protective effect on fat 
accumulation and premature death in lepOb/Ob mice, an established genetic model of obesity and insulin resistance; strikingly, 
however, p66 inactivation improved glucose tolerance in these animals, whitout affecting (hyper)insulinaemia and independent of 
body weight. Protection from insulin resistance was cell-autonomous, since isolated p66KO preadipocytes were relatively resistant to 
insulin desenzitization by free fatty acids. Biochemical studies revealed that p66shc promotes the signal-inhibitory phosphorylation of 
the major Insulin transducer IRS-1, by bridging IRS-1 and the mTOR effector p70S6 Kinase, a molecule previously linked to obesity-
induced insulin resistance. Importantly, IRS-1 was strongly up-regulated in the adipose of p66KO lepOb/Ob mice, confirming that 
effects of p66 on tissue responsiveness to insulin are largely mediated by this molecule. Taken together these findings identify p66shc 
as a major mediator of insulin resistance by excess nutrients, and as a potential molecular target against obesity and type II diabetes.
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ADIPOCYTE INFLAMMATION CAUSES INSULIN RESISTANCE IN LIVER-DERIVED CELLS VIA IL-1b
Nov Ori1, Kohl Ayelet1, Lewis Eli C.1, Bashan Nava1, Dvir Irit2, Ben-Shlomo Shani3, Fishman Sigal3, Wueest Stephan4, Konrad Daniel4, Rudich Assaf1
1Ben Gurion University, Beer Sheva, Israel; 2Sapir Academic College, Hof Ashkelon, Israel; 3Sackler School Of Medicine, Tel Aviv, Israel; 
4University Of Zurich, Zurich, Switzerland
Central obesity is frequently associated with adipose tissue inflammation and hepatic insulin resistance. To identify individual 
mediators and cell-types in this process we utilized in-vitro systems and assessed if insulin resistance in liver cells could be induced 
by medium from TNFα pre-exposed adipocytes. Conditioned-medium (CM) from 3T3-L1 adipocytes pre-treated without or with TNFα 
(CM-TNF) was used to treat Fao cells or primary hepatocytes. CM-TNF-treated Fao cells exhibited ~45% diminution in insulin-
stimulated phosphorylation of insulin receptor, IRS1, IRS2, PKB and GSK3, and in glycogenesis, as compared to CM-treated cells. 
Expression of IL-1b mRNA was elevated 3-fold in TNFα-treated adipocytes, and CM-TNF had 10-fold higher concentrations of IL-1b. 
IL-1b directly induced insulin resistance in primary rat hepatocytes, Fao and HepG2 cells. Moreover, when TNF-induced secretion of 
IL-1b from adipocytes was inhibited by the caspase-1 inhibitor YVAD, or by co-incubation with rosiglitazone, insulin resistance was 
prevented. Furthermore, liver-derived cells treated with IL-1 receptor antagonist (IL-1Ra) were protected against insulin resistance 
induced by CM-TNF. Finally, IL-1b secretion from human omental fat explants correlated with BMI (R2=0.639, p<0.01), and this 
conditioned medium induced insulin resistance in HepG2 cells, inhibitable by IL-1Ra. Our results suggest that adipocyte-derived IL-1b 
may constitute a mediator in the perturbed crosstalk between adipocytes and liver cells in response to adipose tissue inflammation.
P02.38 - The role of adipose tissue in insulin action
ADP3 - A PUTATIVE GENE FOR THE REGULATION OF INSULIN SECRETION
Schulz Nadja1, Himmelbauer Heinz2, Scherneck Stephan1, Kaiser Daniel1, Vogel Heike1, Augustin Robert1, Kluge Reinhart1, Joost Hans-Georg1, 
Schürmann Annette1
1German Institute Of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; 2Centre For Genomic Regulation, Barcelona, Spain
The metabolic syndrome represents one of the most important contemporary health problems. Obesity, its central component, is 
associated with type 2 diabetes and cardiovascular complications. By comparing two genome wide screenings, a quantitative trait 
locus (QTL) analysis performed in the polygenetic obese NZO mouse and a siRNA-mediated mutagenesis in C. elegans, we selected 
Adp3 a gene encoding for an enzyme of mitochondrial b-oxidation. In human studies a splice site mutation of the human ortholog was 
shown to be associated with hyperinsulinism of infancy. Furthermore, down-regulation of its expression resulted in insulin secretion 
independent of the KATP-channel under basal conditions. For the characterisation of the Adp3 gene we generated an Adp3-knockout 
mouse with the gene trap approach and analyzed body weight, body composition, energy expenditure, and glucose tolerance. Under 
high-fat-diet conditions Adp3-/- mice displayed a lower body weight in comparison to Adp3+/+ mice presumably due to an elevated 
body temperature. Food intake and energy expenditure were not altered in knockout mice. Furthermore, Adp3-/- mice exhibited 
impaired glucose tolerance with lower insulin levels. However, in response to oral fat application insulin levels of Adp3-/- mice were 
significantly higher than those of Adp3+/+ mice. Similar effects were obtained after fasting and subsequently refeeding for two hours 
with the high-fat diet indicating that metabolites of the b-oxidation regulate insulin secretion. Furthermore, our data indicate that 
ADP3 is involved in thermogenesis and thereby in the regulation of body weight development.
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INSULIN INDUCES REDD1 ExPRESSION IN ADIPOCYTES
Claire Regazzetti1, Karine Dumas1, Frederic Bost1, Yannick Le Marchand-Brustel1, Jean-François Tanti1, Sophie Giorgetti-Peraldi1
1Inserm U895, Nice, France
Obesity is associated with the development of insulin resistance in adipose tissue. Expansion of the adipose tissue leads to the 
generation of hypoxic areas within this tissue, and we have shown that hypoxia is involved in the development of insulin resistance 
through the direct inhibition of the insulin signaling pathway in adipocytes. In order to understand the mechanisms activated by 
hypoxia and implicated in insulin resistance development, we investigate the role of a hypoxia-responsive protein REDD1 (Regulated 
in DNA Damages Responses). REDD1 is induced by stresses such as hypoxia, oxidative stress and energy depletion. We have 
demonstrated that REDD1 expression is increased in response to hyperinsulinemia. Indeed, in murine and human adipocytes, insulin 
stimulates REDD1 expression through phosphoinositide 3-kinase/mTOR-dependent pathways. Moreover, using echinomycin, a 
hypoxia-inducible factor 1 (HIF-1) inhibitor, and HIF-1alpha small interfering RNA, we demonstrate that insulin stimulates REDD1 
expression only through the transcription factor HIF-1. In addition to transcriptional regulation, insulin increases REDD1 protein level 
through the inhibition of its degradation, which seems to be mediated by a GSK3 dependent pathway. To study the role of REDD1 on 
insulin signaling pathway, we have generated 3T3-L1 adipocytes expressing inducible REDD1. These cells are used to determine the 
implication of REDD1 in adipocyte differenciation, insulin signalling pathway and adipocyte functions in normoxia and in hypoxia. The 
identification of REDD1 as a new player in insulin signaling pathway is an important step to identify new therapeutic targets to treat 
insulin resistance.
P02.40 - The role of adipose tissue in insulin action
ABSCISIC ACID: A NEW HUMAN ADIPOSE TISSUE-DERIVED HORMONE?
Basile Giovanna1, Bruzzone Santina1, Sturla Laura1, Grozio Alessia1, Fruscione Floriana2, Magnone Mirko1, Ruvolo Vittorio3, De Flora Antonio1, 
Zocchi Elena1
1Dept. Of Experimental Medicine, Section Of Biochemistry, And Center Of Excellence For Biomedical Research (CEBR), University Of Genova, 
Genova, Italy; 2Advanced Biotechnology Center, Genova, Italy; 3Santa Corona Hospital, Savona, Italy
The plant hormone abscisic acid (ABA) has been demonstrated to behave as an endogenous pro-inflammatory hormone in humans. 
ABA is released by activated inflammatory cells and stimulates functional activities in these cells. Moreover, glucose induces ABA 
release from pancreatic beta cells and ABA, at nanomolar concentrations, stimulates glucose-dependent and -independent insulin 
release. A 24 h incubation of human abdominal adipose tissue biopsies (AT) with LPS or with IL-8 induced a 8- or 1.5-fold increase in 
ABA content, respectively (basal level 0.3±0.1 pmol/g tissue). Since administration of oral glucose to healthy subjects determines an 
increase of ABA concentration in plasma, we investigated whether AT might represent a source of ABA. Indeed, AT incubated for 2 h in 
the presence of 25 mM glucose released ABA in the culture supernatant (3-fold over control). Next, we investigated whether addition 
of ABA could stimulate cytokine release from AT. Supernatants from AT cultured for 24 h with (or without) 10 µM ABA were analyzed 
by a human cytokine array. ABA stimulated the release of IL-1b, -4, -6 and -10 by 3-, 2-, 5-, and 3-fold, respectively, as compared 
to controls. ABA also enhanced the release of two chemokines, RANTES and MCP-1 (2- and 2.5-fold increase relative to controls, 
respectively). As ABA stimulates insulin release, ABA produced by the adipose tissue may induce disregulated, glucose-independent 
insulin release, possibly leading to insulin-resistance. This may occur particularly in the presence of excess adipose tissue, as in the 
case of the metabolic syndrome, which is characterized by obesity, dyslipidemia, hypertension, insulin resistance.
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CROSS-TALK BETWEEN INSULIN AND GP130 CYTOKINES IN ADIPOCYTES
White Ursula1, Stephens Jacqueline1
1Louisiana State University, Baton Rouge, Usa
The Interleukin (IL)-6 or gp130 family of cytokines is a group of functionally and structurally related proteins that consists of several 
cytokines including leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), 
and neuropoietin (NP). Gp130 cytokines are involved in the regulation of numerous biological processes. These cytokines share 
glycoprotein 130 as a common signal transducer in their receptor complex and typically activate STAT3. Findings in our laboratory 
have shown that several gp130 cytokines have differential effects on both adipogenesis and insulin-stimulated glucose uptake in 
adipocytes in vitro. Our current observations have examined the responsiveness of insulin sensitive tissues to gp130 cytokines in 
rodents. Our studies demonstrate that white adipose tissue (WAT) is the most sensitive to administration of four different gp130 
cytokines as judged by the activation of STAT3 and ERKs 1 and 2. Compared to WAT, liver and skeletal muscle were not responsive to 
cytokine administration in the whole animal. All of the cytokines (CT-1, LIF, OSM, and NP) we examined in vivo resulted in equivalent 
activation of STAT3, but only two of these cytokines were capable of inhibiting insulin action in vitro as judged by AKT phosphorylation. 
Although gp130 cytokines are present in circulation, the roles of these cytokines in insulin responsive tissues have not been 
investigated. Using adipocytes as a model system, our results show that these STAT3 activating cytokines have differential capabilities 
in modulating insulin action and insulin sensitive glucose uptake in adipose tissue in vitro and in vivo.
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P03.42 - Insulin signalling in peripheral tissues
HYPERGLYCAEMIA INDUCES INSULIN RESISTANCE THROUGH ER STRESS ACTIVATION IN L6 SKELETAL MUSCLE CELLS
Iadicicco Claudia1, Raciti Gregory Alexander1, Ulianich Luca1, Vinci Viviana1, Andriulo Giusi1, Buonomo Roberta1, Béguinot Francesco1, Formisano 
Pietro1, Miele Claudia1
1DBPCM & IEOS-CNR, Università Degli Studi Di Napoli Federico II, Naples, Italy
The endoplasmic reticulum (ER) is responsible for the quality control of proteins. When the productive folding process in the ER 
is perturbed by environmental stress conditions, eukaryotic cells activate the unfolded protein response (UPR). Recently, several 
studies reported that ER stress is involved both in pancreatic b-cell dysfunction and in peripheral insulin resistance, the two main 
features of Type2 diabetes. Hyperglycaemia causes insulin resistance and this process appears to be linked to UPR activation. Even 
glucosamine (GlcN), generated during hyperglycaemia, causes insulin resistance and glucose toxicity in muscle. In this work we 
investigated the possible role of high glucose (HG)- and glucosamine-induced ER stress on insulin-resistance in L6 skeletal muscle 
cells. L6 cells were incubated either with 7.5mM GlcN or with 25mM glucose, in presence or absence of insulin (100nM). Upon 
either GlcN or HG treatment, the ER stress markers BiP, Xbp1 and ATF6 mRNA levels were increased by 6, 3 and 2 fold respectively, 
indicating UPR activation. Moreover both GlcN and HG blunted insulin induced 2-deoxy-D-[14C]-glucose (2DG) uptake, Akt and GSK3b 
phosphorylation. Furthermore both GLUT4 mRNA and protein levels decreased by 70% upon GlcN and HG treatment. Interestingly, 
the use of the chemical chaperon 4-Phenyl Butyric Acid (PBA) prevented the induction of ER stress by GlcN and HG and their effects 
on 2DG uptake, Akt phosphorylation and GLUT4 levels. In conclusion, we show for the first time that GlcN and HG are able to activate 
the UPR in skeletal muscle cells, and they may play a role in insulin resistance through the inhibition of Glut4 expression and/or 
translocation.
P03.43 - Insulin signalling in peripheral tissues
TGFBETA IMPAIRS SKELETAL MUSCLE DIFFERENTIATION AND INDUCES AUTOPHAGY BY PED/PEA-15-MEDIATED PATHWAY
Iovino Salvatore1, Oriente Francesco1, Botta Ginevra1, Formisano Pietro1, Béguinot Francesco1
1Department Of Cellular And Molecular Biology And Pathology, University Of Napoli “Federico II”, Napoli, Italy
Loss of muscle mass and de-differentiation occur in a variety of disease, including cancer, chronic heart failure and diabetes. 
Preventing muscle wasting by promoting growth and differentiation has been proposed as a possible therapeutic approach. 
Tgfbeta is an important negative modulator of myogenesis. Recently, it has been shown that TGF beta activates autophagy, which 
plays a critical role in muscle atrophy but the exact mechanisms by which autophagy and Tgfbeta might impair skeletal muscle 
differentiation are still unclear. Western blot and qRT-PCR analysis revealed that in L6 skeletal muscle cells, TGFbeta 1 increased by 
5-fold the expression of PED/PEA-15, a gene overexpressed in type 2 diabetic patients. Moreover, Tgfbeta1 led to LC3I/II conversion 
and increased expression of beclin-1 in L6 cells, peculiar features of autophagy activation. These molecular events paralleled an 
impairment of L6 myotubes differentiation, as revealed by morphological analysis and reduction of myoD1, myogenin and glut4 gene 
expression. Importantly, silencing of PED/PEA-15 by specific shRNA restored the expression of myoD1, myogenin, and glut4 and L6 
differentiation upon TGFbeta 1 stimulation. Interestingly, silencing of PED/PEA-15 also partially reverted the LC3I/II conversion and 
beclin-1 levels. Furthermore, FACS analysis showed that the transfection of PED/PEA-15 cDNA in L6 cells, activated autophagy and 
impaired the myotubes formation. Importantly, the block of autophagy in L6PED, restored myotubes formation. These data indicate 
that Tgfbeta may impair skeletal muscle differentiation by inducing autophagic process and PED/PEA-15 might be a key regulator to 
mediate this effect.
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THE PED/PEA15 DIABETOGENE AS A POTENTIAL THIAZOLIDINEDIONE TARGET
Mirra Paola1, Oriente Francesco1, Teperino Raffaele1, Ciccarelli Marco1, Longo Michele1, Albano Luigi1, Ungaro Paola1, Béguinot Francesco1
1DBPCM, University Of Naples C/o IEOS-CNR, Naples, Italy
Thiazolidinediones (TZDs) are hypoglycemic agents used to treat type 2 diabetes (T2D). TZD target is PPARγ, a nuclear hormone 
receptor able to modulate gene expression upon ligand binding. The overexpression of Phosphoprotein Enriched in Diabetes/
Phosphoprotein Enriched in Astrocytes (PED/PEA15), observed in tissues from T2D subjects and from their first-degree relatives, 
impairs insulin activation of Protein Kinase C zeta (PKCζ) and glucose disposal. Our recent evidence supported TZD down-regulation 
of PED/PEA15 expression. Thus, this study aimed at investigating whether and how TZDs ameliorate insulin sensitivity by modulating 
PED/PEA15 expression. HeLa cells treated with TPA, the prototypical AP1 activator, showed an increase in histone 3 acetylation levels 
at PED/PEA15 promoter according to an increase in PED/PEA15 expression. Interestingly, TPA effect was almost completely reverted 
by Rosiglitazone (RGTZ). Furthermore, TPA increased the binding of AP1 to CRE-like site (a putative AP1 binding site) on PED/PEA15 
promoter, which was reduced by 50% in presence of RGTZ. Overexpression of histone acetyltransferase P300, a coactivator of AP1, 
partially relieved the suppressive effect of PPARγ, suggesting an important role of factors causing histone modifications in TZD 
action. In addition, in L6 skeletal muscle cells, the down-regulation of PED/PEA15 by TZDs was associated with an increase in PKCζ 
activation and in glucose up-take. In conclusion, this study identified PED/PEA15 gene as a potential TZD target in T2D treatment. The 
targeting of PED/PEA15 may provide a novel TZD-independent approach to improve insulin sensitivity, in view of concerns about TZD 
adverse effects.
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THE MAP KINASE ERK1 NEGATIVELY REGULATES FATTY ACIDS OxIDATION IN SKELETAL MUSCLES
Véronique Corcelle3, Jennifer Jager3, Kathiane Laurent3, Gilles Pages1, Isabelle Castan-Laurell2, Philippe Valet2, Yannick Le Marchand-Brustel3, 
Frédéric Bost3, Jean-François Tanti3
1Cnrs, Umr6543, Nice, France; 2Inserm U858, Toulouse, France; 3Inserm U895, Team 7, Nice, France
Accumulation of lipid metabolites in skeletal muscles plays a critical role in the development of insulin resistance by interference 
with insulin signaling and action. The activity of the MAP kinase ERK is increased in muscles of diabetic patients and we have shown 
that Erk1-/- mice have a higher post-prandial metabolic rate and are protected against lipotoxicity and insulin resistance on a high 
fat diet. Here, we investigated whether ERK1 plays a role in the regulation of fatty acids oxidation in skeletal muscles. Ten weeks 
old Erk1-/- and WT mice were studied after 16h of fasting in order to increase lipid flux in muscles. Erk1-/- muscles displayed a 
higher expression of proteins involved in fatty acids oxidation (M-CPT1, LCAD, MCAD) and in oxidative phosphorylation (mitochondrial 
complexes; cytochrome C; UCP3). Mitochondrial complex activity and expression of transcription factors regulating fatty acids 
oxidation steps (PGC1α,PPARα, ERRα, MEF2, FOXO1) as well as their targets were also increased in muscles of Erk1-/- mice. AMPK 
is an important energy sensor which activation promotes fatty acid oxidation by phosphorylating Acetyl CoA Carboxylase (ACC). 
AMPK and ACC phosphorylation were increased in muscles of Erk1-/- mice as compared to WT mice. These modifications increased 
palmitate oxidation rate in isolated muscles. Importantly, short-term treatment of WT mice with a MEK inhibitor increased fatty acids 
oxidation program in muscles. Our results demonstrate that Erk1 negatively controls fatty acids oxidation in muscles suggesting that 
the increased Erk1 activity in muscles of obese patients could contribute to a reduction in the dynamic of fatty acids oxidation
P03.46 - Insulin signalling in peripheral tissues
TBC1D1 DEFICIENCY PROTECTS SKELETAL MUSCLE FROM PALMITATE-INDUCED INSULIN RESISTANCE
Alexandra Chadt1, Hadi Al-Hasani1
1German Institute Of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
We previously identified Tbc1d1 as susceptibility gene for high-fat diet-induced obesity and diabetes in mice. Skeletal muscle from 
TBC1D1-deficient mice show increased fatty acid oxidation (FAO) with concomitant decrease in insulin-stimulated glucose uptake, 
indicating that TBC1D1 regulates substrate preference in skeletal muscle. An impaired adaptation of skeletal muscle fuel preference 
to the availability of glucose and fatty acids as energy substrates has been associated with the development of insulin resistance and 
diabetes. We therefore sought to investigate the role of TBC1D1 in the mediation of lipid-induced insulin resistance in skeletal muscle. 
In both cultured C2C12 myotubes and isolated muscles, depletion of TBC1D1 leads to enhanced FAO accompanied by increased 
expression of genes involved in lipid metabolism including Acadl, Cd36, Fabp3 and Ppargc1. Exposure of C2C12 myotubes and isolated 
skeletal muscles to palmitic acid results in a substantial and dose-dependent reduction of insulin-stimulated AKT phosphorylation, 
and expression of Ppargc1 mRNA, respectively. As a result, in the presence of 1 mM palmitate, the insulin-stimulated glucose uptake 
in isolated skeletal muscles is reduced by >50%. In contrast, depletion of TBC1D1 almost completely prevents the detrimental effect of 
palmitate on insulin-stimulated AKT phosphorylation, Ppargc1 expression and insulin-stimulated glucose uptake, and thus restores 
insulin sensitivity in muscle cells. Our data demonstrate that TBC1D1 deficiency protects skeletal muscle from lipid-induced insulin 
resistance, presumably by enhancing FA oxidation.
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HYPERGLYCEMIA NORMALIZES INSULIN ACTION ON GLUCOSE METABOLISM BUT NOT ON INSULIN SIGNALING
Vind Birgitte F.1, Beck-Nielsen Henning1, Højlund Kurt1, Birk Jesper B.2, Wojtaszewski Jørgen F.P.2
1Odense University Hospital, Odense, Denmark; 2Copenhagen Muscle Research Center, University Of Copenhagen, Copenhagen, Denmark
In type 2 diabetes (T2D), reduced insulin-mediated glucose uptake and glycogen synthesis, is associated with defect insulin 
activation of glycogen synthase (GS) in skeletal muscle. Hyperglycemia may compensate for these defects, but to what extent 
it involves improved insulin signaling to glucose transport and glycogen synthesis remains to be clarified. Whole-body glucose 
metabolism was studied in patients with T2D and matched lean and obese non-diabetic controls by indirect calorimetry and 
euglycemic-hyperinsulinemic clamps. The diabetic subjects underwent a second isoglycemic-hyperinsulinemic clamp maintaining 
fasting hyperglycemia. Muscle biopsies from m. vastus lateralis were obtained for examination of GS and relevant insulin signaling 
components. During euglycemia, insulin-mediated glucose disposal, glucose oxidation, and non-oxidative glucose metabolism 
were reduced in the diabetic group compared to the control groups, and this was associated with impaired insulin-stimulated GS 
activity, deficient dephosphorylation at GS sites 2+2a, and reduced Thr308 and Ser473 phosphorylation of Akt. When studied under 
hyperglycemia, all parameters of insulin-mediated glucose metabolism were normalized compared with the weight-matched 
controls. However, insulin activation of GS, dephosphorylation at GS sites 2+2a, and phosphorylation of Akt at Thr308 and Ser473 
remained impaired. These data confirm that hyperglycemia compensates for impaired glucose metabolism in T2D. In contrast 
to previous less well-controlled studies, we provide evidence that this compensatory effect of hyperglycemia does not involve 
normalization of insulin action on GS and Akt in skeletal muscle.
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P03.48 - Insulin signalling in peripheral tissues
REDUCTION OF MUSCLE CERAMIDE IN MICE FED SATURATED OR UNSATURATED FAT DIETS BY LISOFYLLINE
Frangioudakis Georgia1, Raddatz Katy1, Garrard James2, Nadler Jerry3, Mitchell Todd2, Schmitz-Peiffer Carsten1
1Garvan Institute Of Medical Research, Sydney, Australia; 2University Of Wollongong, Wollongong, Australia; 3Eastern Virginia Medical School, 
Norfolk, Usa
Lipid-induced insulin resistance is associated with accumulation of inhibitory intermediates depending on the prevalent fatty acid 
(FA) species. In cultured myotubes, ceramide and phosphatidic acid (PA) mediate the effects of the saturated FA palmitate and 
the unsaturated FA linoleate, respectively. We hypothesised that myriocin (MYR), an inhibitor of ceramide synthesis, would protect 
against glucose intolerance in saturated fat-fed mice, while lisofylline (LSF), a functional inhibitor of PA synthesis, would protect 
unsaturated fat-fed mice. Mice were fed diets enriched in saturated fat, n-6 unsaturated fat or chow for 6 weeks. Saline, LSF or MYR 
were administered by mini-pumps in the final 4 weeks. Both diets induced glucose intolerance and unexpectedly, both increased 
skeletal muscle ceramide. MYR and LSF improved glucose tolerance in unsaturated fat-fed mice, while LSF was also effective in 
saturated fat-fed mice. Mass spectrometry indicated that both inhibitors reduced levels of the predominant C18 ceramide species, 
while LSF also reduced minor longer chain ceramides. LSF was also better able to reverse the lard diet-induced increase in 
expression of ceramide synthase 1, the major isoform in muscle. In conclusion, fat-feeding results in muscle ceramide accumulation 
and impairs glucose tolerance, independently of the prevalent FA. Although LSF is not known to affect ceramide metabolism, its anti-
inflammatory properties may act indirectly to reverse muscle ceramide accumulation. The demonstration that LSF can ameliorate 
glucose intolerance in vivo in two dietary models indicates it may be a novel intervention for the treatment of insulin resistance.
P03.49 - Insulin signalling in peripheral tissues
FA1 PER SE DOES NOT INDUCE INSULIN RESISTANCE IN HUMAN MYOTUBES
Abdallah Basem2, Teisner Børge1, Beck-Nielsen Henning2, Gaster Michael2
1University Of Southern Denmark, Odense, Denmark; 2Odense University Hospital, Odense, Denmark
Delta like 1/pre-adipocyte factor-1 (Dlk1/Pref-1) is a transmembrane protein expressed by hormonal producing cells in adult human. 
The extracellular domain of the Dlk1 is cleaved into the circulation as a soluble active form named fetal antigen 1 (FA1). Transgenic 
mice with high circulating level of Dlk1/Pref-1 displayed reduced total fat pad mass and were protected against high fat diet-induced 
obesity, associated with increasing whole body insulin resistance due to impaired insulin induced glucose uptake in skeletal muscle 
and adipose tissue. In human, increasing serum levels of FA1 was shown to be associated with obesity and negatively correlated with 
insulin sensitivity. Thus, we aimed here to study the effects of chronic FA1 on the intermediary metabolism in myotubes established 
from lean, obese and type 2 diabetic (T2D) subjects. Myotubes established from lean and obese control subjects, and obese T2D 
subjects were treated with FA1 for 4 days supplemented with/without palmitate (PA). Lipid- and glucose metabolism were studied 
with labelled precursors while quantitative expression of genes were analyzed using Real-Time PCR. Diabetic myotubes express 
a significantly reduced insulin stimulation glucose metabolism compared to lean myotubes and a significantly decreased basal 
PA oxidation. Chronic FA1 exposure did not affect the intermediary metabolism in myotubes. Insulin sensitivity of glucose and lipid 
metabolism was not affected by chronic FA1 exposure in myotubes established from lean, obese and T2D subjects. Chronic FA1 
exposure induces proinflammatoric gene expression (IL6 and CCL2) and reduced markers of adipogen differentiation (ADD1, AP2, 
CD36 and PPAR2). FA1 did not alter the effect of PA on the intermediary metabolism or change the Gene expression related to PA in 
human myotubes. Conclusions: FA1 per se does not induce insulin resistance in human myotubes established from lean, obese and 
Type 2 diabetic subjects.
P03.50 - Insulin signalling in peripheral tissues
ANALYSIS OF INSULIN SENSITIVITY IN P66SHCA KO MICE BY HYPERINSULINEMIC EUGLYCEMIC CLAMP
Sorice Gianpio2, Chiatamone Ranieri Sofia1, Muscogiuri Giovanna2, Pani Giovanni1, Giaccari Andrea2
1Institute Of General Pathology, Rome, Italy; 2Division Of Endocrinology, Rome, Italy
Emerging clinical and experimental evidences point to a major role of tissue oxidative stress in linking ageing and excess body weight with 
insulin resistance (IR); molecular mechanism underlying this connection are however still elusive. The signaling adaptor protein p66shcA 
promotes mitochondrial generation of oxidant species in several models of age-related disease, and p66KO mice live 30% longer than their 
WT littermates; thus, this molecule may represent a critical determinant of the intracellular redox-state imbalance associated with diabetes. 
We have previously shown that genetically obese, hyperinsulinemic (LepOb/Ob) mice lacking p66shcA are partially protected from glucose 
intolerance observed in their p66shcA proficient littermates (Chiatamone et al., submitted), demonstrating that p66shcA promotes IR in this 
setting. However, no major effects of p66shcA on glucose homeostasis were detected in normal, lean mice by standard ipGTT, (1g glucose/
Kg BW) and insulin tolerance test (0.75 U/Kg BW). Prompted by this discrepancy we have set up and performed hyperinsulinemic euglycemic 
clamp (18 mUI∙kg-1∙min-1) on lean mice of the two genotypes. This more reliable assay clearly demonstrated an enhanced insulin sensitivity 
in p66shcA-/- vs. WT mice (glucose infusion rates during the clamp ± SEM: respectively 161 mg∙kg-1∙min-1, ±35; 66 mg∙kg-1∙min-1,±4.4; 
p<0.02). In keeping with this finding, biochemical analysis of the insulin signalling pathway in the adipose tissue of p66shcA null mice 
demonstrated reduced serine phosphorylation (serine307 + serine636-639) of IRS-1, an hallmark of insulin desensitization. These findings 
confirm and extend our observation that p66shcA participates in the regulation of insulin action in an hyperinsulinemic setting, as it occurs 
in ageing-associated metabolic disorders including obesity and metabolic syndrome. While the possible connection between p66-dependent 
oxidative stress and IR needs to be further investigated, our data strongly encourage pharmacological research aimed at blocking the 
deleterious effect of the p66shcA protein to improve glucose homeostasis and prevent type 2 diabetes.
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DIRECT EFFECT OF HYPERLEPTINEMIA ON INSULIN ACTION IN WISTAR RAT SKELETAL MUSCLE
De Solis Alain J.1, Perez-Pardo Paula1, Bogonez Elena1, Carrascosa Jose M.1
1Centro Biologia Molecular Severo Ochoa (CBMSO), UAM-CSIC, Universidad Autonoma De Madrid (UAM), Madrid, Spain
Wistar rats develop hyperleptinemia and whole body insulin resistance during ageing. Here we study how hyperleptinemia influences 
directly insulin action on skeletal muscle (SM) during ageing and the effect of moderate caloric restriction (CR). Insulin action 
on oxidative (soleus) and non oxidative (EDL) SM was determined by analyzing: A) the insulin-induced 2-deoxyglyucose (2-DOG) 
uptake in isolated muscles; and B) muscle insulin signalling after i.v. injection of leptin plus insulin. Studies were carried out on 
3-, 8- and 24-months old rats fed ad libitum, and 8- and 24-months old animals after three months of CR. Insulin-induced 2-DOG 
uptake, phosphorylation of the insulin pathway (insulin receptor b, IRS-1, AKT) and p38MAPK phosphorylation decrease with ageing, 
mainly in soleus. Leptin also stimulates 2-DOG uptake and this effect decreases with ageing. However, leptin has no effect on the 
insulin pathway. CR restores ageing-associated effects on insulin and leptin signalling, but only in 8-month old rats. Pre-treatment 
with high doses of leptin decreases the insulin stimulation of 2-DOG uptake and the phosphorylation of the insulin pathway and 
p38MAPK in leptin sensitive muscles. These data indicate that leptin, acting directly in SM, might impair insulin action in contrast to 
its insulin-sensitizing effects elicited through the CNS. The results show that leptin has a moderate effect on the insulin-signalling 
pathway, and suggest that the blocking effect on insulin-induced glucose uptake could be mediated by the impairment of p38MAPK 
phosphorylation. We conclude that ageing-associated hyperleptinemia could contribute to the development of muscle insulin 
resistance.
P03.52 - Insulin signalling in peripheral tissues
PALMITATE INDUCES ER STRESS AND IMPAIRS INSULIN ACTION IN ISOLATED HUMAN SKELETAL MUSCLE
Skrobuk Paulina1, Kärkkäinen Johannes1, Koistinen Heikki A.1
1Department Of Medicine, Division Of Cardiology, Helsinki University Central Hospital And Minerva Research Institute, Helsinki, Finland
Obesity and high fat diet have been linked to insulin resistance, and may involve endoplasmic reticulum (ER) stress. Here, we studied 
the effect of acute palmitate exposure on insulin action on glucose transport (GT), glycogen synthesis, insulin signaling and ER 
stress. We studied 18 men (47±3 years, BMI 26.2±0.8 kg/m2, fP-gluk 5.5±0.1 mM). Open muscle biopsy was obtained from m. vastus 
lateralis, and small muscle strips were incubated for 4 h with or without (w/o) palmitate (1mM), and with or w/o insulin (1.2 nM). 
Insulin increased GT (in nmol/mg protein/20 min) 1.9-fold (from 0.6±0.05 to 1.2±0.1, p<0.001). With palmitate, basal GT tended to be 
increased (0.9±0.1, p=0.062), insulin-stimulated GT was unchanged (1.2±0.1), and insulin action on GT (insulin-stimulated minus basal) 
reduced by 49 % (p=0.068). Palmitate reduced insulin-stimulated glycogen synthesis 18 % (70±13 vs 85±15 nmol/g/h, p<0.02), but did 
not affect AKT-Ser473 or AS160-phosphorylation. When men were divided by BMI, insulin increased GT with palmitate in lean, but not 
in overweight men. Similarly, when analyzed by glucose tolerance, insulin increased GT with palmitate in men with normal glucose 
tolerance, but not in men with impaired fasting glucose (IFG). This palmitate-induced defect was associated with blunted insulin-
stimulated AS160-phosphorylation in muscle from IFG men. Palmitate induced ER stress (1.3-fold increased phosphorylation of eIF2α) 
in overweight but not in lean men. Thus, acute exposure to palmitate impairs insulin action in human muscle strips. This effect is 
more pronounced in men with overweight or IFG, and may involve activation of ER stress.
P03.53 - Insulin signalling in peripheral tissues
QUANTITATIVE PROTEOMIC STUDY OF TYPE 2 DIABETIC AND HEALTHY MYOTUBES
Thingholm Tine E.1, Jensen Ole N.2, Beck-Nielsen Henning 1, Gaster Michael1
1Odense University Hospital, Odense, Denmark; 2Univ. Of Southern Denmark, Odense, Denmark
One of the hallmarks of Type 2 Diabetes (T2D) is insulin resistance (IR) in peripheral target tissues. Skeletal muscle is a key tissue site 
of IR, with evidence of decreased insulin-stimulated glucose uptake and storage as glycogen. Although a number of abnormalities 
have been identified in skeletal muscle from T2D subjects, the exact molecular mechanism for IR has not been established. Using 
mass spectrometry we have characterized the basal proteome of myoubes established from T2D subjects and compared them to 
myoubes from healthy, lean or obese subjects. Myotubes were labeled using iTRAQ as this strategy can be directly implemented on 
subsequent in vivo studies. Combining Strong Cation Exchange and sensitive mass spectrometry using a combination of different 
fragmentation strategies on a LC-ESI-LTQ-orbitrap gave a thorough and informative characterization of the myotube proteome. 
Human myotubes are a valuable model system as the diabetic phenotype is conserved in myotubes established from diabetic 
subjects. However, the basal proteome of human myotubes had still not been investigated. Therefore, we ran four comprehensive 
experiments in order to compare the basal proteome of myotubes from obese, lean and obese T2D subjects. We have identified 
3593 unique proteins. A total of 32 proteins were found to be upregulated in T2D myotubes, whereas 25 proteins were found to be 
downregulated. Bioinformatics analysis showed that many enzymes playing key roles in energy-related pathways were upregulated 
in T2D myotubes whereas structural proteins were downregulated when compared to the two healthy controls. We are now in the 
process of evaluating these comprehensive datasets.
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P03.54 - Insulin signalling in peripheral tissues
PTP1B PLAYS AN ESSENTIAL ROLE IN THE DEVELOPMENT OF AGE-RELATED INSULIN RESISTANCE
Gonzalez-Rodriguez Agueda1, Mas-Gutierrez Jose A3, Carrascosa Jose M2, Ros Manuel3, Valverde Angela M4
1Ciber De Diabetes Y Enfermedades Metabolicas Asociadas, Madrid, Spain; 2Universidad Autonoma De Madrid, Madrid, Spain; 3Universidad Rey 
Juan Carlos, Madrid, Spain; 4Consejo Superior De Investigaciones Cientificas, Madrid, Spain
Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of insulin signaling and a therapeutic target for type 2 diabetes 
mellitus (T2DM). It is well known that aging is one of the risk factors to increase the susceptibility to metabolic diseases. The purpose 
of this study was to evaluate the differences in insulin sensitivity between wild-type and PTP1B-/- mice during aging. Wild-type mice 
showed augmented fat depots, increased adipocyte size and body weight at 15 months of age as compared to young mice at 12 weeks. 
However, adiposity did not increase in PTP1B-/- mice with aging. Levels of pro-inflammatory cytokines together with the appearance 
of crown-like structures positive for F4/80 staining were elevated in white adipose tissue (WAT) from wild-type mice with aging. By 
contrast, levels of pro-inflammatory cytokines and WAT morphology of aged PTP1B-/- mice did not differ from the young controls. ITT 
tests revealed insulin resistance in 15 month-old wild-type mice compared to mice lacking PTP1B at the same age. Moreover, PTP1B 
deficiency resulted in a more rapid clearance of glucose as compare to wild-type controls. At the molecular level, both PTP1B mRNA 
and protein content were up-regulated in liver and muscle from aged wild-type mice compared to the young stage. On the other 
hand, the expression of p85α was down-regulated in liver and muscle from PTP1B-/- with aging. In both tissues, an age-dependent 
activation of stress kinases and, conversely, attenuation of insulin receptor tyrosine phosphorylation and its downstream signaling 
was observed in wild-type mice. However, PTP1B deficiency protected against these effects. Overall, our data provide the possibility to 
explore the inhibition of PTP1B as a therapeutically approach against age-dependent T2DM.
P03.55 - Insulin signalling in peripheral tissues
PROTEIN-TYROSINE PHOSPHATASE 1 B CONTRIBUTION TO GLYCOGEN METABOLISM
Alonso-Chamorro María3, Nieto-Vázquez Iria2-3, García-Guerra Lucía3, Montori-Grau Marta1-2, Gómez-Foix Anna María1-2, Fernández-Veledo 
Sonia2-3, Lorenzo Margarita2-3
1Dpto. Biochemistry. Faculty Of Biology. University Of Barcelona, Barcelona, Spain; 2Ciber Of Diabetes And Metabolic Syndromes (ciberdem), 
Madrid, Spain; 3Dpto. Biochemistry And Molecular Biology II. Faculty Of Pharmacy. Complutense University, Madrid, Spain
Protein-tyrosine phosphatase 1 B (PTP1B) is known to be involved in many intracellular signalling processes, mainly acting as a 
negative regulator on the insulin signalling pathway. As many studies have described, the expression levels of this protein are higher 
in some insulin-resistant conditions, as obesity and type 2 diabetes. This study focuses on the role of PTP1B on glycogen metabolism 
in a line of immortalized myocytes deficient in this protein, in basal and under a TNF-α-induced insulin resistant condition. Glycogen 
content and glycogen synthesis, as well as glycogen synthase (GS) and glycogen phosphorylase (GP) enzymatic activities, were 
measured. The possible signalling pathways involved were assayed by western blot procedures. Our in vitro studies revealed that 
insulin positively stimulates GS activity and glycogen content, and this action is enhanced in PTP1B deficient myocytes. We verified 
the potent glycogenolytic effect of TNF-α, and the inhibitory effect of the cytokine on glycogen synthesis, content, and activation of 
GS. Moreover, we described a novel role for insulin on GP regulation, so that GP degradation is achieved for low insulin doses. In 
our model, absence of PTP1B restores insulin action in myocytes pretreated to TNF-α, thus confirming its protective role against an 
insulin resistant situation, probably owed to an enhanced insulin action on glucose and glycogen metabolism. This could be of special 
interest in the development of new treatments against type 2 diabetes. We thank the support of CIBERDEM CB07-08-0007 from ISCIII, 
INSINET S-SAL-159-2006 (Madrid Community) networks, and the project BFU-2008-04043 (Ministry Science and Innovation).
P03.56 - Insulin signalling in peripheral tissues
ROLE OF SEx HORMONES IN GLUCOSE AND LIPID METABOLISM IN HUMAN SKELETAL MUSCLE
Salehzadeh Firoozeh1, Al-Khalili Lubna1
1Karolinska Institutet, Stockholm, Sweden
Background: we have shown earlier, that human skeletal muscle cells exhibit no intrinsic sex differences on glucose and lipid 
metabolism. Sex hormones play an important role in substrate utilization. Aims: to determine whether testosterone or estradiol 
treatment 1-may reveal intrinsic sex differences in metabolism, 2- have different role on lipid and glucose metabolism. Methods: 
Myotubes obtained from women and men donors were treated with testosterone or estradiol (10nM (4 days) or 10µM (20 min)). 
Insulin-stimulated glycogen synthesis and palmitate oxidation were assessed. Lysates were collected for western blotting and 
mRNA expression (4 days, only). Results: 4 days testosterone treatment enhanced glycogen synthesis and insulin-stimulated 
Akt phosphorylation in myotubes from women donors. Testosterone enhanced AMPK phosphorylation and lipid oxidation. mRNA 
expression showed a differential response to sex hormones treatment with no sex differences. Acute sex hormones treatment 
decreased basal and insulin stimulated glycogen synthesis. Testosterone treatment only impaired insulin associated lipolysis. 
Discussion: 4 days testosterone treatment showed sex dependent effect on lipid and glucose metabolism, but not acute treatment. 
Both sex hormones independent of sex origin of cells, changed the mRNA expression of several genes involved in lipid oxidation. In 
this study, we are able to suggest an important role of testosterone on glucose and lipid metabolism in human skeletal muscle cells. 
Estradiol role on metabolism was found only acutely at high concentration and there is a sexual difference on cellular metabolism 
with testosterone treatment.
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A GERMLINE TRUNCATING MUTATION IN PI3K (P85A) IN A PATIENT WITH SEVERE INSULIN RESISTANCE
Huang-Doran Isabel5, Rocha Nuno M5, Hakeem Vaseem F1, Dattani Mehul2, Siddle Kenneth5, Savage David B5, Foukas Lazaros3, O’Rahilly Steve5, 
Barroso Ines4, Semple Robert K5
1Barnet And Chase Farm Hospitals Nhs Trust, Barnet, Uk; 2University College London Institute For Child Health, Great Ormond Street Hospital 
For Children, London, Uk; 3Institute Of Healthy Ageing & Department Of Genetics, Evolution And Environment, University College London, 
London, Uk; 4Metabolic Disease Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Uk; 5University Of Cambridge 
Metabolic Research Laboratories, Institute Of Metabolic Science, Addenbrooke’s Hospital, Cambridge, Uk
Phosphoinositide 3-kinase (PI3K) is an essential mediator of key cellular actions of insulin and other growth factors, and its activity is 
upregulated by somatic mutations in many neoplasia, leading to keen interest in PI3K inhibitors as cancer therapeutics. We report a 
lean 15 year old female with low birth weight who presented at 12 years with features of severe insulin resistance including diabetes 
mellitus, widespread acanthosis nigricans and severe hyperandrogenism, but no lipodystrophy. Fasting insulin was 1140pmol/L 
and glucose 4.7mmol/L. Plasma lipids and sex hormone binding globulin were normal, and there was no hepatic steatosis. 
Adiponectin was suppressed at 0.7mg/L (gender and BMI-matched normal range 2.6-12.6mg/L). Whole exome sequencing revealed 
a heterozygous truncating mutation in PIK3R1, Tyr657STOP, which encodes the p85α regulatory subunit of PI3K and its shorter splice 
variants, p55α and p50α. Levels of PIK3R1 transcripts were normal in EBV-transformed lymphoblastoid cells from the proband, while 
cDNA sequencing suggested stoichiometric expression of wildtype and mutant alleles. Immunoblotting revealed both full-length 
and truncated p85α, p55α and p50α proteins, with truncated proteins more highly expressed than their full-length counterparts. 
We thus describe a patient with impaired growth and severe insulin resistance associated with a germline truncating mutation in 
PIK3R1. Further studies will yield insights into the role of PI3K in human metabolic regulation in vivo, and may offer important lessons 
regarding metabolic side effects of long term PI3K inhibition.
P04.58 - Genetic and epigenetic control of insulin action
HEPATOCYTE NUCLEAR FACTOR (HNF)-4α-DRIVEN EPIGENETIC SILENCING OF HUMAN PED/PEA-15 GENE
Ungaro Paola1, Teperino Raffaele1, Mirra Paola1, Longo Michele1, Ciccarelli Marco1, Raciti Gregory Alexander1, Nigro Cecilia1, Miele Claudia1, 
Formisano Pietro1, Béguinot Francesco1
1DBPCM, University Of Naples C/o IEOS-CNR, Naples, Italy
Overexpression of PED/PEA-15 determines insulin resistance and impaired insulin secretion and may contribute to progression 
toward type 2 diabetes. Recently, we found that the transcription factor hepatocyte nuclear factor (HNF)-4α binds to PED/PEA-15 
promoter and represses its transcription. However, the molecular details responsible for regulation of PED/PEA-15 gene remain 
unclear. By using gain and loss of function approaches we have investigated the hypothesis that HNF-4α controls chromatin 
remodelling at the PED/PEA-15 promoter in human cell lines. We have demonstrated that HNF-4α expression and binding induce 
chromatin remodelling at the −250 to 50 region of PED/PEA-15, indicating that remodelling is limited to two nucleosomes located 
at the proximal promoter. Chromatin immunoprecipitation assays also revealed concomitant HNF-4α-induced deacetylation of 
histone H3 at Lys9 and Lys14, and increased dimethylation of histone 3 at Lys9. The latter was followed by reduction of histone 3 Lys 4 
dimethylation. HNF-4α was also shown to target the histone deacetylase complex associated with silencing mediator of retinoic acid 
and thyroid hormone receptor, both at the PED/PEA-15 promoter, and at GRB14 and USP21 regulatory regions, leading to a reduction 
of mRNA levels. Moreover, HNF-4α silencing and PED/PEA-15 overexpression were accompanied by a significant reduction of hepatic 
glycogen content. These results show that HNF-4α serves as a scaffold protein for histone deacetylase activities, thereby inhibiting 
liver expression of genes including PED/PEA-15. Dysregulation of these mechanisms may lead to upregulation of the PED/PEA-15 
gene in type 2 diabetes.
P04.59 - Genetic and epigenetic control of insulin action
MTNR1B GENE VARIANTS EFFECTS IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES
Bonetti Sara1, Trombetta Maddalena1, Boselli Linda1, Turrini Fabiola1, Trabetti Elisabetta2, Malerba Giovanni2, Pignatti Pier Franco2, Bonora Enzo1, 
Bonadonna Riccardo1
1Department Of Medicine, University Of Verona, Verona, Italy; 2Department Of Life And Reproduction Sciences, University Of Verona, Verona, Italy
Background: the high affinity melatonin receptor, MTNR1B, is expressed in brain, retina and endocrine pancreas. In non-diabetic 
subjects, the MTNR1B variant rs10830963 is associated with increased levels of fasting glucose (G), reduced beta cell function (BF) and 
increased risk of developing type 2 diabetes (T2D). We investigated the role of MTNR1B in determining clinical and pathophysiological 
traits in patients with newly diagnosed T2D. Methods. 494 GAD-negative and drug-naïve patients (age 57.7±10.3 years, BMI 29.9±5.1 
kg/m2, HbA1c 7.0±1.4 %) with newly diagnosed T2D underwent standard clinical characterization. Furthermore, beta cell function 
(BF) and insulin sensitivity (SI) were assessed by state-of-art methods.We genotyped the following tag SNPs which reportedly capture 
~94% of genetic variability of MTNR1B locus: rs7102746 e rs11523890 upstream to, rs10830963 within and rs9666752 downstream to 
MTNR1B. Results.The rs11523890 G allele (frequency: 0.65) and the diabetes risk allele G of rs10830963 (frequency: 0.26) were both 
associated with reduced DC (p=0.002 and p<0.03).In the combinatory rs11523890-rs10830963 genotype, six patients were homozygous 
for both non risk alleleles (CC-AA) and had the best BF (p<0.01) and the worst SI (p<0.01). Finally, the rs9666752 A allele (frequency: 
0.52) was associated with increased HbA1c (+0.22±0.09%, p<0.02). Conclusions: MTNR1B may play a relevant role in the regulation of 
G levels and BF in patients with newly diagnosed T2D. These data, if confirmed, could lead to clinical and therapeutic applications, 
including, but not limited to, identification of specific subgroups of patients for diagnostic-therapeutic purposes.
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P04.60 - Genetic and epigenetic control of insulin action
GENETIC VARIANTS INVOLVED IN MITOCHONDRIAL OxIDATIVE METABOLISM ARE ASSOCIATED WITH TYPE 2
Snogdal Lena Soender1, Wod Mette1, Højlund Kurt1, Henriksen Jan Erik1, Beck-Nielsen Henning1, Vestmar Marie2, Sparsoe Thomas2, Grarup 
Niels2, Pedersen Oluf B.2, Hansen Torben2, Witte Daniel3, Joergensen Torben4, Lauritzen Torsten5, Sandbaek Anneli6
1Dept. Of Endocrinology, Odense University Hospital, Odense, Denmark; 2Hagedorn Research Institute, Gentofte, Denmark; 3Steno Diabetes 
Center, Gentofte, Denmark; 4Faculty Of Health Sciences, University Of Copenhagen, Copenhagen, Denmark; 5Research Centre For Prevention And 
Health, Glostrup University Hospital, Glostrup, Denmark; 6Dept. Of General Practice, Faculty Of Health Sciences, University Of Aarhus, Aarhus, 
Denmark
Type 2 Diabetes (T2D) is characterized by insulin resistance and failure of the pancreatic beta cells to compensate for this defect. 
Several studies have demonstrated a link between insulin resistance and impaired mitochondrial oxidative phosphorylation (OxPhos) 
in skeletal muscle. Recently, mitochondrial defects have also been implicated in beta-cell dysfunction in T2D. We hypothesized that 
single nucleotide polymorphisms (SNPs) in OxPhos genes could contribute to the pathogenesis of T2D. Exploring results from a 
meta-analysis of genome wide association studies (DIAGRAM Consortium), we found that among 2542 SNPs in 119 OxPhos genes, 46 
SNPs showed potential association with T2D (uncorrected p<0.01). SNPs that were in linkage disequilibrium (r2>0.8) were excluded 
from further analysis. The resulting 10 SNPs in or near 6 OxPhos genes were genotyped in 4,089 T2D patients and 5,043 controls 
with normal glucose tolerance. Rs1466100 in COX5B (OR=1.67, p=0.004) and rs9915302 in COX10 (OR=1.14, p=0.02) were significantly 
associated with T2D. In a meta-analysis combining our results with data from an available subset of the DIAGRAM data, we 
demonstrated that three SNPs (rs10775377, rs8077302, rs9915302) in COX10 and a SNP (rs2267584) in a gene (UPK1A) next to COX6B1 
were significantly associated with T2D. In particular, the rs9915302 variant in COX10 showed strong association with T2D (OR=1.14, 
p=7.7x10-6). Our data suggest that genetic variants in or near genes encoding subunits in complex IV (COX5B, COX6B1, COX10) 
contribute to the pathogenesis of T2D. The observed association of variants in COX5B, COX10 and NDUFV3, with markers of insulin 
secretion and postprandial hyperglycae.
P04.61 - Genetic and epigenetic control of insulin action
GENETIC MARKERS FOR METABOLIC SYNDROME AND HYPERADROGENY IN WOMEN WITH POLYCYSTIC OVARIES
Florin Grigorescu1, Redha Attaoua1, Serban Radian2, Felicia Hanzu1, Simona Fica2, Monica Gheorghiu2, Mihai Coculescu2
1Iurc, Molecular Endocrinology, Montpellier, France; 2Institute Of Endocrinology, Bucharest, Romania
Polycystic ovary syndrome (PCOS) is characterized by anovulation, hyperandrogeny (HA) and insulin resistance. To understand its 
genetic determinants we investigated insulin receptor (INSR) and fat mass and obesity associated (FTO) genes in controls (n = 100) 
and PCOS women from Central Europe (n = 207) with 53% obesity, mean HOMA of 4.6 and 46.9% metabolic syndrome (MetS). For 
INSR, we genotyped 5 single nucleotide polymorphisms (SNPs) around exon 9 while for FTO gene, beside previously SNP rs1421085 
we refined the locus by genotyping Retinoblastoma-like (RBL-2) gene (rs8043918) and other SNPs in the linkage disequilibrium (LD) 
block of intron 1. Genotyping was performed by SSO-PCR or sequencing (CEQ-8000) and association of haplotypes (PHASE program) 
was performed with logistic regression. SNP rs1421085 of FTO was strongly associated with Mets (P < 0.001, OR 3.6 95%CI 1.6-8.1) with 
a gene-dosage effect, but without effect on HA. RBL-2 gene did not improved association while four other SNPs confirmed association 
of the LD block. INSR gene by one haplotype (h9) and rs2963 was also associated with PCOS, but association with the MetS (P < 
0.001, OR 6.5 95%CI 2.1-19.8) was independent from FTO. Moreover, there was a good correlation (ANOVA) between h9 and HA while 
subgroup analysis indicated the association of INSR to infertility. We conclude that both INSR and FTO are influential genes in PCOS 
but their independent effects suggest that there may be two components contributing to the severity of PCOS, one related to HA and 
ovarian function and another dictating systemic insulin resistance in relation to obesity and cardiovascular complications.
P05.62 - Environmental control of insulin action and nutrient metabolism
CHARACTERIZATION OF TRANSGENIC MOUSE MODEL OVERExPRESSING C REACTIVE PROTEIN
Hribal Marta Letizia1, Procopio Teresa1, Ruffo Mariafrancesca1, Fiorentino Teresa Vanessa1, Sesti Giorgio1
1University Magna Graecia, Catanzaro, Italy
Increased plasma C reactive protein (CRP) levels are associated with type 2 diabetes and related diseases. To investigate if CRP 
affects glucose metabolism in vivo, we analyzed transgenic mice with PEPCK-driven CRP overexpression (TgCRP). Young TgCRP 
mice had a normal glucose metabolism with only slightly increased fasting glucose. However by 6-months of age, TgCRP mice had 
developed hyperglycemia both in a fasting (108±14, 128.9±36 mg/ml, p‹0.05) and in a fed (135±30, 160±29 mg/ml, p‹0.05, n=18-20) state 
and had reduced fed insulin levels (3.3±2.3, 2.33±1.2 ng/ml p‹0.02, n=10-12). Interestingly, when we performed A-GSIS tests, we found 
that TgCRP mice released significantly less insulin at all time points (p‹0.01). On the other hand intraperitoneal glucose tolerance 
tests (IPGTT) show that they had also became glucose intolerant (p‹0.05, n=10-12). We then hypothesize that the mild metabolic 
phenotype of TgCRP mice would be exacerbated under High Fat Diet (HFD). Indeed, after 24 weeks of HFD, TgCRP had gained more 
weight than WT mice (46.6±3.4 and 51.5±3.69 g, p‹0.01, n=10-12), had significantly higher fed (204±55.32, 257±50.28 mg/dl) and fasting 
(133.6±31.9, 147.7±30.38 mg/dl, p‹0.05, n=10-12) glucose levels and higher fed insulin levels (8±4 and 16±5 ng/ml, p‹0.05, n=8-10). IPGTT 
and insulin tolerance tests (ITT) show that TgCRP had developed a significantly higher degree of glucose intolerance and insulin 
resistance than their WT littermates (p‹0.001, for IPGTT and p‹0.05 for ITT, n=8). Our data suggest that the effect of a chronic low-
grade inflammatory state, mimicked by CRP overexpression, on glucose metabolism is exacerbated by stress factors, such as aging 
or HFD.
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P05.63 - Environmental control of insulin action and nutrient metabolism
PKC DELTA AND METABOLIC DISEASE
Greene Michael1, Burrington Christine1, Chongkrairatanakul Tepsiri1, Johnson Andrew1, Kangwanpornsiri Atipon1
1Bassett Research Institute, Cooperstown, Usa
In metabolic diseases, lipid accumulation in cells and tissues that are unaccustomed to storing excess lipids can result in insulin 
resistance, cellular damage, and even cell death. To determine whether PKCd plays a role in a lipid mediated metabolic disease of the 
liver, we determined whether hepatic PKCd is activated in the progression from steatosis to steatohepatitis. Indeed, PKCd activation 
occurred through out the time course of the development of steatohepatitis induced by feeding a lipogenic methionine and choline 
deficient (MCD) diet. PKCd activation was coincident with the activation of the ER stress response in the liver and induction of serum 
alanine aminotransferase (ALT). Next, MCD medium with fatty acids was found to inhibit insulin signaling in hepatic cells. Further, 
ALT and CHOP induction and significantly elevated PERK and JNK phosphorylation were detected in cells treated with palmitic acid in 
MCD medium. In contrast, ALT and CHOP induction and PERK and JNK phosphorylation were completely blocked in PKCd knockdown 
cells, indicating the requirement for PKCd in ER stress activation and cellular damage. To test whether PKCd was necessary for 
palmitic acid induced cell death, control or PKCd knockdown cells were incubated with MCD medium without or with palmitic acid. 
Palmitic acid significantly reduced cell viability, DNA content, and increased the number of apoptotic nuclei in control cells but not in 
PKCd knockdown cells. Taken together, our data indicates that PKCd regulates ER stress and cellular damage and even cell death. In 
summary, PKCd may be a good therapeutic target for metabolic diseases.
P05.64 - Environmental control of insulin action and nutrient metabolism
THE IMPACT OF AN HIGH PROTEIN DIET ON STRESS AND BEHAVIOR
Coppola Anna2, Wenner Brett2, Stevens Robert2, Levin Edward1, Newgard Christopher2
1Dept. Psychiatry, Duke University Medical Center, Durham, NC, USA; 2Sarah W. Stedman Nutrition And Metabolism Center, Duke University 
Medical Center, Durham, NC, USA
In the last decades the increase in protein intake reached levels two times higher than those recommended by the American Diabetes 
Association. More than 20% of dietary protein is comprised by Branched Chain Aminoacids (BCAAs). A previous study conducted in 
our laboratory demonstrated a direct effect of BCAAs supplementation in the development of insulin resistance and diabetes. In this 
study we investigate the role of a diet rich in protein in the pathophysiology of mood disorders and depression. Chronic elevation in 
BCAAs influences the transport of aromatic amino acids (tyrosine and tryptophan) across the Large neutral Amino acid Transporter 
1, located at the brain blood barrier, contributing to reduced production of monoamines in the central nervous system. Rats fed 
with a diet supplemented with BCAAs showed a significant decrease in the concentration of tryptophan in brain tissues, and a 
consequent decrease in serotonin. Behavioral assessments were performed using different emotional tests, in all of which rats fed 
with the high BCAA diet showed an increase in depressed-like behavior compared to the control groups. Moreover, we were able to 
rescue the depressed behavior in rats fed with high BCAA diet by supplementing their diet with tryptophan in drinking water. These 
results suggest that chronic high BCAA diet in rats may lead to the development of mood disorders, likely in relation with decrease 
in tryptophan concentration in the brain and consequent dysregulation of the serotonin system. Such dysregulation may induce 
impairment of the adaptive response of neuronal pathways to stress conditions, ultimately leading to the etiology of depression.
P05.65 - Environmental control of insulin action and nutrient metabolism
HIGH FAT DIET RICH IN LARD OR FISH OIL AND HEPATIC INSULIN RESISTANCE: ROLE OF MITOCHONDRIAL FUNCTION
Lionetti Lillà1, Mollica Maria Pina1, Donizzetti Immacolata1, Cavaliere Gina1, Gifuni Giorgio1, Pignalosa Angelica1, De Filippo Chiara1, Gaita Marcello1, 
Barletta Antonio1, Putti Rosalba1
1Department Of Biological Science, Naples, Italy
Introduction: the present study aimed to evaluate the effect of different dietary fat sources (lard or fish oil) on hepatic insulin 
resistance induced by chronic overfeeding. The focus was on mitochondrial function which play important roles in the development 
of hepatic injury and insulin resistance. Methods: three groups of rats were fed, for 6 weeks, three different diets: standard diet 
(N rats), high fat diet rich in lard (40% J/J, L rats), or in fish oil (40% J/J, F rats). Histological and immunohistochemical analyses 
were performed in liver section. Peroxisome proliferator-activated receptor α (PPARα) and transforming growth factor-b1 (TGFb-1) 
contents were analyzed by immunocitochemistry and western blot. Measurement of insulin stimulated phosphorylation of protein 
kinase B (PKB/AKT) was performed. In isolated liver mitochondria, fatty acid oxidation, carnitine-palmitoyl transferase (CPT) activity, 
as well as energy efficiency and oxidative stress were assessed. Results: F and L rats livers showed moderate diffusely mixed 
steatosis. PPARα content and fatty acid oxidation progressively increased in L and F rats compared to N ones. L rats showed: a) the 
widest glycogen depleted areas in PAS (Periodic acid-Schiff reactive) methods, c) the lowest insulin-induced AKT-phosphorylation d) 
the highest mitochondrial oxidative stress and energy efficiency and d) the highest TGFb-1 content. Conclusions: high fat diet rich in 
fish oil, compared to high fat diet rich in lard, leads to a relatively lower grade of hepatic fat accumulation and insulin resistance, as 
showed by insulin-induced AKT phosphorylation and glycogen content, by decreasing mitochondrial energy efficiency and oxidative 
stress.
naples, Italy
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P05.66 - Environmental control of insulin action and nutrient metabolism
INSULIN RESISTANCE AND HIGH FAT DIET RICH IN LARD OR FISH OIL: SKELETAL MUSCLE MITOCHONDRIAL FUNCTION
Mollica Maria Pina1, Lionetti Lillà1, Gifuni Giorgio1, Cavaliere Gina1, Pignalosa Angelica1, Gaita Marcello1, De Filippo Chiara1, Donizzetti Immacolata1, 
Putti Rosalba1, Barletta Antonio1
1Department Of Biological Science, Naples, Italy
The present study is focused on the effect of high fat diet rich in lard or in fish oil on skeletal muscle mitochondrial function and 
on insulin resistance development taking into account that mitochondrial dysfunction plays an important role in insulin resistance. 
Methods: Three groups of rats were fed for 6 weeks: standard diet (N), high fat diet rich in lard (40% J/J) (L) or high fat diet rich in 
fish oil (40% J/J) (F). Total body oxygen consumption, energy balance analysis, serum triglycerides, cholesterol and leptin levels, and 
oral glucose tolerance test were performed. At skeletal muscle level, histological and immunohistochemical analyses, mitochondrial 
energy efficiency, oxidative stress, and measurement of insulin stimulated phosphorylation of protein kinase B (PKB/AKT) were 
performed. Results: L rats showed increased body weight and lipid gains, triglyceride, cholesterol and leptin serum levels and a 
reduced tolerance to oral glucose load compared to F rats. L rats showed: a) the widest glycogen depleted areas in PAS (Periodic 
acid-Schiff reactive) methods, b) the lightest immunostaining for adipocyte differentiation-related protein (ADRP), c) the lowest 
insulin-induced AKT-phosphorylation and d) the highest mitochondrial oxidative stress and energy efficiency. Conclusions: In chronic 
overnutrition, high fat diet rich in fish oil, compared to high fat diet rich in lard, induces a lower glucose dependent insulin secretion, 
as well as a lower adiposity by decreasing total body and skeletal muscle mitochondrial energy efficiency and by improving insulin 
signaling response.
P06.68 - b- and α-cells in insulin-resistance states
GLUCOSAMINE-INDUCED BETA CELL DYSFUNCTION: THE ROLE OF ENDOPLASMIC RETICULUM STRESS
Lombardi Angela1, De Vitis Stefania1, Turco Stefano1, Di Jeso Bruno1, Garbi Corrado2, Raciti Gregory Alexander2, Miele Claudia2, Ulianich Luca2
1Disteba, Università Del Salento, Lecce, Italy; 2DBPCM & IEOS-CNR, Università Degli Studi Di Napoli “Federico II”, Napoli, Italy
Under diabetic conditions, ER stress is induced and the JNK pathway is activated; how this activation influences pancreatic beta 
cell function remains unclear. In the present study, we investigate the effects of Glucosamine (GlcN), generated by the hexosamine 
pathway during hyperglycaemia, on ER stress and JNK pathway activation in cultured beta cells (INS-1E) and in isolated pancreatic 
mouse islets. Upon GlcN treatment the mRNA levels of the ER stress markers BiP/GRP78, Chop/GADD153 and ATF6 were increased 
by 3.5 2 and 3 fold respectively in mouse islets. Moreover, GlcN treatment decreased by 70% the mRNA levels of both GLUT2 and GK, 
and decreased by 80% the mRNA levels of the insulin gene (INS1) with a parallel downregulation of the transcription factor PDX1. 
Similar results were obtained with INS-1E cells. Pretreatment of INS-1E cells with the chemical chaperon PBA (2.5mM) for 24h 
partially prevented ER stress induced by GlcN, thereby reducing BiP/GRP78 and CHOP/GADD153 mRNA levels. The inibitory effect 
of GlcN on GLUT2, INS1 and PDX1 mRNA levels was almost completely abolished by PBA. GlcN reduced the capability of INS-1E to 
secrete insulin after glucose stimulation. Glucose-induced insulin secretion was restored, when cells were preincubated with PBA 
for 24h in the presence of GlcN. Finally, pretreatment for 1h of INS-1E cells with the selective JNK-inhibitor SP600125 (20µM) was 
effective in preventing the downregulation of INS1 and its upstream regulator PDX1, exerted by GlcN. These studies suggest that 
glucosamine induced ER stress and subsequent activation of the JNK pathway may be responsible, at least in part, for glucotoxicity-
induced beta cell dysfunction.
P06.69 - b- and α-cells in insulin-resistance states
IR-B MEDIATED PI(3,4)P2 GENERATION BY PI3K-C2A ACTIVATES AKT1 IN INSULIN-PRODUCING CELLS
Leibiger Barbara2, Moede Tilo2, Uhles Sabine2, Barker Christopher J.2, Creveaux Marion2, Domin Jan1, Berggren Per-Olof2, Leibiger Ingo B.2
1Renal Section, Faculty Of Medicine, Imperial College, London, Uk; 2The Rolf Luft Research Center For Diabetes And Endocrinology, Karolinska 
Institutet, Stockholm, Sweden
Phosphatidylinositide 3-kinases (PI3Ks) play central roles in insulin signal-transduction. While the contribution of class Ia PI3K 
members has been extensively studied, the role of class II members remains poorly understood. The diverse actions of class II 
PI3K-C2α have been attributed to its lipid product PI(3)P. By applying pharmacological inhibitors, transient over-expression and 
siRNA-based knockdown of PI3K- and PKB/Akt isoforms, together with PI-lipid profiling and life-cell confocal and TIRF microscopy, 
we now demonstrate that PI3K-C2α in response to insulin generates PI(3,4)P2, which allows the selective activation of PKBα/Akt1. 
Knockdown of PI3K-C2α expression and subsequent reduction of PKBα/Akt1 activity in the pancreatic b-cell impaired glucose-
stimulated insulin release, at least in part, due to reduced glucokinase expression and increased AS160 activity. Our results identify 
signal-transduction via PI3K-C2α as a novel pathway whereby insulin activates PKB/Akt and thus discloses PI3K-C2α as a potential 
drugable target in type 2 diabetes. The high degree of co-distribution of PI3K-C2α and PKBα/Akt1 with insulin receptor B-type, but 
not A-type, in the same plasma membrane microdomains lends further support to the concept that selectivity in insulin signaling is 
achieved by the spatial segregation of signaling events. Grant support from the Swedish Diabetes Association, the Swedish Research 
Council, the Novo Nordisk Foundation, Eurodia (FP6-518153), Berth von Kantzow´s Foundation, JDRF, and the Family Erling-Persson 
Foundation.
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P06.70 - b- and α-cells in insulin-resistance states
THE ROLE OF SERUM GLUCOCORTICOID INDUCIBLE KINASE 1 (SGK1) IN INSULIN SECRETING CELLS
Schulz-Raffelt Gabriele1, Berchtold Susanne1, Michael Diana1, Ranta Felicia1, Häring Hans-Ulrich1, Ullrich Susanne1
1Internal Medicine Iv And Clinical Chemistry, University Hospital Tübingen, Tübingen, Germany
Chronic elevation of glucocorticoids is known to impair insulin secretion. The underlying mechanism involves changes in protein 
expression mediated by the activation of the glucocorticoid receptor. Previously, we demonstrated the prominent induction of SGK1, 
an enzyme with 54% homology to PKB. The aim of the present study was to examine the influence of SGK1 on insulin/IGF-1 signalling 
pathways in insulin secreting cells. Endogenous expression of SGK1 was induced by treatment of INS-1E cells with dexamethasone 
(dexa). Western blotting revealed an induction of SGK1 and a 2-fold increase of IRS-2 protein. Whereas dexa dramatically augmented 
SGK1 mRNA no change in IRS-2 mRNA was observed. In cells transfected with SGK1 the degradation of IRS-2 protein was significantly 
inhibited. Despite the increase in IRS-2 protein, dexa reduced tyrosine phosphorylation of IRS-2. The analysis of downstream 
signalling revealed that PKB phosphorylation was also inhibited whereas FOXO1 phosphorylation was paradoxically increased in 
dexa-treated cells. When SGK1 activity was selectively inhibited by GSK650394 or with siRNA against SGK1 the phosphorylation 
of FOXO1 was not inhibited. Phosphorylation of FOXO1 was also unchanged in cells transfected with either constitutive active or 
dominant negative SGK1. These data suggest that SGK1 exerts anti-apoptotic effects in insulin secreting cells by reducing IRS-2 
protein degradation. Although increased phosphorylation of FOXO1 does not depend on SGK1, dexa mediated inhibition of IRS-2 and 
PKB phosphorylation may contribute to increased apoptosis observed under glucocorticoid excess and to the development of steroid-
induced diabetes mellitus.
P06.71 - b- and α-cells in insulin-resistance states
THE SUPPRESSOR OF CYTOKINE SIGNALLING 2, SOCS2, IS A KEY REPRESSOR OF INSULIN SECRETION
Lebrun Patricia4, Cognard Emmanuelle4, Gontard Pierre4, Bellon-Paul Rachel4, Filloux Chantal4, Berthault Marie-France1, Magnan Christophe1, 
Ruberte Jesus3, Luppo Mariana3, Pujol Anna 3, Pachera Nathalie2, Herchuelz André2, Bosch Fatima3, Van Obberghen Emmanuel4
1Cnrs Eac 4413, Paris, France; 2Laboratoire De Pharmacodynamie Et De Thérapeutique, Bruxelles, Belgium; 3Cbateg, Ciberdem, Barcelona, Spain; 
4Inserm U907, Ifr50, Nice, France
Suppressor of cytokine signalling (SOCS) proteins are powerful inhibitors of pathways involved in survival and function of pancreatic 
beta cells. Whereas SOCS1 and SOCS3 have been involved in immune and inflammatory processes in beta cells, respectively, nothing 
is known about SOCS2 implication in the pancreas. We generated transgenic mice constitutively producing SOCS2 in beta cells 
(ßSOCS2) to define whether this protein is implicated in beta cell functioning and/or survival. Constitutive expression of SOCS2 in 
beta cells leads to hyperglycaemia and glucose intolerance. This phenotype is not a consequence of decreased beta cell mass or 
inhibition of insulin synthesis. However, insulin secretion to various secretagogues is profoundly altered in intact animals and isolated 
islets. Interestingly, constitutive SOCS2 production dampened the rise in cytosolic free calcium concentration induced by glucose, 
while glucose metabolism is unchanged. Moreover, tg islets have a depletion in endoplasmic reticulum Ca2+ stores, suggesting that 
SOCS2 interferes with calcium fluxes. Finally, in ßSOCS2 mice proinsulin maturation is impaired, leading to an altered structure of 
insulin secretory granules and augmented levels of proinsulin. The latter is likely to be due to decreased production of prohormone 
convertase 1 (PC1/3), which plays a key role in proinsulin cleavage. We demonstrate that SOCS2 is a potent regulator of proinsulin 
processing and insulin secretion in beta cells. While its constitutive expression is insufficient to induce overt diabetes, it causes 
glucose intolerance. Thus, increased SOCS2 production could be an important event predisposing to beta cell failure.
P06.73 - b- and α-cells in insulin-resistance states
TSC1-TSC2 COMPLEx AND IR ISOFORMS IN ß CELLS: IMPLICATIONS IN INSULIN RESISTANCE
Guillen Carlos1, Bartolome Alberto1, Benito Manuel1
1Universidad Complutense De Madrid, Madrid, Spain
Tuberous sclerosis complex proteins 1-2 (TSC1-TSC2) complex integrates both nutrient and hormonal signaling and is a critical 
negative regulator of mammalian target of rapamycin complex 1 (mTORC1). The use of different b cell lines expressing or not the 
insulin receptor (IR +/+ and IR -/-), or with a reconstituted expression of IR isoform A or B (Rec A and Rec B), revealed that both PI3K/
Akt/TSC/mTORC1 and MEK/ERK pathways mediate insulin signaling in either IR +/+, IRA or IRB expressing cells. However, glucose 
signaling was mediated by MEK/ERK and AMPK pathways as assessed in IR -/- cells. The effect of insulin on Akt phosphorylation was 
completely inhibited by the use of the PI3K inhibitor wortmannin in IR +/+ and Rec B cells, a partial inhibitory effect being observed 
in Rec A cell line. The knockdown of TSC2 expression upregulated the downstream basal phosphorylation of p70S6K and mTOR. 
More importantly, upregulation of p70S6K signaling impaired insulin-stimulated phosphorylation of Akt Ser473 and p70S6K in IR +/+ 
and Rec B, but not in Rec A cell lines. In fact, insulin receptor substrate-1 Ser307 phosphorylation signal in Rec B was stronger than 
in Rec A cell line upon insulin action. Rec A cells induced a higher proliferation rate as compared with Rec B or IR +/+ upon serum 
stimulation. Thus, we propose that the regulation of TSC2 phosphorylation by insulin or glucose independently integrates b cell 
proliferation signaling, the relative expression of IRA or IRB isoforms in pancreatic b cells playing a major role.
naples, Italy
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P06.74 - b- and α-cells in insulin-resistance states
PALMITATE AFFECTS INSULIN SIGNAL IN PANCREATIC ALPHA CELLS.
Mascali Loriana Grazia1, Piro Salvatore1, Maniscalchi Eugenia Tiziana1, Monello Adelina1, Urbano Francesca1, Iacoviello Linda1, Rabuazzo Agata 
Maria1, Purrello Francesco1
1Dipartimento Di Medicina Interna E Specialistica, Lab. di Medicina Molecolare, Università Degli Studi Di Catania, Ospedale Garibaldi Italy, 
Catania, Italy
Under physiological conditions high glucose or insulin levels inhibit glucagon secretion; this regulation is altered in T2DM. Since 
insulin directly affects glucagon secretion in alpha cells, an alteration in insulin receptor function or signaling could impair this 
regulatory effect. The IR/IRS-1/PI3K/Akt pathway is known to regulate glucagon secretion in alpha cells. In this study we investigated 
the effects of chronic exposure to palmitate on insulin receptor (IR) phosphorylation and insulin signaling in pancreatic alpha cells. 
We cultured α-TC1-6 with palmitate (0.5 mM) for 48 h. After chronic palmitate exposure, we acutely stimulated the cells with insulin 
(10-9 M). At the end of insulin stimulation IR/IRS-1/PI3K/Akt pathway downstream was investigated. Palmitate exposure (48 h) 
determined a decrease of IR-P (after acute insulin stimulation at 10-9 M for 5 min.) in palmitate groups (8±2 vs 19±2 AU in control 
cells, n=5, p<0.05). In cells cultured with palmitate we found a decrease of IRS-1-P Tyr-612 (2 ± 0.5 AU vs 12 ± 2 AU in control cells; 
n=5, p<0.01). In addition, we found a decrease of PI3K-P in palmitate groups (8±2 AU in control cells vs 2±1 AU in palmitate cells, n=5, 
p<0.05). The AKT-P levels were also decreased in palmitate groups both at Thr 308-P (2 ± 2 AU vs 20 ± 6 AU in control cells; n=5, 
p<0.05) and at Ser 473-P (3 ± 2 AU vs 12 ± 2 AU in control cells; n=5, p<0.05). In α-TC1, a mouse pancreatic alpha cell line, the chronic 
exposure to palmitate affects the intracellular insulin pathway. In particular, the phosphorylation of IR/IRS-1/PI3K/Akt were impaired, 
thus suggesting that trough this mechanism FFA might induce insulin resistance in alpha cells.
P06.75 - b- and α-cells in insulin-resistance states
ANTIDEPRESSANTS OF THE SSRIS FAMILY INHIBIT INSULIN SECRETION AND ACTION IN PANCREATIC BETA CELLS
Isaac Roi1, Boura-Halfon Sigalit1, Gurevitch Diana1, Levkovitz Yechiel 2, Zick Yehiel 1
1The Weizmann Institute Of Science, Rehovot, Isreal; 2Shalvata Mental Health Center, Sackler Faculty Of Medicine, Tel-Aviv University, Tel-Aviv, 
Israel
Selective serotonin reuptake inhibitors (SSRIs) are antidepressants used for the treatment of mood and anxiety disorders. We have 
previously shown that selected SSRIs induce Ser/Thr phosphorylation of insulin receptor substrate (IRS) proteins and promote 
cellular insulin resistance. Because IRS proteins are key mediators of beta cell function we set to determine the effects of SSRIs on 
IRS proteins in beta cells. Here we demonstrate that incubation (1-2 h) of Min6, a beta cell line, or primary cultures of murine islets 
with the SSRIs paroxetine, fluoxetine or sertraline inhibited insulin-induced Tyr phosphorylation of IRS-2 and the activation of its 
downstream targets Akt and S6K1. Inhibition was dose-dependent with half-maximal effects at ~15-20 µM. It correlated with a rapid 
phosphorylation and activation of a number of IRS kinases including JNK, p38 MAPK and GSK3b. The effect was specific because PKB 
(Akt), or ERK were not activated by the SSRIs. Inhibition of IRS-2 action by SSRIs was associated with inhibition (~50%) of glucose-
stimulated insulin secretion in primary cultures of pancreatic islets. Inhibition occurred upon 2 h incubation with 30 µM of sertraline. 
Secretion induced by basic secretagogues (KCl and Arg) was not affected by these drugs. These results implicate IRS kinases, 
activated by SSRIs as inhibitors of insulin secretion and beta cell function. Given that SSRIs promote insulin resistance while inhibiting 
insulin secretion, these drugs might accelerate the transition from an insulin resistant state to overt diabetes.
P06.76 - b- and α-cells in insulin-resistance states
THE SER473 AKT SPECIFIC PHOSPHATASE PHLPP PLAYS A CENTRAL ROLE IN BETA-CELL DYSFUNCTION
Procopio Teresa1, Greco Annalisa1, Fiorentino Teresa Vanessa1, Andreozzi Francesco1, Hribal Marta Letizia1, Sesti Giorgio1
1University Magna Graecia, Catanzaro, Italy
Chronic exposure of pancreatic beta-cells to high glucose levels is associate with reduced insulin secretion, impaired replication and 
decreased activation of Akt, a serine-treonine kinase that plays a key role in beta-cell homeostasis. The molecular players involved 
in this phenomenon are however not completely known. In this study, we demonstrate that in the rat INS-1 cell line exposed to high 
(30 mM, INS-1HG) glucose for 10-15 passages, the expression of the AktSer473-specific phosphatase PHLPP1/2 was significantly 
increased both at mRNA (PHLPP1 250±22%; PHLPP2 320±24%,p<0.05, n=10) and protein (PHLPP1 132±22%; PHLPP2 176±34%, p<0.05, 
n=4) level as compared to INS-1 cultured for an equal number of passages at physiological glucose concentrations (INS-1LG). This 
increase was paralleled by a significant decrease of Akt phosphorylation on Ser473 after insulin stimulation in INS-1HG as compared 
to INS-1LG (-50±12%, p<0.05, n=6); by contrast the phosphorylation of Thr308 was only slightly, and not significantly, reduced; 
interestingly we observed a small, but significant, reduction in total Akt expression levels in INS-1HG as compared to INS-1LG 
(-15±2%, p<0.05,n=3). The decreased activation of Akt was mirrored by a decreased insulin-stimulated phosphorylation of the major 
Akt substrates: -37±3% for p70S6K, -35±4% for peIF2alpha, -53±6% for 4eBP1, -60±8% for CREB and -30±5% for Foxo-1 in INS-1HG 
as compared to INS-1LG (p<0.05, n=3, for all). Our results, contributing to the elucidation of the mechanisms by which hyperglycemia 
affects the multiple functions controlled by Akt, could provide indications for novel therapeutic approach to deal with beta-cell failure.
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P06.77 - b- and α-cells in insulin-resistance states
PKC DELTA MEDIATED REGULATION OF CYTOSOLIC/NUCLEAR TRAFFICKING OF P21 IN BETA CELL
Ranta Felicia1, Theilig Thea1, Leveringhaus Johannes1, Häring Hans-Ulrich1, Ullrich Susanne1
1Internal Medicine And Clinical Chemistry, University Hospital Tübingen, Tübingen, Germany
Increased apoptotic cell death and reduced proliferation is believed to contribute to b-cell failure during the development of type 
2 diabetes mellitus. The aim of the present study was to examine the effects of the pro-apoptotic kinase PKCd on proliferation of 
insulin secreting cells. INS-1E cells stably infected with kinase dead PKCd (PKCdKN) displayed reduced cell growth while cells 
overexpressing wild type PKCd (PKCdWT) showed normal growth rate. Cell cycle analysis using propidium iodide staining revealed 
that PKCdKN cells accumulate in G2 (80% of the cells), whereas the cell cycle distribution pattern of PKCdWT cells did not differ 
from control INS-1E cells (60% of the cells in G1 and 30% in G2). The G2/M marker p-ser10-histone H3 was detected in 17.4% of the 
PKCdKN cells but only in 5.8% of PKCdWT and 8.3% of control INS-1E cells. No significant change in total protein was observed 
by Western blotting of cell cycle proteins cdc2, FAK and p27. In contrast, the amount of p21 protein was reduced in PKCdWT cells. 
Immunohistochemical analysis of subcellular distribution showed extrusion of p21 from the nucleus in PKCdWT cells. In control 
cells 8.1% of nuclei and in PKCdKN cells 24.2% of nuclei stained positive for p21. Inhibition of the nuclear export machinery with 
leptomycin B neither induced nuclear accumulation of p21 in PKCdWT cells nor augmented the accumulation of p21 in PKCdKN nuclei. 
Phosphorylation of p21 was increased in PKCdWT but not in PKCdKN cells. These observations suggest that PKCd supports cell cycle 
progression by phosphorylation of p21 that inhibits nuclear translocation of p21. This effect of PKCd on p21 may sustain proliferation of 
b-cell.
P06.78 - b- and α-cells in insulin-resistance states
DIRECT EFFECTS OF RAPID ACTING INSULIN ANALOGS ON INSULIN SIGNALING IN HUMAN PANCREATIC ISLETS
D’Aleo Valentina1, Lupi Roberto2, Del Guerra Silvia1, Gualtierotti Giulio1, Pandolfi Rachele1, Boggi Ugo1, Vistoli Fabio1, Filipponi Franco1, Marchetti 
Piero1
1Department Of Endocrinology And Metabolism, Metabolic Unit, University Of Pisa, Pisa, Italy; 2Department Of Endocrinology And Kidney, 
Metabolic Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Background and Aims. Rapid acting insulin analogs (RAIA: Lispro, Li; Aspart, As; Glulisine, Gl) have been introduced to optimize 
insulin treatment in diabetes. Since insulin signaling system (SigSys) is present in pancreatic islets and can modulate beta-cell 
function and survival, we studied the effects of As, Gl and regular insulin (RI) on isolated human islets (IHI). Materials and Methods. 
IHI were cultured for 48h in the presence of 5.5 (g) or 22.2 (G) mmol/l glucose, either with or without the addition of As, Gl or RI (10 
nmol/l). Functional (glucose-stimulated insulin secretion, GSIS) and molecular studies were performed. Results. Basal C-peptide 
secretion (pmol/l) was 1287±540 at g and increased to 3130±1666 at G (p<0.05). The presence of RAIA or RI did not affect this feature 
significantly. GSIS was significantly reduced in islets pre-exposed to G (SI 1.2±0.1), respect to g (SI, 2.2±0.5) (p<0.01), but was not 
further affected by the added insulins. Compared to g, pre-exposure to G caused an increase of IRS1 and IRS2 and a reduction of 
insulin receptor (IR) gene expression. No significantly change was observed in PI3K expression. IR expression was inhibited by RI 
in the islets kept at g and induced by As and RI in the islets pre-cultured at G. Modest changes were observed as for the expression 
of IRS1 and IRS2, whatever the incubation condition. PI3K expression was significantly induced by Gl and As at g, but not at G. 
Conclusions. Tested RAIA and RI have different effects on the expression of molecules involved in the early steps of the insulin 
signaling system in human islets, with the overall action also depending on the degree of glucose exposure.
P06.79 - b- and α-cells in insulin-resistance states
ALTERATIONS OF INSULIN SIGNALING PATHWAY IN TYPE 2 DIABETIC ISLETS AND THE BENEFICIAL EFFECTS OF METFORMIN
Del Guerra Silvia1, D’Aleo Valentina1, Gualtierotti Giulio1, Pandolfi Rachele1, Boggi Ugo1, Vistoli Fabio1, Filipponi Franco1, Del Prato Stefano1, 
Marchetti Piero1, Lupi Roberto2
1Department Of Endocrinology And Metabolism, Metabolic Unit, University Of Pisa., Pisa, Italy; 2Department Of Endocrinology And Kidney, 
Metabolic Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Background and Aims. In Type 2 diabetes deregulation of insulin signaling pathway (ISP) leads to reduced insulin action in several 
tissues and seems to be involved also in the regulation of pancreatic beta-cell mass and function. Materials and Methods. We 
evaluated several steps of ISP in isolated human islets obtained from the pancreas of 18 non-diabetic (ND) and 14 Type 2 diabetic 
multiorgan donors (T2DM). The glucose-stimulated insulin secretion (GSIS), the islets cell viability (ICV), the insulin receptor (IR), 
IRS1 and IRS2, and PI3K (p110 alpha subunit) mRNA expression and PI3K, IRS1 and IRS2 protein expression and/or phosphorylation, 
was evaluated. Results. Compared to ND, in T2DM islets GSIS, ICV and IR (-80±10%), IRS1 (-75±13.2%), IRS2 (-67±23%), and PI3K 
(-87±5.8%) mRNA expression were significantly reduced (all p<0.001). In addition, PI3K protein expression and IRS1 and IRS2 protein 
phosphorylation were significantly lower in T2DM (12.74±1.81, 40.0±17.1% and 44.2±10.0%, respectively) respect to ND islets (21.5±1.25, 
67.4±17.3% and 79.6±18.0% respectively) (all p<0.05).The presence of metformin in the culture medium of T2DM islets restores beta-
cell function, improves ICV, determines a significant increase of IR, IRS1, IRS2 and PI3K mRNA expression, and significantly increases 
both the PI3K protein expression and IRS-1 and IRS-2 phosphorylation. Conclusions. These results show that ISP is impaired at 
multiple levels in T2DM islets, and its changes appear to be pharmacologically reversible and associated with an improvement both 
of the beta-cell function and viability. Improving insulin action in the beta-cells might represent an additional target of Type 2 diabetes 
therapy.
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P06.80 - b- and α-cells in insulin-resistance states
ExENDIN-4 INHIBITS PALMITATE-INDUCED APOPTOSIS IN PANCREATIC BETA CELLS.
Natalicchio Annalisa1, Labarbuta Rossella1, Orlando Maura Roberta1, Tortosa Federica1, Leonardini Anna1, Cignarelli Angelo1, Melchiorre 
Mariangela1, Peschechera Alessandro1, Marchetti Piero2, Perrini Sebastio1, Laviola Luigi1, Giorgino Francesco1
1Endocrinology & Metabolic Diseases, University Of Bari,, Bari, Italy; 2Endocrinology And Metabolism Of Transplantation, Aou, University Of Pisa, 
Pisa, Italy
Free fatty acids (FFA) induce beta-cell damage when their levels are increased, contributing to the pathogenesis of type 2 diabetes. 
GLP-1 and exendin-4 (ex-4) increase the survival of beta-cells exposed to various pro-apoptotic stimuli, including FFA. The aim of this 
study was to investigate the mechanisms of FFA-induced beta-cell apoptosis and the potential protective effects of GLP-1 mimetics 
on this response in the rat insulin-secreting cell INS-1 and in human islets. Exposure of both INS-1 cells and human islets to 0.5 
mM palmitate up to 48 h induced a 2.5-fold increase in cell apoptosis, measured by evaluation of cytosolic oligosomes (p<0.05) and 
cleaved caspase-3 (p<0.05). Palmitate induced a 3.5-fold increase in the phosphorylation of JNK1/2, evaluated by both immunoblotting 
and immunofluorescence (p<0.05), and a 3.8-fold increase in the mRNA levels of the JNK substrate c-jun (p<0.05), evaluated by 
qRT-PCR. Preincubation with 10 µM SP600125, a specific JNK inhibitor, prevented palmitate-induced apoptosis (p<0.05 vs. palmitate-
treated cells). Treatment with 10 nM ex-4 for 16 h inhibited both palmitate-induced activation of JNK1/2 (p<0.05 vs. palmitate-treated 
cells) and apoptosis (p<0.05 vs. palmitate-treated cells) in both rat insulin-secreting cells INS-1 and human islets. Furthermore, 
ex-4 inhibited palmitate-induced phosphorylation of MKK4 and MKK7 (p<0.05 vs. palmitate-treated cells), and increased the protein 
content of Islet-Brain 1 (IB1) (p<0.05). These results demonstrates that the ability of ex-4 to prevent FFA-induced apoptosis involves 
inhibition of the JNK pathway, identifying a mechanism by which GLP-1 receptor agonists may halt beta-cell death.
P07.81 - Insulin action in the CNS
INSULIN REGULATES TYROSINE HYDROxYLASE ExPRESSION IN NEURONAL PC12 CELLS.
Fiory Francesca1, Perruolo Giuseppe1, Liotti Antonietta1, Miele Claudia1, Barbagallo Alessia Paola Maria1, Formisano Pietro1, Béguinot Francesco1
1DBPCM & IEOS/CNR, Università Degli Studi Di Napoli Federico II, Napoli, Italia
Impairment of insulin synthesis or action is associated with neurodegenerative disease and with a decline in cognitive function. 
Recent studies show that diabetes represents a risk factor for dementia. Streptozotocin-diabetic rats have lower catecholamines 
levels in the corpus striatum and immunoreactive tyrosine hydroxylase (TH), the rate limiting enzyme in catecholamines synthesis, 
is decreased in nigrostriatal neurons of the genetically diabetic BB Wistar rats. Moreover, insulin treatment raised TH mRNA levels 
in intact adrenals. We have evaluated insulin ability to regulate the TH levels in pc12 cells. Insulin induces IR and IRSs tyrosine 
phosphorylation and PKB and ERK activation in pc12 cells. Treatment of pc 12 cells with 100nM insulin for 2 hours leads to a 7 fold 
increase in mRNA levels of TH. TH protein levels are also increased upon 2, 4 and 6 hours of insulin treatment. Pretreatment of 
pc12 cells for 30’ with 50 µM LY294002, a PI3K inhibitor, or for 1h with 50 µM PD98059 an ERK inhibitor, completely abolished insulin 
induced increase of TH mRNA and protein levels. Hif1-alpha is the alpha subunit of a heterodimeric basic helix-loop-helix factor 
activated by ERK and PI3K in response to growth factor and hypoxia. It is known that Hif1-alpha is able to bind TH promoter. The 
pretreatment of pc12 cells for 16h with 100nM chetomin, a Hif1-alpha inhibitor, almost completely abolished insulin positive effect 
on TH mRNA. These results suggest that insulin effect on TH mRNA is mediated by Hif1-alpha activation through an ERK/PI3K 
dependent mechanism. Thus, improvement of insulin signal transduction in brain could preserve neurotransmitters content in 
diabetic condition.
P07.82 - Insulin action in the CNS
INSULIN SIGNALING IN HUMAN PRIMARY ASTROCYTES
Heni Martin1, Hennige Anita M.1, Staiger Harald1, Häring Hans-Ulrich1
1Department Of Internal Medicine, Division Of Endocrinology, Diabetology, Angiology, Nephrology And Clinical Chemistry, Tübingen, Germany
Aims In the human brain, there are at least as many astrocytes as neurons. Astrocytes are known to modulate neuronal function 
in several ways. Thus, they potentially contribute to cerebral insulin actions. Therefore, we examined whether primary human 
astrocytes are insulin-responsive and if their metabolical functions are affected by the hormone. Methods Commercially available 
Normal Human Astrocytes (Lonza) were grown in the recommended medium. Major players in the insulin signaling pathway were 
detected by real time RT-PCR and Western blotting. Phosphorylation levels were detected by phospho-specific antibodies. Glucose 
uptake and glycogen synthesis were assessed using radio-labeled glucose. Lactate levels were measured enzymatically. Results 
We detected expression of key proteins for insulin signaling, such as insulin receptor b-subunit, insulin receptor substrat-1, Akt / 
protein kinase B and glycogen synthase kinase 3, in human astrocytes. Dose-dependent Akt phosphorylation and PI-3 kinase activity 
was detected following insulin stimulation. Neither increased glucose uptake nor lactate secretion after insulin stimulation was 
present in this cell type. However, we found increased glucose incorporation into glycogen after insulin stimulation. Conclusion 
This study demonstrated that human astrocytes are insulin-sensitive at the molecular level. We identified glycogen synthesis as a 
relevant function of insulin signaling in these brain cells. Thus, this cell type may therefore be involved in insulin-mediated changes of 
neuronal activity.
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PED/PEA-15 DOWN-REGULATES DOPAMINE LEVELS IN TRANSGENIC ANIMALS
Perruolo Giuseppe3, Viggiano Davide1, Fiory Francesca3, Cassese Angela3, Scorziello Antonella2, Sadile Adolfo1, Annunziato Lucio2, Béguinot 
Francesco3, Formisano Pietro3
1Dip. Di Medicina Sperimentale, Napoli, Italy; 2Dip. Di Neuroscienze Università Di Napoli “Federico II”, Napoli, Italy; 3DBPCM & IEOS/CNR, 
Università Degli Studi Di Napoli Federico II, Napoli, Italia
PED 15 gene is expressed at high levels in specific cerebral areas and in tissues of patients with type 2 diabetes (T2D) and in their 
first-degree relatives (FDR). PED 15 transgenic mice (PED-TG) develop impaired glucose tolerance and insulin resistance. Impairment 
of insulin synthesis or action is associated with neurodegenerative disease and with a decline in cognitive function. We investigated 
whether PED-15 overexpression may alter neurological functions. Motor function in PED-TG mice was investigated by measuring the 
time to climb an inclined platform and the time to rotate 180 degrees after placed nose down on an incline (negative geotaxis). PED-TG 
showed a two-fold increased time of climbing and impaired negative geotaxis. Moreover, grip strength testing, hanging wire test and 
pole test excluded significant differences in muscular force. Footprint analysis excluded locomotor ataxia. Learning rate for motor 
ability tasks, on a rotarod, and for spatial tasks, measured with Barnes Maze was also significantly slower in PED-TG. Moreover, PED-
TG mice suspended by the tail always crossed their legs when hung upside-down, an aberrant behaviour (foot-clasping reflex). No 
gross impairment of cerebral structures, including striatum size, was noticed by morphological examination. Nevertheless, tyrosine 
hydroxylase content was 60% lower in caudate-putamen protein extracts from PED-TG compared to controls, as assessed by Western 
blot analysis. Immunostaining of brain slides from PED-TG mice revealed a reduced content of TH and of dopamine. Our data support 
the hypothesis that PED/PEA-15 overexpression in mice reduces dopamine levels thus inducing a Parkinson-like syndrome.
P07.84 - Insulin action in the CNS
AEROBIC ExERCISE IMPROVES COGNITION FOR OLDER ADULTS WITH GLUCOSE INTOLERANCE
Baker Laura3, Frank Laura3, Foster-Schubert Karen1, Green Pattie2, Wilkinson Charles2, Mctiernan Anne1, Plymate Stephen2, Fishel Mark2, 
Watson G Stennis3, Duncan Glen3, Mehta Pankaj4, Craft Suzanne2
1Fred Hutchinson Cancer Research Center, Seattle, Usa; 2Department Of Veterans Affairs Medical Center, Seattle, Usa; 3University Of Washington, 
Seattle, Usa; 4New York State Institute For Basic Research In Developmental Disabilities, New York, Usa
Type 2 diabetes increases risk of cognitive impairment and Alzheimer’s disease. Although the benefits of aerobic exercise for physical 
health are well-documented, exercise effects on cognition have not been examined for older glucose intolerant adults at increased 
risk of cognitive impairment. Using a randomized controlled design, 28 adults (57-83 yrs old) with glucose intolerance completed 
6 months of aerobic exercise or stretching, which served as the control. Outcome variables included pre- and post-intervention 
measures of cardiorespiratory fitness, glucose disposal during hyperinsulinemic-euglycemic clamp, fat distribution quantified 
by DEXA, fasting plasma levels of insulin, cortisol, brain-derived neurotrophic factor, IGF-1, b-amyloid, and cognitive measures of 
executive function and short-term memory. Cardiorespiratory fitness improved for the aerobic group and was unchanged for the 
stretching control group (MANOVA, P=0.03). Aerobic exercise enhanced executive function (MANCOVA, P=0.04) and improved insulin 
sensitivity (P=0.05). Across all subjects, 6-month changes in cardiorespiratory fitness and insulin sensitivity were positively correlated 
(P=0.01). For Ab42, circulating levels tended to decrease for the aerobic group relative to controls (P=0.09). The results of our pilot 
trial using rigorous controlled methodology suggest a cognition-enhancing effect of aerobic exercise for older glucose intolerant 
adults. Although replication is critical, these findings may have important therapeutic implications for a growing number of adults at 
risk not only for type 2 diabetes but also for significant cognitive decline associated with neurodegenerative disease.
P07.85 - Insulin action in the CNS
PIOGLITAZONE ALTERS COGNITIVE PERFORMANCE AND INSULIN SENSITIVITY IN AD MICE
Di Pietro Natalia1, Masciopinto Francesca2, Pipino Caterina1, Bomba Manuela2, Corona Carlo2, Consoli Agostino3, Sensi Stefano Luca2, Pandolfi Assunta1
1Department Of Biomedical Sciences, Aging Research Center, CE.S.I., “Gabriele D’Annunzio” University Foundation, University “G. D’Annunzio”, 
Chieti, Italy; 2Molecular Neurology Units,  Aging Research Center, CE.S.I., “Gabriele D’Annunzio” University Foundation, University “G. 
D’Annunzio”, Chieti, Italy; 3Department Of Medicine And Aging Sciences, Aging Research Center, CE.S.I., “Gabriele D’Annunzio” University 
Foundation, University “G. D’Annunzio”, Chieti, Italy
Thiazolidinediones (TZDs) help to restore insulin sensitivity in patients suffering from Type 2 Diabetes. Interestingly, recent evidence 
indicate that TZDs reduce mild cognitive impairment in aging individuals. In this study, we evaluated whether chronic treatment with 
a specific TZD, pioglitazone (PIO), affects the cognitive performance and the insulin metabolism of a triple transgenic (3xTg) model of 
Alzheimer’s disease (AD). These mice overexpress mutant APP, PS1 and hyperphosphorylated tau and are considered an excellent AD 
model. Starting at 3 months of age (m.o.a.), 3xTg and control mice were treated for 9 months with either a control or PIO-containing 
(20 mg/kg body weight/day) diet. During the 9 months period, treated and untreated mice were constantly monitored for weight, food 
consumption, blood fasting glucose levels, fasting serum insulin levels (ELISA) and intra-peritoneal glucose tolerance test (IPGTT). 
Cognitive performance of treated and control mice at 9 and 12 m.o.a. was also evaluated using behavioural tests such as the Y Maze, 
the novel object recognition test, and the Morris water maze. Preliminary results of the study indicate that mice fed with PIO-
containing diet showed a time-dependent gain in body weight compared to control diet animals. Interesting gender-related effects 
were also noted as female 3xTg show changes in glucose metabolism (IPGTT) and a downward trend in the insulin levels. Intriguingly, 
such metabolic alterations were correlated with an improvement in their cognitive performance. In conclusion, our results indicate 
that Pioglitazone can affect both insulin metabolism and the cognitive performance of a 3xTg mouse model of AD.
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P09.86 - Insulin-action and cancer
PROINSULIN IS A LIGAND OF ISOFORM A OF THE INSULIN RECEPTOR
Sacco Antonella1, Malaguarnera Roberta1, Pandini Giuseppe2, Vigneri Riccardo2, Belfiore Antonino1
1Endocrinology Unit, Department Of Clinical And Experimental Medicine, University Of Catanzaro, Catanzaro, Italy; 2Endocrinology Unit, 
Department Of Internal Medicine And Medical Specialties, University Of Catania, Catania, Italy
Obesity and type 2 diabetes mellitus (T2DM) are associated with a significantly increased risk of cancer. Hyperinsulinemia 
concomitant with insulin resistance, features of both obesity and T2DM, are major cancer risk factors. Since insulin resistance 
is characterized by an increased proinsulin (Pro-I):insulin ratio, Pro-I may contribute to cancer development in insulin resistant 
patients. Aims: to evaluate whether Pro-I may bind to the two IR isoforms (IR-A and IR-B) with different affinities and whether 
Pro-I may stimulates biological effects through IR-A or IR-B. Methods: we used mouse R- fibroblasts stably transfected with cDNA 
encoding for human IR-A or IR-B (R-/IR-A and R-/IR-B cells). MCF-7 human breast cancer cells were used as a complementary 
approach. Results: Pro-I was able to phosphorylate IR-A with a EC50 of 12±2 nM, similar to that of IGF-II. In contrast, EC50 for IR-B 
was 73±5 nM. Accordingly, Pro-I was able to displace 125I insulin from IR-A with a similar EC50 value while displaced 125I insulin from 
IR-B only at much higher concentrations. Evaluation of biological effects in MCF-7 cells, indicated that Pro-I was as effective as IGF-II 
in inducing cell proliferation and migration. Conclusions: Pro-I binds to and activates IR-A, but not IR-B, with a similar affinity as IGF-
II and induces cell growth and migration in breast cancer cells at nanomolar concentrations. These findings may be relevant to the 
mechanisms involved in the increased cancer risk of insulin resistant patients and may stimulate novel preventive and/or therapeutic 
approaches to malignancies associated with insulin resistance. Acknowledgement: we thank Eli Lilly for providing Pro-I.
P09.87 - Insulin-action and cancer
INSULIN ANALOGUE EFFECTS THROUGH INSULIN RECEPTOR ISOFORMS AND IGF1R
Sciacca Laura1, Cassarino Maria Francesca1, Genua Marco1, Scuderi Laura1, Squatrito Sebastiano1, Vigneri Riccardo1
1Endocrinology, Department Of Internal And Specialistic Medicine, University Of Catania, Garibaldi–Nesima Hospital, Catania, Italy
Five insulin analogues are currently approved for treating diabetic patients. They activate cell signalling and biological responses 
via insulin receptor isoforms (IR-A and IR-B), each having specific characteristics for eliciting cell responses. The molecular and 
biological effects of these analogues on receptor isoforms in comparison to native insulin are not well defined, and their effects on 
the IGF1 receptor (IGF1R) are controversial. We evaluated the effect of short- (lispro, aspart, glulisine) and long-acting (glargine, 
detemir) insulin analogues in three engineered cell models (R-, IGF1R-deprived mouse fibroblasts transfected with and expressing 
either only human IR-A or IR-B or IGF1R). Receptor binding and phosphorylation, Akt and ERK activation, cell proliferation and colony 
formation were evaluated. Insulin, IGF1 and the carcinogenic analogue B10Asp were used as controls. All short-acting analogues 
produced molecular and biological effects similar to those of insulin. Relative to insulin, long-acting analogues more strongly 
activated the ERK pathway via both IR-A and IGF1R and increased cell proliferation. At the concentration tested, no analogue (except 
B10Asp via IR-A) had increased transforming activity. In conclusion cell models that permit comparisons of the activity of insulin with 
insulin analogues on one single receptor without interference of other receptors, indicate that only minor differences exist between 
insulin and short-acting analogues. In contrast, long-acting analogues activate the mitogenic signalling pathway more effectively than 
insulin and cause increased cell proliferation.
P09.88 - Insulin-action and cancer
HIGH ExPRESSION OF IGF-1R AND DOMINANCE OF IR-A OVER IR-B IN FEMALE SPRAGUE DAWLEY RAT MAMMARY GLAND TISSUE
Hvid Henning1, Vienberg Sara2, Hansen Bo F.2
1Pathology, Novo Nordisk A/s, Copenhagen, Denmark; 2Insulin Biology, Novo Nordisk A/s, Copenhagen, Denmark
It has previously been reported that supra-pharmacological doses of the insulin analogue X10 (B10D) increased the incidence of 
mammary tumors in female Sprague Dawley rats(1). Sprague Dawley rats are known to have a high incidence of spontaneously 
occurring mammary gland tumors(2) and are recommended for assessment of the mitogenic potential of insulin analogues in 
vivo(3). However, expression of IGF-1R and IR in mammary gland tissue from young female Sprague Dawley rats has not been 
thoroughly characterized. The aim of the present study was to examine expression of IGF-1R and IR in rat mammary gland tissue and 
compare to expression in liver and skeletal muscle. We used quantitative RT-PCR to examine the relative expression of IGF-1R, IR, 
IR-A and IR-B mRNA in rat liver, soleus muscle, mammary gland and laser micro-dissected mammary gland alveolar lobules and 
glandular connective tissue. Furthermore, we used immunohistochemistry to examine expression of IGF-1R and IR in sections of 
rat mammary gland, liver and skeletal muscle. We found that mammary gland tissue from young female Sprague Dawley rats has a 
high expression of IGF-1R mRNA and that IR-A mRNA was expressed at higher levels than IR-B mRNA in the mammary gland tissue. 
However, the expression of IR mRNA was lower in mammary gland than in liver and soleus muscle. These findings were confirmed by 
immunohistochemistry, where we observed stronger staining of IGF-1R than of IR in mammary gland epithelial cells in comparison 
to liver and skeletal muscle. In conclusion, these findings indicate the Sprague Dawley rat is useful for assessing both IGF-1R- and 
IR-mediated responses of insulin analogues in vivo.
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CROSS-TALK BETWEEN RAPID ESTROGEN ACTIONS AND INSULIN SIGNALING IN BREAST CANCER
Garrido Pablo1, Alonso Ana1, Morán Javier1, González Celestino1
1Physiology Area. Department Of Functional Biology. Oviedo University, Oviedo, Spain
The relationship between estrogen and some types of breast cancer have been clearly established. However, the possible cross-
talking between estrogen and insulin signalling could have an important role for development and the maintenance of breast cancer 
that has not been fully understood. This study was designed to test the rapid effects of 17b-estradiol on glucose metabolism in a 
positive estrogen receptor breast cancer cell line, through the possible relationship between key components of insulin signalling 
and acute steroid treatment. We used the estrogen receptor α positive breast cancer cell line, MCF 7 cultured in 25 cm2 flasks 
in Complete Dulbecco’s Modified Eagle’s Medium (DMEM). Briefly, before each experiment, cells were serum starved for 24 h in 
phenol red-free DMEM (PRF). After 17b-estradiol or 17b-estradiol BSA coupled treatment, IRS-1 tyrosine phosphorylation, Akt serine 
phosphorylation and Glut4 translocation to the plasmatic membrane were analyzed by western-blotting. Moreover, interactions 
between IRS-1 and p85α were analyzed by immunoprecipitation. We found that the acute treatment with 17b-estradiol seems to 
increase Glut4 translocation, and this is related to the activation of several components of insulin signaling. However, our results 
show a lower Glut4 translocation to plasma membrane in acute treatment with 17b-estradiol-BSA compared to estradiol treatment, 
and this is also reflected on the insulin signaling components that we have analyzed. Taking together, we can say that our results 
open a new pathway in controlling tumor progression, focusing in tumor physiology and energy intake.
P09.90 - Insulin-action and cancer
TARGETING INSULIN ACTION REGULATORS; A NOVEL SYNDROME OF IGF1 AND INSULIN SUPERSENSITIVITY
Groeneveld Matthijs P.1, Huang-Doran Isabel1, Chandrasekera Hemantha2, Porter Keith1, Mcnulty Sid2, Furlong Niall J.2, Siddle Kenneth1, Barroso 
Inês3, O’Rahilly Stephen1, Semple Robert K.1
1Metabolic Research Laboratories, Institute Of Metabolic Science, University Of Cambridge, Cambridge, United Kingdom; 2Whiston Hospital, 
Prescot, Merseyside, United Kingdom; 3Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom
Insulin and insulin-like growth factor type 1 (IGF-1) exert metabolic and mitogenic effects on target cells via closely similar signalling 
pathways. Most likely for this reason, severe insulin resistance and hyperinsulinaemia commonly produces pseudoacromegaloid 
tissue overgrowth. We now report two siblings born to non-consanguineous, clinically unaffected Europid parents with childhood 
overgrowth and progressive pseudoacromegaly with obesity in adulthood without any evidence of growth hormone hypersecretion or 
pituitary adenoma. Serum IGF-1 levels were also repeatedly normal. Surprisingly, metabolic studies revealed strikingly low insulin 
excursions after an oral glucose load, well below the fifth centile for age- and sex-matched, non-diabetic volunteers, consistent with 
very high systemic insulin sensitivity. In addition, both siblings had disproportionately low plasma leptin and high plasma adiponectin 
levels compared to matched controls. Ex vivo studies in dermal fibroblasts failed to reveal cell autonomous abnormalities in insulin-
induced AKT and ERK phosphorylation and in dephosphorylation of the same enzymes after insulin withdrawal. Genetic screening 
to date has ruled out coding defects in the receptors for insulin, IGF-1 and IGF-2, protein tyrosine phosphatase 1B, and the adaptor 
proteins GRB10 and GRB14. Whole exome sequencing is currently underway. We propose that this syndrome is caused by loss of a 
negative regulator of insulin and IGF-1 action, and elucidation of its putative genetic basis will not only yield insights into regulation of 
insulin and IGF-1 action in vivo, but will also inform efforts to target insulin resistance pharmacologically.
P09.91 - Insulin-action and cancer
DIFFERENTIAL SIGNALLING BY INSULIN, INSULIN-LIKE GROWTH FACTOR-I AND INSULIN ANALOGUES STUDIED BY 
QUANTITATIVE PHOSPHOPROTEOMICS
Knudsen Louise1, Akimov Vyacheslav2, Nøhr Larsen Jane1, B. Oleksiewicz Martin3, De Meyts Pierre1, Blagoev Blagoy2
1Insulin And Incretin Biology, Hagedorn Research Institute, Gentofte, Denmark; 2Biochemistry And Molecular Biology, University Of Southern 
Denmark, Odense, Denmark; 3Molecular Microbiology, Intercell Ag, Vienna, Austria
Differential signalling is an evolutionary conserved mechanism in organisms to respond appropriately to changes in their 
environment, which is the key to survival and reproductive success. In mammals, the insulin/IGF-I signalling pathways are involved 
in the regulation of metabolism, growth and reproduction. Activation of the insulin receptor (IR) by insulin analogues and insulin 
mimetic peptides can lead to differential metabolic and mitogenic signalling. Work by us and others suggests that internalization rate, 
residence time on IR, IGF-IR affinity and phosphorylation of downstream signalling proteins contribute to the degree of mitogenicity. 
In this study we set out to find novel protein biomarkers which could identify supermitogenic insulin analogues, using quantitative 
phosphoproteomics with high accuracy mass spectrometry. We used multiplex stable isotope labelling by amino acids in cell culture 
(SILAC) in human mammary adenocarcinoma cells (MCF-7) in combination with phosphotyrosine immunoprecipitation and identified 
more than 1600 phosphorylated proteins in the signalling pathways, of which approximately 200 were regulated more than 2-fold. We 
found that tyrosine phosphorylation of ERBB3 and SHIP2 was significantly increased upon stimulation of MCF-7 cells with IGF-I and 
a supermitogenic insulin analogue (H2) in contrast to stimulation with human insulin (HI), a low mitogenic insulin mimetic peptide 
(S597) and a low mitogenic insulin analogue (X2), which did not cause phosphorylation of these two proteins at all. Furthermore no 
marked tyrosine phosphorylation of IRS-2 was observed upon stimulation with IGF-I and H2 in contrast to stimulation with HI, S597 
and X2.
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SGK1: INSULIN AND STEROID DEPENDENT SURVIVAL SIGNALS
Amato Rosario1, Menniti Miranda1, Scumaci Domenica1, D’Antona Lucia1, Porciatti Giovanni1, Saccomanno Milena1, Cuda Giovanni1, Perrotti Nicola1
1Department Of Experimental And Clinical Medicine “ G. Salvatore”, Catanzaro, Italy
Serum Glucorticoid regulated kinase (Sgk1), an enzyme activated by insulin, Igf1, Interleukin 2 and steroids, increases the number 
of epithelial sodium channels in kidney principal cells and is considered a key regulator of transepithelial sodium transport, thus 
playing a role in insulin resistance associated hypertension. Sgk1 is activated through PDK1/mTOR. The latter phosphorylates Sgk1 
at S422 to prime it for phosphorylation by PDK1 at T256. By yeast two hybrid screening we demonstrated that Sgk1 interacts with 
phosphomannomutase 2 (PMM2), Lysophospholipase and transportin beta, potentially affecting protein glycosylation, phospholipid 
signaling and nuclear transport. Sgk1 also transduces insulin, growth factor and steroids dependent survival signals. We recently 
demonstrated that Insulin activated Sgk1 down-regulates p53 through MDM2 that directs p53 to ubiquitylation and proteosomal 
degradation. Preliminary data show that the activity of Sgk1 is also necessary to export p53 from the nucleus to the cytoplasm where 
it is inactivated by ubiquitylation. By 2DGE and mass spectrometry we found that specific silencing for Sgk1 in colon cancer cell affects 
the expression of proteins such as RanGTP, RANBP1 and CRM1 involved in the nuclear export and in genomic stability. In particular 
Ran-binding protein 1 activity is required for the organization and function of the mitotic spindle. In fact Sgk1 specific silencing was 
associated with a reduced number of aneuploid metaphases in Hela and RKO cells. Sgk1 interacting peptides,identified by phage 
display, can be used to design small molecules that may find an application in the treatment of human tumors and hypertension.
P09.93 - Insulin-action and cancer
PHOSPHORYLATION OF AKT IN RAT MAMMARY GLAND IN SITU AFTER ADMINISTRATION OF INSULIN AND IGF-1
Hvid Henning1, Hansen Bo F.2
1Pathology, Novo Nordisk A/s, Copenhagen, Denmark; 2Insulin Biology, Novo Nordisk A/s, Copenhagen, Denmark
Insulin-mediated effects in rat mammary gland tissue are of key importance during non-clinical development of insulin analogues. 
However, the acute effect of insulin in rat mammary gland is not well described, and detailed examination of insulin signalling 
in mammary gland tissue requires application of in situ techniques, as the mammary gland parenchyma is embedded in a 
subcutaneous layer of adipocytes(1). The aim of the present study was to examine phosphorylation of Akt, found downstream of IR 
and IGF-1R(2), in rat mammary gland using immunohistochemistry after a single treatment of young female Sprague Dawley rats with 
human insulin or human IGF-1 (600 nmol/kg). Rat liver, which has high expression of IR and low expression of IGF-1R, was included 
for comparative purposes, and western blotting for P-Akt in tissue-lysates was performed to support immunohistochemistry. In liver 
sections we observed strong staining of P-Akt in all hepatocytes following treatment with insulin. Treatment with IGF-1 also induced 
phosphorylation of Akt in hepatocytes, although less pronounced than insulin. In mammary gland tissue from animals treated 
with insulin, staining for P-Akt was observed in adipocytes in the fat pad, but also in mammary gland epithelium, where P-Akt was 
detected in cytoplasm and nuclei. Interestingly, treatment with IGF-1 induced stronger phosphorylation of Akt in the mammary gland 
epithelium than insulin, and an increased number of mammary gland epithelial cells were stained for P-Akt. In conclusion, these 
findings show IR and IGF-1R expressed in the rat mammary gland are functional, and suggest rat mammary gland epithelium is more 
responsive to IGF-1 than insulin.
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EVALUATION OF THE METABOLIC TO MITOGENIC POTENCY RATIO FOR B10-SUBSTITUTED INSULIN ANALOGS
Glendorf Tine1, Knudsen Louise1, Stidsen Carsten E.1, Hansen Bo F.1, Hegelund Anne Charlotte1, Sørensen Anders R.1, Nishimura Erica1, Kjeldsen 
Thomas1
1Novo Nordisk A/s, Måløv, Denmark
Insulin analogs with acidic amino acid substitutions at position B10 have previously been shown to display increased mitogenic 
potencies compared to human insulin and the underlying molecular mechanisms have been subject to much scrutiny and debate. 
However, B10 is still an attractive position for amino acid substitutions given its important role in hexamer formation by the 
coordination of zinc. In the study reported here, we prepared a panel of ten singly-substituted B10 insulin analogs with different 
amino acid side chain characteristics and systematically investigated insulin and IGF-I receptor binding affinities, insulin receptor 
dissociation rates as well as cellular metabolic and mitogenic potencies. We identified several B10 insulin analogs devoid of 
disproportionate increases in mitogenic compared to metabolic potencies including B10V, which resembled human insulin. Analogs 
B10D and B10E with significantly increased insulin and IGF-I receptor affinities as well as decreased insulin receptor dissociation 
rates displayed significantly enhanced mitogenic potencies. For the remaining analogs with less pronounced changes in receptor 
affinities and insulin receptor dissociation rates, no apparent correlation between insulin receptor occupancy time and mitogenicity 
was detected.
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ENGINEERING OF INSULIN RECEPTOR ISOFORM-SELECTIVE INSULIN ANALOGS
Glendorf Tine1, Stidsen Carsten E.1, Norrman Mathias1, Nishimura Erica1, Sørensen Anders R.1, Kjeldsen Thomas1
1Novo Nordisk A/s, Måløv, Denmark
The insulin receptor (IR) exists in two isoforms, IR-A and IR-B, and their expression pattern is regulated in a tissue-specific manner. 
The C-terminal end of the insulin B chain is highly important for receptor binding and a comprehensive structure-function analysis 
of the aromatic triplet together with the bordering positions in the B chain C-terminus was therefore performed. We employed 
total amino acid scanning mutagenesis and the resulting single-substitution insulin analogs were individually evaluated in terms 
of relative IR-A and IR-B binding potencies compared to human insulin and discovered a new class of receptor isoform-selective 
analogs. The initial library screening and the following engineering of library combinations resulted in the discovery of analogs 
with 2-4-fold differences in relative binding affinities for the two receptor isoforms compared to human insulin. Both IR-A and IR-B 
selective analogs were identified. Our results demonstrate that a mutation at position B25 alone or in combination with mutations at 
position B27 in the insulin molecule confer IR isoform selectivity. Insulin receptor isoform-selective analogs may hold a potential for 
becoming future tissue-specific/tailored insulin analogs with novel and improved clinical benefits.
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DETAILED ANALYSIS OF INSULIN RECEPTOR PHOSPHORYLATION AFTER STIMULATION WITH INSULIN x10
Hansen Bo Falck1, Jensen Pia1
1Insulin Biology, Novo Nordisk A/s, Måløv, Denmark
Insulin X10 has been found to have a 2-3 fold increased affinity for the insulin receptor (IR), a 2-3 fold increased metabolic potency, 
and in contrast a 4-10 fold increased mitogenic potency. Also, a sustained IR tyrosine kinase activity upon removal of the X10 signal 
was found. Finally, administration of X10 for 52 wk resulted in dose dependent increase in the incidence of malignant mammary 
tumors in female rats. We speculated that the difference between X10 and HI could be explained by differences in specific 
phosphorylation of the IR. Phosphorylation after stimulation with X10 and HI was investigated in BHK cells expressing either the short 
(HIRA) or the long (HIRB) human insulin receptor. Phospho-site-specific-ELISA plates were used to measure phosphorylation of Y972, 
Y1158 and Y1334. These 3 sites represents the juxtamembrane, the kinase and the C-terminal domain of the IR respectively. Sustained 
phosphorylation was seen at all 3 phosphorylation sites. The area under the phosphorylation curve was ~3 fold increased with X10 at 
all sites for both HIRA and HIRB. Interestingly, in dose response experiments X10 was found to have relative (to insulin) potencies for 
phosphorylation of 520, 756 and 239% for Y972, Y1158 and Y1334 respectively for HIRA. For HIRB the values were 599, 939 and 355%. 
Thus, a considerable difference in relative potencies for X10 exists for the different phosphorylation sites on the IR. Phosphorylation of 
the kinase domain seems to compare with the mitogenic potency of X10, while phosphorylation of the C-terminal compares with the 
metabolic potency of X10. Thus, kinase domain phosphorylation might be a major determinant of mitogenic potency.
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CONTROL OF BREAST CANCER CELL GROWTH BY ADIPOCYTE-RELEASED FACTORS
D’Esposito Vittoria1, Passaretti Federica1, Hammarstedt Ann2, Valentino Rossella1, Miele Claudia1, Smith Ulf2, Béguinot Francesco1, Formisano Pietro1
1DBPCM & IEOS/CNR, Università Degli Studi Di Napoli Federico II, Napoli, Italy; 2Laboratory For Diabetes Research, Department Of Molecular And 
Clinical Medicine/Diabetes, Institute Of Medicine, Sahlgrenska Universitetssjukhuset, Göteborg, Sweden
Epidemiologic studies provide compelling evidence that obesity is a risk factor for both cancer incidence and mortality. It is now clear 
that adipocytes, which represent very abundant cell types surrounding cancer cells, could influence several aspects of tumorigenesis, 
from promoting local invasion to angiogenesis and metastasis. However, the molecular mechanisms involved in the adipocyte control 
of the malignant phenotype remain poorly understood. We have studied the mechanisms by which adipocytes may affect breast 
cancer cell phenotypes. We have obtained evidence that conditioned medium (CM) of adipocytes derived from human adipose tissue 
was capable to elicit growth of MCF7 breast cancer cells more effectively than CM of undifferentiated precursors. Similarly, CM from 
3T3-L1 cells induced growth of MCF7 cells, in a time-dependent manner. Cytometric analysis revealed that these changes are due 
to reduced apoptosis instead of increased proliferation. Multiplex screening for growth factors in the CM revealed that VEGF, FGF 
and PDGF secretion is higher by pre-adipocytes than by adipocytes, suggesting a major involvement of these cells in promoting 
angiogenesis. In contrast, the content of IGF-1 produced by adipocytes is two-fold higher than that released by pre-adipocytes. Thus, 
IGF-1 could be a good candidate in mediating survival effect of adipocyte CM. Moreover, treatment of MCF7 with the IGF-1R inhibitor 
AG1024 reverted the adipocyte CM effect on cell growth. In conclusion, adipocyte-derived factors promote breast cancer cell growth by 
inhibiting apoptosis. This effect is more evident in adipocytes than in pre-adipocytes and is, at least in part, mediated by IGF-1.
naples, Italy
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A CASE-CONTROL STUDY OF DIABETES MELLITUS AND CANCER RISK
Stanzione Brigida1, De Angelis Carmine1, Falato Claudette1, De Placido Sabino1, Arpino Grazia1
1Università Degli Studi Di Napoli Federico II, Napoli, Italy
AIM: Increased body mass index (BMI) and plasma glucose, hypertension (HTN), plasma glucose and dislipidemia have been linked 
to the development of cancer, though no conclusive evidence is available yet. We evaluated the association of each of these metabolic 
abnormalities with cancer development on a large population of patients. METHODS: We conducted a general practitioners-based 
case-control study involving 16,155 patients with pathologically diagnosed cancer between January 2005 and December 2008 
and 32,310 healthy controls matched by age, sex and year of registration. Information on risk factors was collected using clinical 
computerized medical records from 639 general practitioners assisting 915,689 inhabitants of the Campania, a southern region of 
Italy. The association between cancer and risk factors was analyzed by multivariate logistic regression. RESULTS: Median age for 
cancer onset was 63 years. Overall, cigarette smoking, family history of cancer, HCV infection, liver disease (mostly including alcoholic 
cirrhosis) were significant risk factors for cancer. Among the metabolic disorders, only diabetes mellitus (DM) was significantly 
associated with cancer onset (OR 1,161; 95% CI, 1,077-1,251) especially in colon (OR 1.30; 95% CI, 1.04-1.62), liver (OR 2.42; 95%CI, 1.62-
3.61), lung (OR 1.33; 95% CI; 1.06-1.66) and pancreatic (OR 2.64; 95% CI; 1.65-4.22) hystotypes.
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FASTING GLUCOSE AS A PREDICTIVE MARKER OF OUTCOMES IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH 
AVASTIN- AND ERBITUx-BASED REGIMENS: NULL RESULTS FROM THE AVEC STUDY
Barba Maddalena1, Sperati Francesca1, Carlomagno Chiara2, De Placido Sabino2, Nasti Guglielmo3, Iaffaioli Vincenzo Raffaele3, Caolo Giuseppina1, 
Serpico Danila2, Crispo Anna3, Capurso Gabriele4, Delle Fave Gianfranco4, Muti Paola1
1Regina Elena National Cancer Institute, Rome, Italy; 2Federico II Medical School, Naples, Italy; 3G. Pascale National Cancer Institute, Naples, 
Italy; 4II Medical School, University La Sapienza, Rome, Italy
CONTEXT: emerging data supports the cross talk between insulin and insulin-like growth factors, vascular endothelial growth factors 
and epidermal growth factor receptor. OBJECTIVES: in metastatic colorectal cancer patients, we aimed to investigate the potential 
role of pre-treatment fasting glucose in predicting 1) objective response to bevacizumab/cetuximab and 2) time to development of 
resistance to bevacizumab/cetuximab. METHODS: we conducted a retrospective analysis on 230 patients with histologically confirmed 
metastatic colorectal cancer, who were treated with either bevacizumab or cetuximab from January 2004 through April 2010. Diabetic 
patients were excluded. We used the Kruskal Wallis test and the Pearson’s Chi2 test to compare study participants through tertiles of 
pre-treatment fasting glucose. We applied logistic regression models to investigate the relationship between pre-treatment fasting 
glucose and objective response. We performed survival analyses using the Kaplan-Meier method and used the Log-rank test to 
compare the survival curves through tertiles of fasting glucose. RESULTS: when compared to patients in the lowest tertile of fasting 
glucose, patients in the highest tertile were more likely to be older and heavier at baseline (age in years: 59.5±11 vs. 53.4±10.3, p=0.002 
and body mass index: 27.3±4.7 vs. 24.3±3.5, p=0.044). Women in the highest tertile were more likely to be postmenopausal (81.5% 
vs. 53.6%, p=0.014). Objective response to bevacizumab or cetuximab-based regimens was not associated to pre-treatment fasting 
glucose, neither was time to development of resistance to the latter biological agents.
P09.99 - Insulin-action and cancer
PED/PEA-15 MODULATES COxSACKIE AND ADENOVIRUS RECEPTOR (CAR) ExPRESSION VIA ERK-MEDIATED SIGNALS IN GLIOMA 
CELLS
Botta Ginevra1, Perruolo Giuseppe1, Libertini Silvana1, Cassese Angela1, Abagnale Antonella1, Passaro Carmela1, Barbato Sara1, Formisano Pietro1, 
Portella Giuseppe1
1Department Of Molecular And Cellular Biology And Pathology, University Of Napoli “Federico II”, Napoli, Italy
Phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes (PED/PEA)-15 is an anti-apoptotic protein, whose 
overexpression is a common feature of type 2 diabetes and impairs insulin action in vitro and in vivo. Elevated PED/PEA-15 levels 
have also been detected in several tumor-derived cell lines, including human glioma cells. Indeed, PED/PEA-15 induces resistance 
to chemotherapic agents in these cells. To investigate the efficacy of adenovirus vectors-mediated gene therapy, we studied the 
effect of the oncolytic adenovirus dl922/947 on the human glioma cell lines U343MG and U373MG, expressing low and high PED/
PEA-15 levels, respectively. U373MG cells showed higher infectivity and sensitivity compared to U343MG. Adenoviral entry into cells 
is mediated by the cell surface receptor Coxsackie and Adenovirus Receptor (CAR), whose levels closely correlate with adenoviral 
entry. Understanding the mechanisms regulating CAR expression and localisation will contribute to increase the efficacy of oncolytic 
adenoviruses. Western blot and cytofluorimetric analysis showed higher total and membrane CAR levels in U373MG compared 
to U343MG cells. In addition, U373MG cells displayed decreased ERK1/2 nuclear/cytosolic ratio, compared to U343MG cells. Both 
ERK2 overexpression and genetic silencing of PED/PEA-15 by antisense oligonucleotides increased ERK nuclear accumulation and 
reduced CAR expression and adenoviral entry. Our data indicate that PED/PEA-15 modulates CAR expression and adenoviral entry 
by sequestering ERK1/2 in the cytosol. These results may represent the molecular basis for novel therapeutic strategies for the 
treatment of human gliomas.
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ADENOVIRAL GENE TRANSFER OF PLD1-D4 RESULTS IN ENHANCED INSULIN SENSITIVITY IN TGPED MICE
Cassese Angela1, Ilardi Annalisa1, Urbani Corinna1, Nigro Cecilia1, Pastore Lucio2, Formisano Pietro1, Miele Claudia1, Béguinot Francesco1
1DBPCM & IEOS-CNR, Naples, Italy; 2Ceinge-Biotecnologie Avanzate, Naples, Italy
Ped/pea-15 is a gene commonly overexpressed in tissues from type 2 diabetic individuals and in their First Degree Relatives. Ped/
pea-15 transgenic mice showed impaired glucose tolerance and insulin resistance. PED/PEA-15 binds phospholipase D1 (PLD1), 
stabilizing the protein and enhancing its activity. The interaction is mediated by D4, the C-terminal domain of PLD1. In muscle of 
TgPED, the increased activity of PLD1 results in hyperactivation of PKCα, which inhibits insulin-induced activation of PKCζ. In this 
work, we demonstrated that overexpression of D4 improves insulin sensitivity and glucose tolerance in mice TgPED. We generated 
an adenoviral vector containing the D4 (Ad-D4) to induce its expression in TgPED. In muscle of TgPED infected with Ad-D4, the D4 
is expressed and reduces the interaction PED/PLD1 activation of PKCα by restoring insulin-stimulated activation of PKCζ. In TgPED, 
Ad-D4 restores insulin sensitivity (ITT AUC mg/dl/120’ wt: Ad-GFP:7930±4062.3, Ad-D4:8408±779.6; TgPED:Ad-GFP:11155±2893.8, 
Ad-D4:6532,8±2683.3, p<0.001 vs TgPED Ad-GFP) and ameliorates glucose tolerance (GTT AUC mg/dl/120’ wt:Ad-GFP:20155±5040, Ad-
D4:18676±3046; TgPED:Ad-GFP:31127±6617, Ad-D4:15619±2490, p<0.0001 vs TgPED Ad-GFP). Furthermore, D4 expression in TgPED 
decreases fasting insulin, FFA, triglycerides levels and finally, increases insulin-induced glucose uptake in skeletal muscles. In 
conclusion, adenoviral delivery of PLD1-D4 rescues insulin sensitivity and glucose tolerance in vivo. Thus, interfering with PED/PLD1 
interaction represents a major strategy for developing new molecules for the treatment of type 2 diabetes.
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THE LACK OF BETA 2 ADRENOCEPTOR IN MICE IMPAIRS GLUCOSE TOLERANCE AND INSULIN SECRETION
Santulli Gaetano2, Lombardi Angela1, Sorriento Daniela2, Iovino Salvatore1, Anastasio Antonio2, Del Giudice Carmine2, Trimarco Bruno2, Béguinot 
Francesco1, Miele Claudia1, Formisano Pietro1, Iaccarino Guido2
1“Federico II” University - Dpt. Cellular And Molecular Biology And Pathology “Luigi Califano”, & CNR-IEOS, Institute Of Sperimental 
Endocrinology And Oncology “Gaetano Salvatore”, Naples, Italy; 2“Federico II” University - Dpt. Clinical Medicine, Cardiovascular & Immunologic 
Sciences, Naples, Italy
The reciprocal regulation of sympathetic nervous system and insulin relays on molecular mechanisms not fully understood. Beta 
2 adrenergic receptors (b2ARs) are involved in insulin production and glucose uptake. We characterized the metabolic phenotype 
of mice with deletion of b2AR gene (KO, n=21). As controls we used C57BL/6 mice (WT, n=17). KO mice exhibited decreased glucose 
tolerance compared to WT (GTT AUC, KO: 40981±6890 vs WT 19293±2127, p<0.01). However, KO mice did not feature peripheral insulin 
resistance compared to WT (ITT AUC, KO: 8281±1125 vs WT 13915±1811, p<0.01). Clamp studies in KO mice revealed a 2-fold decreased 
Glucose Infusion Rate, a 2-fold increase in Endogenous Glucose Production and increased rate of Glucose Disappearance, suggesting 
that insulin resistance develops at hepatic level in KO mice. KO mice showed also impaired insulin response to hyperglycemia 
compared to WT. Histological analysis of pancreatic tissues displayed a normal architecture of KO insulae and both total insulin and 
glucagone content were comparable in KO and WT mice. However, whilst in insulae isolated from WT mice glucose induced insulin 
secretion by 3-fold, insulae from the KO mice exhibited a blunted response to glucose. Glucagon secretion was not different in KO and 
WT mice. Increasing b2AR expression in KO mice isolated insulae by the infection of an adenoviral construct bearing the b2AR cDNA, 
restored the ability of KO insulae to secrete insulin in response to glucose. Our results indicate that b2AR plays a critical role in the 
regulation of glucose metabolism and insulin secretion, offering new insights to develop therapeutic strategies for management of 
diabetes.
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GLOBULAR ADIPONECTIN ACTIVATES P38MAPK/NF-KB PATHWAYS RESULTING IN INCREASED CYCLOOxYGENASE-2 ExPRESSION 
AND VCAM 1-DEPENDENT MONOCYTE ADHESION IN HUMAN ENDOTHELIAL CELLS
Addabbo Francesco2, Nacci Carmela2, De Benedictis Leonarda2, Leo Valentina2, Quon Michael J.1, Montagnani Monica2
1National Institutes Of Health, Bethesda, Usa; 2University Aldo Moro, Bari, Italy
The globular fragment of adiponectin (gAd) results from enzymatic cleavage of full-length Ad (fAd) in peripheral tissues. Recent 
reports suggest that gAd/fAd ratio increases in patients with metabolic syndrome, but physiological role of gAd is still uncertain. 
Activation of signaling pathways related to production of endothelial mediators by gAd and fAd were investigated in Human 
Aortic Endothelial Cells (HAEC) in primary culture. Both fAd and gAd (10 microg/ml, 10 min) increased p42/44MAPK and AMPK 
phosphorylation (by WB). gAd –but not fAd- increased p38MAPK phosphorylation, degradation of IkB and nuclear translocation of p65 
protein (by WB and IF analysis). Prolonged stimulation (1-8 h) with gAd, but not with fAd, also increased mRNA levels (by RT-PCR) 
and protein expression/function of cyclo-oxygenase-2 (COX-2) (by WB and ELISA). Pre-treatment of HAEC with p38MAPK inhibitor 
SB203580 (10 microM, 1 h), or with NF-kB inhibitor BAY 11-7082 (20 microM, 1h) reduced COX-2 overexpression in response to gAd. 
In HAEC lacking AdipoR1 (by siRNA) COX-2 overexpression by gAd was abrogated. In control HAEC, gAd also increased expression 
of VCAM-1 (by RT-PCR, ELISA and WB) and subsequently enhanced adhesion of activated monocytes (by IF). These gAd-mediated 
effects were reduced by pre-treatment of HAEC with BAY 11-7082 and enhanced by COX-2 inhibitor NS-398 (10 microM, 1 h). Thus, 
gAd possesses the distinct ability to activate pro-inflammatory signaling pathways in endothelium. Our results may have important 
implications for adiponectin role in the vasculature under pathophysiological conditions.
naples, Italy
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EFFECTS OF SELECTIVE AND REVERSIBLE INHIBITION OF LIVER CARNITINE PALMITOYL TRANSFERASE 1
Conti Roberto1, Tassoni Emanuela1, Giannessi Fabio1, Federici Massimo2
1Sigma-Tau, Pomezia, Italy; 2Tor Vergata, Rome, Italy
Teglicar, a reversible inhibitor of the liver isoform of Carnitine Palmitoyl-Transferase 1 (L-CPT1), reduces gluconeogenesis by 
decreasing pyruvate carboxylase activity through inhibition of liver fatty acid oxidation. Teglicar, in a phase II study on type II diabetic 
patients, reduced HOMA index and showed a clear tendency to reduce fasting blood glucose levels. As increased hepatic triglyceride 
content (HTGC) has been observed in some animal studies, and liver triglyceride elevation may correlate with insulin-sensitivity 
deterioration, we investigated the effects of Teglicar on both HTGC and insulin sensitivity in rats and db/db mice. Long-term Teglicar 
administration (30 days, 80 mg/kg) to healthy rats reduced basal insulin levels by 60%, while slightly reducing basal glycemia after 16 
hours fast (-20%, n.s.). Liver and peripheral insulin sensitivity, assessed by hyperinsulinemic-euglycemic clamp, were not affected, 
even if HTGC was increased. In db/db mice treated with Teglicar (100 mg/kg/d; 15 days), a significant reduction of glycemia in fed 
condition, with an improved insulin tolerance test, was observed. Phosphorylation of IRS-1, IRS-2, AKT and GLUT4 translocation after 
60’ from insulin stimulation was not affected by Teglicar treatment in both liver and gastrocnemius muscle, although a not significant 
increase of HTGC (+84%) was measured. Interestingly, the treatment increased basal signal phosphorylation in both tissues. In 
conclusion, our study confirms the feasibilty of specifically targeting L-CPT-1 with Teglicar, which may potentiate metformin action in 
reducing post-absorptive glycemia in type II diabetic patients, as shown in mouse preclinical models.
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FIRST EVIDENCE OF GLUCOSE-INDUCED INCREASE OF PLASMA ABSCISIC ACID LEVELS IN HUMANS
Bruzzone Santina1, Ameri Pietro2, Briatore Lucia2, Basile Giovanna1, Salis Annalisa1, Mannino Elena1, Andraghetti Gabriella2, Murialdo Giovanni2, 
Cordera Renzo2, De Flora Antonio1, Zocchi Elena1
1Dept. Of Experimental Medicine, Section Of Biochemistry And Center Of Excellence For Biomedical Research, University Of Genova, Genova, Italy; 
2Dept. Of Endocrinological And Medical Sciences, University Of Genova, Genova, Italy
The plant hormone abscisic acid (ABA) has been demonstrated to be released from glucose-challenged rodent and human pancreatic 
beta cells. Moreover, nanomolar concentrations of ABA stimulates both glucose-dependent and -independent insulin secretion. 
Therefore, we started a preliminary in vivo study on whether a glucose load was accompanied by enhanced plasma levels of ABA. We 
determined plasma ABA concentrations in healthy subjects during prolonged (240 minutes) oral or intravenous glucose tolerance 
test (OGTT, IVGTT). In all subjects undergoing OGTT (n=10), plasmatic ABA concentrations increased 3-7 times over basal values, with 
a peak at 60-120 min after glucose administration. A significant positive correlation was found between ABA area under the curve 
(AUC) and glucose, but not insulin, AUC (p <0.05). In 3 out of 5 IVGTT, little or no increase in ABA levels was observed. In the remaining 
two subjects, ABA increase was similar to that during OGTT. Thus, we provide the first evidence of a physiological rise of plasma 
ABA concentrations after a glucose load in humans. ABA is likely secreted by pancreatic islets and possibly also by the adipose 
tissue. Incretins may mediate the consistent and stronger stimulation of ABA release by oral glucose. Next, we compared fasting 
ABA concentrations in healthy subjects and non-obese type 2 diabetic subjects (T2DM). Patients with T2DM had significantly higher 
plasma ABA concentrations compared to healthy subjects (2.39±0.77 nM, n=4, and 1.04±0.38 nM, n=17, respectively, p<0.0001). This 
suggests that chronic hyperglycemia is associated with a sustained increase in ABA levels.
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DEVELOPMENT OF COMPOUNDS INHIBITORS OF THE INTERACTION BETWEEN INSULIN RECEPTOR AND GRB14
Cornelia Hampe1, Cyril Fayolle1, Richard Eudes2, Cécile Pierre-Eugene1, Maria Miteva2, Bruno Villoutreix2, Anne-Françoise Burnol1, Tarik Issad1
1Institut Cochin, Inserm U1016, Cnrs-Umr8104, Université Paris Descartes, Paris, France; 2Mti, Inserm Umr 973, Université Paris Diderot, Paris, 
France
Insulin binding to its receptor (IR) stimulates its tyrosine kinase activity, which in turns activates intracellular signalling pathways. 
Growth factor receptor-bound protein 14 (Grb14) is an adaptor that binds to and inhibits the tyrosine kinase activity of the IR. Its 
expression is increased in some tissues of type 2 diabetic patients. Therefore, small molecule inhibitors of the IR-Grb14 interaction 
may help improve insulin action in diabetes. Using IR fused to luciferase and Grb14 fused to YFP, we have developed a BRET 
(Bioluminescence resonance Energy Transfer) assay that can be used in high-throughput screening for the search of inhibitors 
of IR-Grb14 interaction. In parallel, using structured-based virtual screening, we have selected 1000 molecules (out of compound 
collection containing 300000 molecules) with high-score for potential inhibition of the IR-Grb14 interaction. These compounds were 
then purchased and experimentally evaluated for inhibition of IR-Grb14 interaction using the BRET assay. Nine molecules were 
reproducibly detected in 3 independent screens as having inhibitory activity on BRET between IR and Grb14. The effects of these 
compounds (C1 to C9) were then further studied in BRET and co-immunoprecipitation experiments. The most efficient compound, 
C8, inhibited BRET between IR and Grb14 by 45-50% at a concentration of 25 micromolar. In co-immunoprecipitation experiments, 
the effect of this compound was even more pronounced, as it markedly reduced the amount of IR that could be recovered in Grb14 
immunoprecipitate. The use of C8 as a lead compound should now allow developing new molecules with high therapeutic interest for 
the treatment of diabetes.
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FOOD SECURITY REGULATION, CONSUMER PROTECTION AND PREVENTION OF LIFESTYLE-RELATED DISEASES
Miletti Antonella1, Botta Consiglia1
1Federico II University Of Naples, Naples, Italy
Current evidence indicates that lifestyle-related diseases are determined by both environmental and genetic factors. The European 
legislation concerning the safety and wholesomeness of food, based on Regulation. 178/2002, has introduced a number of measures 
to provide the basis for the assurance of an high level of protection of human health and consumers interest in relation to food. This 
includes the risk analysis, precautionary principle, protection of consumers interest, traceability of food, the European food safety 
authority, and the rapid alert system. We have examined this problem further. The results of our studies show that all of these rules 
are not sufficient to protect human health as the consumer interest in relationship to nutrition and health has increased substantially 
in Europe. In addition, functional foods have not been defined by EU legislation, even if their benefits have been widely demonstrated 
in a number of research studies which establish the scientific basis to support claims for functional components or for the foods 
containing them. In conclusion a close relationship and mutual cooperation between food functional studies and more suitable 
regulations becomes even more necessary. It is anticipated that such attitude may deliver substancial contributions to both the 
prevention of life-style diseases including type 2 diabetes and to consumer protection.
P11.107 - Diabetes complications
METHYLGLYOxAL IMPAIRS INSULIN SECRETION AND GENE ExPRESSION IN BETA-CELLS INTERFERING WITH INSULIN SIGNALING
Fiory Francesca1, Lombardi Angela1, Giudicelli Jean2, Béguinot Francesco1, Miele Claudia1, Van Obberghen Emmanuel2
1DBPCM & IEOS/CNR, Università Degli Studi Di Napoli Federico II, Naples, Italy; 2Inserm U907, Nice, France
Insulin resistance in beta-cells plays a role in beta-cells dysfunction in type 2 diabetes. Increased production of AGEs and 
methylglyoxal (MGO), a precursor of AGEs formation, contributes to the insulin-resistance condition. It is known that in L6 cells MGO 
interferes with insulin signal transduction by binding to IRS1/2 and decreasing their tyrosine phosphorylation in response to insulin. 
Moreover, prolonged incubation of beta-cells with MGO seems to inhibit insulin secretion. In this work we have evaluated MGO effects 
on insulin signal transduction and on insulin secretion in INS-1E beta-cells. Pretreatment of INS-1E cells with 1mM MGO for 30’ 
inhibits tyrosine phosphorylation of IRSs proteins and the activation of the PI3K/PKB/GSK3 pathway in response to insulin. Treatment 
with 100nM insulin for 30’ increases the expression of ins-1, glucokinase and pdx-1 genes by 40%, 50% and 55% respectively. Insulin 
action on gene expression is dramatically reduced by pretreatment with 1mM MGO for 30’. Moreover, MGO inhibits glucose-induced 
insulin secretion. Pretreatment of INS-1E cells for 90’ with 40mM LiCl, a GSK3 inhibitor, restores GSK3 phosphorylation in presence 
of MGO and reverts MGO inhibitory effect on glucose-induced insulin secretion. These results suggest that MGO action on insulin 
secretion is mediated at least in part by GSK3 activation. Understanding the molecular basis of MGO action will allow to develop new 
strategies to preserve and/or improve beta-cells function in type 2 diabetic patients, whose plasmatic levels of MGO are increased.
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INSULIN RECEPTOR REGULATES NORMAL CELLULAR CYTOSKELETON ASSEMBLY IN SKIN EPITHELIAL CELLS
Dror Erez1, Weingarten Galina1, Wertheimer Efrat1
1Tel Aviv University Sackler Medical Faculty, Tel Aviv, Israel
In diabetes the wound healing process is impaired, and the healed wounds are characterized by decreased strength. Most research is 
devoted to the secondary effects of diabetes associated neuronal- and microvascular pathologies on the wound healing process. One 
can hypothesize, however, that these skin pathologies might result from impaired insulin signaling. We have previously found that 
insulin is a major regulator of skin processes, and that insulin receptor (IR) inactivation in skin results in impaired wound healing. We 
further found that such inactivation of the IR in the skin cells resulted in abnormal cytoskeletal structure, mainly of the keratin 1 (K1) 
protein - a main component of the skin cell cytoskeleton. This abnormality was associated with changes in the K1 phosphorylation 
and K1 impaired assembly. These results were further corroborated using a human-based cell line in which the IR was inactivated 
by gene-specific shRNA. IR silencing resulted in the changes in K1 phosphorylation and assembly, which resembled the changes 
occurring in the murine skin and skin cells. Functionally, both murine and human IR null cells demonstrated decreased proliferation, 
decreased attachment to extracellular components and impaired migration - processes which are important for proper wound 
healing. These results have scientific significance, identifying a new regulatory role of insulin in cytoskeletal assembly; as well as 
clinical significance, demonstrating the importance of skin function per se and insulin regulation of skin, suggesting that impaired 
insulin signaling in skin, as occurs in diabetes, might contribute directly to impaired wound healing.
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TIMP3 DEFICIENCY ACCELERATES DIABETIC NEPHROPATHY
Cavalera Michele1, Fiorentino Loredana1, Fabrizi Marta1, Mavilio Mara1, Lauro Davide1, Menini Stefano2, Pugliese Giuseppe2, Lauro Renato1, 
Federici Massimo1
1University Of Rome Tor Vergata, Rome, Italy; 2Sapienza University Of Rome, Rome, Italy
Activation of TACE/ADAM17 is a key step in the progression of glomerulopathy, even though the exact role of ADAM17 and its inhibitor 
TIMP3 in a hyperglycemic environment is still unclear. Therefore, we analyzed mice treated with streptozocin (STZ) to induce 
diabetes. STZ-WT and STZ-Timp-3-/- kidneys by IHC, real time PCR and WB. STZ-Timp-3-/- mice showed 1) significantly incresead 
mean glomerular area and fractional mesangial area (p<0.05 and p<0.001), 2) a thicker glomerular basement membrane, due to an 
increased amount of type IV collagen deposition (p<0.01), 3) increased macrophage infiltration, measured by F4/80 staining (p<0.01), 
4) increased expression of NOX4, RAGE and N-Carboxymethyl-lysine, a major product of oxidative modification of glycated proteins 
(p<0.01 for all). 5) increased expression of MCP-1, and decreased nephrin and WT1 expression two markers of podocyte functions, 
is reduced in STZ-Timp-3-/- mice compared to the WT littermates (p<0.01 for all). gene profiling experiments on kidneys revealed 
up-regulation of different classes of genes involved in inflammation (Cxcl9, Ccr5, Mcp-1, Mcp-5, Aif-1, Cd36, Mgl-1, Mgl-2), renal cells 
proliferation and fibrosis (Pdgf-d, Tgfb3, Fgf, Ghr), lipid metabolism (Fabp5, Fasn, Ldlr, Acaca, Acms3) and transport (Slc13a1, Slc7a13, 
Slc7a6, Slco4c1, Slc12a3, Glut8) in STZ-Timp-3-/- mice compared to WT ones. We also found a significant reduction in the expression 
of genes connected to control of oxidative stress such as Foxo1 and Foxo3a in the kidney of STZ-Timp-3-/- mice. In conclusion, our 
preliminary results show that Timp3 plays a protective role in preventing the progression of diabetic renal nephropathy.
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ROLE OF ENDOPLASMIC RETICULUM STRESS IN ENDOTHELIAL DAMAGE INDUCED BY HYPERGLYCEMIA
Fiorentino Teresa Vanessa1, Procopio Teresa1, Andreozzi Francesco1, Arturi Franco1, Sesti Giorgio1, Hribal Marta Letizia1
1University Magna Graecia, Catanzaro, Italy
Despite intense research the molecular processes by which diabetes promotes atherosclerosis have not been fully elucidated yet. 
The aim of this study is to test the hypothesis that hyperglycemia, acting through the glucosamine (GlcNAc) pathway may induce 
endothelial dysfunction promoting protein misfolding in the endoplasmic reticulum (ER) and consequently ER stress. To this end 
human umbilical vein endothelial cells (HUVECs) were treated with 7.5 mM GlcNAc for 24, 48, 72, 96 hrs and in parallel with Mannitol, 
as hyperosmolarity control, and with high glucose (15 mM) in the presence or absence of azaserine, a specific inhibitor of the 
hexosamine pathway. Expression levels of four ER stress markers were evaluated by RT-PCR and Western Blot: Calnexin expression 
increased steadily (p≤0.05, n=9) at 24, 48, 72 and 96 hrs in GlcNAc treated HUVECs as compared to control cells, while pPERK, Bip 
and CHOP levels gradually increased after 24, 48, 72 hrs (p≤0.001, n=9). ER stress induction was paralleled by an increased synthesis 
of proinflammatory cytokines and adhesion molecules; GlcNAc treatment promoted NFkB activation, assessed by ELISA, after 48 
hrs (p≤0.05, n=5), induced JNK phosphorylation (p≤0.05, n=4), IL-6, CRP, TNFα synthesis and ICAM, VCAM, PAI-1 expression (p≤0.05, 
n=7) after 24 hrs. ER stress activation, caused by GlcNAc, was also associated with an increased cell apoptosis, assessed by DNA 
laddering. In conclusion, in endothelial cells, hyperglycemia, mimicked by GlcNAc exposure in our in vitro model, induces ER stress, 
promotes an inflammatory/procoagulatory state and induces cell apoptosis compromising the structural and functional integrity of 
the endothelium.
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DELETION OF THE CAMK4 GENE IN MICE DETERMINES A HYPERTENSIVE PHENOTYPE
Santulli Gaetano1, Sorriento Daniela1, Cipolletta Ersilia1, Del Giudice Carmine1, Anastasio Antonio1, Trimarco Bruno1, Iaccarino Guido1
1“Federico II” University - Department Of Clinical Medicine, Cardiovascular & Immunologic Sciences, Naples, Italy
Calcium/calmodulin-dependent kinase 4 (CaMK4) belongs to the CaMK family and is expressed in selected cellular types, where it 
regulates calcium-dependent signaling. In particular, its presence in the endothelium suggests a yet undisclosed role for this kinase 
in the regulation of vascular. Furthermore, Genome-Wide Analysis showed an association between elevated blood pressure (BP) and 
a polymorphism of human CaMK4 gene. To evaluate the role of CaMK4 in BP homeostasis, we characterized the phenotype of mice 
with deletion of the CaMK4 gene (KO, n=18) and wild type littermates (WT, n=16). Vasorelaxant responses to AcetylCholine (ACh), 
Isoproterenol (Iso) and Nitroprusside (Np) were assessed on ex vivo aortic rings preparations, pre-constricted with phenylephrine. 
KO presented BP levels than WT. Interestingly, this increase paralleled the development of cardiac size, with worsening of ultrasound 
assessed cardiac function. KO vessels showed an attenuated endothelium-dependent vasorelaxation to ACh and to Iso, while no 
differences were observed in endothelium independent vasorelaxant responses to Np. Moreover, KO mice exhibited a decreased 
glucose tolerance compared to WT (GTT AUC, KO: 32127±3652 vs WT 18913±1843, p<0.05). Finally, in vitro experiments performed on 
cultured endothelial cells isolated from the aorta of WT mice, CaMK4 co-immunoprecipitated with eNOS and phosphorylated it in Ser 
1177 in response to ionomycin or VEGF. These responses were lost in KO endothelial cells. So, CaMK4 participates in BP homeostasis 
through the control of eNOS activity. Our findings might also shed light on the association of hypertension and insulin resistance.
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PED/PEA-15 CONTROLS WOUND HEALING AND FIBROBLAST MOTILITY
Buonomo Roberta1, Giacco Ferdinando1, Vasaturo Angela2, Trisi Umberto1, Iadicicco Claudia1, Béguinot Francesco1, Formisano Pietro1
1DPBCM & CNR-IEOS, Naples, Italy; 2Department Of Chemistry Engineering “Federico II” Univeristy Of Naples, Naples, Italy
PED/PEA-15 is a gene overexpressed in patients affected by type 2 diabetes in which failure in wound healing is a common feature 
that severely affects morbidity and mortality. We evaluated skin wound healing in transgenic mice overexpressing PED/PEA-15 
(PEDTg) and in fibroblasts isolated from PEDTg mice. Upon 3 days after the injury, the wound edges distance was 2-fold higher in 
PEDTg mice compared to their wild-type littermates (Wt). Moreover, the wounded skin of PEDTg exhibited about 70% reduction of 
activated fibroblasts and collagen fibres content. Skin fibroblasts isolated from PEDTg mice subjected to scratch assays, showed a 
significantly reduced healing ability compared to control (Wt:55%±23 vs PEDTg:40%±22; p‹0.005). Significant differences were also 
observed in the presence of Mytomicin C, an inhibitor of mytosis (Wt: 37%±14 vs Tg: 24%± 8,22;P<0.05). In time-lapse experiments, 
PEDTg fibroblasts displayed about 2-fold lower velocity (PEDTg: 0.5±0.09 m/min; p<0.05 vs Wt: 0.9±0.08 µm/min) and diffusion 
coefficient (PEDTg: 3.9±1.2 µm2/min; p<0.05 vs Wt: 8.3±2.7m2/min) compared with Wt. These changes were accompanied by 
reduced spreading and decreased formation of stress fibres and focal adhesion plaques. At molecular level, PEDTg fibroblasts 
displayed decreased RhoA membrane content and increased cytosolic abundance of phosphorylated ERK1/2. Inhibition of ERK1/2 
activity by PD98059 restored RhoA membrane translocation, cytoskeleton organization and cell motility and completely rescued 
wound healing ability of PEDTg fibroblasts. Thus, PED/PEA-15 overexpression may affect the fibroblast motility by a mechanism 
mediated by ERK1/2 de-localization and inhibition of RhoA
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ANGIOTENSIN(1-7) ACTIVATES ENOS VIA THE PI3K-AKT PATHWAY IN ENDOTHELIAL CELLS
Tassone Eliezer J1, Sciacqua Angela1, Andreozzi Francesco1, Laino Irma1, Musca Donatella1, Naccarato Paola1, Presta Ivan1, Sesti Giorgio1, 
Perticone Francesco1
1University Of Catanzaro “Magna Graecia”, Catanzaro, Italy
The renin–angiotensin system (RAS) regulates endothelial function. The reduced bioavailability of nitric osside (NO), typical of 
endothelial dysfunction, predicts of the development of atherosclerosis. Recent studies focus attention on new members of the RAS, 
as angiotensin 1-7 (ang1-7), with effects even opposite to those displayed by angiotensin II (ang II). In the present study, we have 
explored the effects of ang(1–7) on NO production in HUVECs and the ability of this peptide to counterregulates the effects of ang II. 
Human endothelial cells in culture were stimulated either with ang II or ang(1-7) or insulin in the presence or not of wortmannin 
(50nM), an inhibitor of the phosphatidylinositol 3kinase (PI3K). Trasducer protein phosphorylation activity was assessed by Western 
blot using specific antibodies (anti eNOS, p-eNOS Ser1177, AKT e pAKT Ser473). NO production was determined using an NO detection 
system that measures the ability of NOS to convert L14C-Arginine into L14C-Citrulline. We demonstrated that, in contrast to Ang II, 
Ang(1-7) activates the PI3K/AKT thereby inducing the phosphorylation of eNOS on Ser1177, and restoring the effects of insulin. This 
stimulation was blunted in presence of the PI3K inhibitor, wortmannin. The effects of ang(1-7) on eNOS activation was followed by an 
increase in NO production. In HUVECs ang(1-7) counterregulates the actions of ang II, inducing NO production, through the PI3K/AKT/
eNOS patway, similar to insulin. These data confirm the positive role of ang(1-7) on insulin action. The balance between ang II and 
ang(1-7) may have a role in the development of hypertension, insulin-resistance and cardiovascular disease.
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METHYLGLYOxAL IMPAIRS INSULIN SIGNALING AND ENDOTHELIAL FUNCTION IN VITRO AND IN VIVO
Nigro Cecilia1, Ilardi Annalisa1, Vinci Viviana1, Scotto Di Carlo Vanessa1, Formisano Pietro1, Béguinot Francesco1, Miele Claudia1
1DBPCM & IEOS-CNR, Università Degli Studi Di Napoli Federico II, Naples, Italy
It has now become evident that insulin exerts a direct action on vascular cells, thereby conditioning the outcome and progression of 
vascular complication associated with diabetes. However, the mechanisms through which insulin signaling is impaired in the vascular 
endothelium remain still unclear. Chronic hyperglycaemia per se promotes insulin resistance and plays a pivotal role in the outcome 
and progression of diabetes-associated vascular complications. Hyperglycaemia may act through different mechanisms, including 
generation of methylglyoxal (MG) and advanced glycation end products (AGEs). In this work we evaluated the role of MG and AGEs 
in the generation of insulin-resistance in vascular cells and isolated mouse aortae. Both MG and AGEs induced a dose- and time-
dependent decrease of insulin-stimulated IRSs phosphorylation, Akt activation and GSK3 phosphorylation in both NIH3T3 fibroblasts 
and bovine aortic endothelial cells (BAEC). This was paralleled by a 60% decrease of insulin-induced NO production in BAEC. 
Intraperitoneally administration of MG (50mg/kg) to C57 mice for 7 weeks caused insulin resistance (ITT AUC: C57MG 10163±1979 
vs C57 7787±1174 mg/dl/120’, p=0.01) and reduced serum NO by 2.5-fold compared to untreated mice. Lysates of aortae from MG-
treated mice revealed a reduction of insulin-induced Akt activation. These results suggest that both AGEs and MG impair insulin 
signaling and insulin effect on endothelial NO production both in vitro and in vivo. Understanding the molecular mechanisms by which 
hyperglycaemia compromises insulin action in vascular cells may allow to develop new strategies to preserve endothelial function in 
diabetic subjects.
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REACTIVE GLUCOSE METABOLITES IN PAINFUL DIABETIC NEUROPATHY
Angelika Bierhaus1, Peter P. Nawroth1
1Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany 
There is only a vague understanding of the mechanisms mediating pain in diabetic neuropathy, particularly, since lowering blood 
glucose does not reduce pain in all patients with diabetes. The reactive glycolytic metabolite methylglyoxal (MG) is detoxified by the 
glyoxalase-system (GLO-1). Since (i) peripheral nerves demonstrate particularly low levels of GLO-1, (ii) GLO-1 activity is reduced 
in diabetes and (iii) plasma levels exceeding 600 nM of MG discriminate between diabetic patients with and without pain, we 
hypothesized that elevated MG-levels might contribute to metabolic hyperalgesia and neuropathic pain. When pain perception was 
studied in healthy and 8 weeks diabetic mice, a reduction of GLO-1 either by diabetes, siRNA-approaches or genetic ablation of GLO-1 
resulted in increased thermal hyperalgesia. The functional significance of the MG/GLO-1-balance was confirmed in healthy wild-type 
mice treated with the GLO-1 inhibitor SpBrBzGSHCp2, which demonstrated a significant increase in thermal hyperalgesia. Accordingly, 
overexpression of GLO-1 reduced thermal hyperalgesia in healthy and diabetic mice. Most importantly, i. p. injection of MG into 
healthy wild-type mice caused a significant increase in thermal hyperalgesia within short time. Cultured sensory neurons incubated 
with MG demonstrated extensive MG-modifications of arginine residues of the voltage-gated sodium channel Nav1.8, which in turn 
facilitated firing into nociceptive neurons. MG induced thermal hyperalgesia in mice was also mirrored by an increased blood flow in 
brain regions involved in pain processing. Similar changes were observed in STZ-induced and genetic experimental diabetes models, 
but were absent in Nav1.8
-/--mice. These data provide firm evidence for a novel pathway in which the small reactive metabolite MG 
directly induces hyperalgesia and thus might provide new therapeutic options for the treatment of pain in diabetic neuropathy.
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